Trial Outcomes & Findings for Efficacy and Safety Study of Eltrombopag in Pediatric Patients With Thrombocytopenia From Chronic Idiopathic Thrombocytopenic Purpura (ITP) (NCT NCT00908037)

Last Updated: 2018-10-12

Results Overview

Participants who achieved a platelet count \>=50 Gi/L at least once between Day 8 and Day 43 (first 6 weeks of Part 2) in the absense of rescue treatment were reported. A 95% confidence interval was calculated by the exact binomial method.

Recruitment status

COMPLETED

Study phase

PHASE2

Target enrollment

82 participants

Primary outcome timeframe

From Day 8 up to Day 43 of Part 2

Results posted on

2018-10-12

Participant Flow

Pediatric participants (par.) meeting eligibility criteria were enrolled into 3 cohorts depending upon age. Cohort 1 enrolled participants who were between 12 and 17 years old, Cohort 2 enrolled participants who were between 6 and 11 years old, and Cohort 3 enrolled participants who were between 1 and 5 years old.

15 par. were randomized to a 24-Week (Wk) Open-Label (OL) eltrombopag Dose-Finding period (pd) (Part 1) then did not continue. 67 par. were randomized to a 7-Wk Double-Blind placebo-controlled pd (Part 2), followed by a 24-Wk OL eltrombopag-only pd (Part 2/3) and a 4-Wk Follow-Up pd.

Participant milestones

Participant milestones
Measure	Part 1 (Dose-Finding Period) Cohort 1 Participants aged between 12 and 17 years received a 24-week Open-Label treatment of eltrombopag administered as a tablet. The starting dose of eltrombopag was 25 milligrams (mg), once daily (QD). The participants of East Asian ancestry began at 12.5 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 1 (Dose-Finding Period) Cohort 2 Participants aged between 6 and 11 years received a 24-week Open-Label treatment of eltrombopag administered as a tablet. The starting dose of eltrombopag was based on the body weight. Participants with a weight of \<27 kilograms (kg) received 12.5 mg QD (approximately 0.5 - 0.7 mg/kg QD) and participants with a weight of \>=27 kg received 25 mg QD (approximately 0.5 - 0.8 mg/kg QD). The maximum dose allowed was 2 mg/kg and could not exceed 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 1 (Dose-Finding Period) Cohort 3 Participants aged between 1 and 5 years received a 24-week Open-Label treatment of eltrombopag administered as a dry powder for oral suspension. The starting dose of eltrombopag was 0.7 mg/kg QD. Participants of East Asian ancestry began at 0.5 mg/kg/day. The maximum dose allowed was 2 mg/kg, and could not exceed 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 1-Placebo Participants aged between 12 and 17 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.	Part 2 (Randomized Period) Cohort 1- Eltrombopag Participants aged between 12 and 17 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was 37.5 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 2-Placebo Participants aged between 6 and 11 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.	Part 2 (Randomized Period) Cohort 2-Eltrombopag Participants aged between 6 and 11 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was based on the body weight, participants with a weight of \<27 kg received 25 mg QD and participants with a weight of \>=27 kg received 50 mg QD. Participants of East Asian ancestry with a body weight of \<27 kg received 12.5 mg QD and participants with a weight of \>=27 kg received 25 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 3-Placebo Participants aged between 1 to 5 years received eltrombopag matching placebo administered as a dry powder for oral suspension QD for 7 weeks.	Part 2 (Randomized Period) Cohort 3- Eltrombopag Participants aged between 1 to 5 years received eltrombopag administered as a dry powder for oral suspension for 7 weeks. The starting dose of eltrombopag was 1.5 mg/kg QD and the dose calculations were based on the body weight. Participants of East Asian ancestry began at 0.8 mg/kg/day. The maximum dose allowed was 2 mg/kg, unless otherwise approved by the investigator, and could not exceed 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2/3 (Eltrombopag Open-Label Period) Cohort 1 All participants aged between 12 and 17 years and completing Part 2 of the study received an Open-Label treatment of eltrombopag administered as a tablet in Part 2/3. Participants who received placebo in Part 2 received 24 weeks of treatment of eltrombopag starting at 37.5 mg QD up to Week 31 of the study. Participants who received 7 weeks of eltrombopag treatment in Part 2 received an additional 17 weeks of treatment to complete a total of 24 weeks continuing at the same dosage at the end of Part 2. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2/3 (Eltrombopag Open-Label Period) Cohort 2 All participants aged between 6 and 11 years and completing Part 2 of the study received an Open -Label treatment of eltrombopag administered as a tablet in Part 2/3. Participants with difficulty swallowing a tablet in Part 2 were administered eltrombopag as a dry powder for oral suspension in Part 2/3. Participants who received placebo in Part 2 received 24 weeks of treatment of eltrombopag based on body weight up to Week 31 of the study. Participants with a body weight of \<=27 kg received 25 mg QD and participants with a body weight of \>=27 kg QD received 50 mg QD. Participants who received 7 weeks of eltrombopag treatment in Part 2 received an additional 17 weeks of treatment to complete a total of 24 weeks continuing at the same dosage at the end of Part 2. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2/3 (Eltrombopag Open- Label Period) Cohort 3 All participants aged between 1 and 5 years and completing Part 2 of the study received an Open-Label treatment of eltrombopag administered as a dry powder for oral suspension in Part 2/3. Participants who received placebo in Part 2 received 24 weeks of treatment of eltrombopag up to Week 31 of the study at 1.5 mg/kg QD. Participants of East Asian ancestry received 0.8 mg/kg/day. Participants who received 7 weeks of eltrombopag treatment in Part 2 received an additional 17 weeks of treatment to complete a total of 24 weeks continuing at the same dosage at the end of Part 2. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.
Part1 (24 Week Dose-Finding Period) STARTED	5	5	5	0	0	0	0	0	0	0	0	0
Part1 (24 Week Dose-Finding Period) COMPLETED	5	5	5	0	0	0	0	0	0	0	0	0
Part1 (24 Week Dose-Finding Period) NOT COMPLETED	0	0	0	0	0	0	0	0	0	0	0	0
Part 2 (7 Week Randomized Period) STARTED	0	0	0	8	16	9	19	5	10	0	0	0
Part 2 (7 Week Randomized Period) COMPLETED	0	0	0	7	13	9	15	5	5	0	0	0
Part 2 (7 Week Randomized Period) NOT COMPLETED	0	0	0	1	3	0	4	0	5	0	0	0
Part 2/3(Eltrombopag Open-Label Period) STARTED	0	0	0	0	0	0	0	0	0	24	28	15
Part 2/3(Eltrombopag Open-Label Period) COMPLETED	0	0	0	0	0	0	0	0	0	21	24	12
Part 2/3(Eltrombopag Open-Label Period) NOT COMPLETED	0	0	0	0	0	0	0	0	0	3	4	3

Reasons for withdrawal

Reasons for withdrawal
Measure	Part 2 (Randomized Period) Cohort 1-Placebo Participants aged between 12 and 17 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.	Part 2 (Randomized Period) Cohort 1- Eltrombopag Participants aged between 12 and 17 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was 37.5 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 2-Eltrombopag Participants aged between 6 and 11 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was based on the body weight, participants with a weight of \<27 kg received 25 mg QD and participants with a weight of \>=27 kg received 50 mg QD. Participants of East Asian ancestry with a body weight of \<27 kg received 12.5 mg QD and participants with a weight of \>=27 kg received 25 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 3- Eltrombopag Participants aged between 1 to 5 years received eltrombopag administered as a dry powder for oral suspension for 7 weeks. The starting dose of eltrombopag was 1.5 mg/kg QD and the dose calculations were based on the body weight. Participants of East Asian ancestry began at 0.8 mg/kg/day. The maximum dose allowed was 2 mg/kg, unless otherwise approved by the investigator, and could not exceed 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2/3 (Eltrombopag Open-Label Period) Cohort 1 All participants aged between 12 and 17 years and completing Part 2 of the study received an Open-Label treatment of eltrombopag administered as a tablet in Part 2/3. Participants who received placebo in Part 2 received 24 weeks of treatment of eltrombopag starting at 37.5 mg QD up to Week 31 of the study. Participants who received 7 weeks of eltrombopag treatment in Part 2 received an additional 17 weeks of treatment to complete a total of 24 weeks continuing at the same dosage at the end of Part 2. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2/3 (Eltrombopag Open-Label Period) Cohort 2 All participants aged between 6 and 11 years and completing Part 2 of the study received an Open -Label treatment of eltrombopag administered as a tablet in Part 2/3. Participants with difficulty swallowing a tablet in Part 2 were administered eltrombopag as a dry powder for oral suspension in Part 2/3. Participants who received placebo in Part 2 received 24 weeks of treatment of eltrombopag based on body weight up to Week 31 of the study. Participants with a body weight of \<=27 kg received 25 mg QD and participants with a body weight of \>=27 kg QD received 50 mg QD. Participants who received 7 weeks of eltrombopag treatment in Part 2 received an additional 17 weeks of treatment to complete a total of 24 weeks continuing at the same dosage at the end of Part 2. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2/3 (Eltrombopag Open- Label Period) Cohort 3 All participants aged between 1 and 5 years and completing Part 2 of the study received an Open-Label treatment of eltrombopag administered as a dry powder for oral suspension in Part 2/3. Participants who received placebo in Part 2 received 24 weeks of treatment of eltrombopag up to Week 31 of the study at 1.5 mg/kg QD. Participants of East Asian ancestry received 0.8 mg/kg/day. Participants who received 7 weeks of eltrombopag treatment in Part 2 received an additional 17 weeks of treatment to complete a total of 24 weeks continuing at the same dosage at the end of Part 2. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.
Part 2 (7 Week Randomized Period) Protocol Violation	0	1	3	1	0	0	0
Part 2 (7 Week Randomized Period) Lost to Follow-up	0	2	0	4	0	0	0
Part 2 (7 Week Randomized Period) Withdrawal by parent/ guardian	1	0	1	0	0	0	0
Part 2/3(Eltrombopag Open-Label Period) Lack of Efficacy	0	0	0	0	0	0	1
Part 2/3(Eltrombopag Open-Label Period) Lost to Follow-up	0	0	0	0	1	0	2
Part 2/3(Eltrombopag Open-Label Period) Withdrawal by parent/guardian	0	0	0	0	1	0	0
Part 2/3(Eltrombopag Open-Label Period) Adverse Event	0	0	0	0	0	2	0
Part 2/3(Eltrombopag Open-Label Period) Physician Decision	0	0	0	0	1	0	0
Part 2/3(Eltrombopag Open-Label Period) Randomized but did not receive treatment	0	0	0	0	0	2	0

Baseline Characteristics

Efficacy and Safety Study of Eltrombopag in Pediatric Patients With Thrombocytopenia From Chronic Idiopathic Thrombocytopenic Purpura (ITP)

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Part 1 Eltrombopag Dose-Finding Period n=15 Participants Participants (par) aged between 1 and 17 years (Cohort 1 age group: 12 to 17 years, Cohort 2: 6 to 11 years and Cohort 3:1 to 5 years) received eltrombopag for 24 weeks. The starting dose for Cohort 1 was 25 mg, and par of East Asian ancestry received 12.5mg QD. For Cohort 2 starting dose was based on the body weight. Par with a bodyweight of \<27 kg received 12.5 mg QD, par with a body weight of \>=27 kg received 25 mg QD; par of East Asian ancestry with a body weight \<27 kg received 12.5 mg QD, and with a body weight of \>=27 kg received 25 mg QD. For Cohort 3, the starting dose was 0.7 mg/kg QD and 0.5 mg/kg/day for par of East Asian ancestry and the dose calculations were based on the body weight. The maximum dose allowed for all Cohorts was 75mg daily. For all par, individual dose titration was allowed based upon platelet response.	Part 2 (Randomized Period) Cohort 1-Placebo n=8 Participants Par aged between 12 and 17 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks. All par completing Part 2 of the study received an OL treatment of eltrombopag administered as a tablet in Part 2/3. Par who received placebo in Part 2 received 24 weeks of OL treatment of eltrombopag in Part 2/3 starting at 37.5 mg QD up to Week 31 of the study. The maximum dose allowed was 75 mg daily. All par enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 1- Eltrombopag n=16 Participants Par aged between 12 and 17 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was 37.5 mg QD. All par completing Part 2 of the study received an OL treatment of eltrombopag administered as a tablet in Part 2/3. Par who received 7 weeks of eltrombopag treatment in Part 2 received an additional 17 weeks of treatment to complete a total of 24 weeks continuing at the same dosage at the end of Part 2. The maximum dose allowed was 75 mg daily. All par enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 2-Placebo n=9 Participants Par aged between 6 and 11 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks. All par completing Part 2 of the study received an OL treatment of eltrombopag administered as a tablet in Part 2/3. Par with difficulty swallowing a tablet in Part 2 were administered eltrombopag as a dry powder for oral suspension in Part 2/3. Par who received placebo in Part 2 received 24 weeks of treatment of eltrombopag based on body weight up to Week 31 of the study. Par with a body weight of \<=27 kg received 25 mg QD and par with a body weight of \>=27 kg QD received 50 mg QD. The maximum dose allowed was 75 mg daily. All par enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 2-Eltrombopag n=19 Participants Par aged between 6 and 11 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was based on the body weight, par with a weight of \<27 kg received 25 mg QD and par with a weight of \>=27 kg received 50 mg QD. Par of East Asian ancestry with a body weight of \<27 kg received 12.5 mg QD and par with a weight of \>=27 kg received 25 mg QD. All par completing Part 2 of the study received an OL treatment of eltrombopag administered as a tablet in Part 2/3. Par with difficulty swallowing a tablet in Part 2 were administered eltrombopag as a dry powder for oral suspension in Part 2/3. Par who received 7 weeks of eltrombopag treatment in Part 2 received an additional 17 weeks of treatment to complete a total of 24 weeks continuing at the same dosage at the end of Part 2. The maximum dose allowed was 75 mg daily. All par enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 3-Placebo n=5 Participants Par aged between 1 to 5 years received eltrombopag matching placebo administered as a dry powder for oral suspension QD for 7 weeks. All par completing Part 2 of the study received an OL treatment of eltrombopag administered as a dry powder for oral suspension in Part 2/3. Par who received placebo in Part 2 received 24 weeks of OL treatment of eltrombopag up to Week 31 of the study at 1.5 mg/kg QD. Par of East Asian ancestry received 0.8 mg/kg/day. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 3- Eltrombopag n=10 Participants Par aged between 1 to 5 years received eltrombopag administered as a dry powder for oral suspension for 7 weeks. The starting dose of eltrombopag was 1.5 mg/kg QD and the dose calculations were based on the body weight. Par of East Asian ancestry began at 0.8 mg/kg/day. All par completing Part 2 of the study received an OL treatment of eltrombopag administered as a dry powder for oral suspension in Part 2/3. Par who received 7 weeks of eltrombopag treatment in Part 2 received an additional 17 weeks of treatment to complete a total of 24 weeks continuing at the same dosage at the end of Part 2. The maximum dose allowed was 75 mg daily. All par enrolled in the study underwent individual dose titration based upon platelet response.	Total n=82 Participants Total of all reporting groups
Age, Continuous	9.1 Years STANDARD_DEVIATION 4.61 • n=5 Participants	14.6 Years STANDARD_DEVIATION 1.69 • n=7 Participants	13.7 Years STANDARD_DEVIATION 1.58 • n=5 Participants	8.6 Years STANDARD_DEVIATION 2.24 • n=4 Participants	8.2 Years STANDARD_DEVIATION 1.87 • n=21 Participants	3.6 Years STANDARD_DEVIATION 1.34 • n=8 Participants	3.3 Years STANDARD_DEVIATION 1.34 • n=8 Participants	9.3 Years STANDARD_DEVIATION 4.49 • n=24 Participants
Sex: Female, Male Female	8 Participants n=5 Participants	3 Participants n=7 Participants	8 Participants n=5 Participants	8 Participants n=4 Participants	14 Participants n=21 Participants	2 Participants n=8 Participants	5 Participants n=8 Participants	48 Participants n=24 Participants
Sex: Female, Male Male	7 Participants n=5 Participants	5 Participants n=7 Participants	8 Participants n=5 Participants	1 Participants n=4 Participants	5 Participants n=21 Participants	3 Participants n=8 Participants	5 Participants n=8 Participants	34 Participants n=24 Participants
Race/Ethnicity, Customized African American/African Heritage	2 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	1 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants	3 Participants n=24 Participants
Race/Ethnicity, Customized Asian - Japanese/East Asian Heritage	2 Participants n=5 Participants	1 Participants n=7 Participants	0 Participants n=5 Participants	1 Participants n=4 Participants	1 Participants n=21 Participants	0 Participants n=8 Participants	1 Participants n=8 Participants	6 Participants n=24 Participants
Race/Ethnicity, Customized White - White/Caucasian/European	9 Participants n=5 Participants	7 Participants n=7 Participants	14 Participants n=5 Participants	8 Participants n=4 Participants	17 Participants n=21 Participants	5 Participants n=8 Participants	7 Participants n=8 Participants	67 Participants n=24 Participants
Race/Ethnicity, Customized Unknown	1 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants	1 Participants n=24 Participants
Race/Ethnicity, Customized White - Arabic/North African Heritage	0 Participants n=5 Participants	0 Participants n=7 Participants	1 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	1 Participants n=8 Participants	2 Participants n=24 Participants
Race/Ethnicity, Customized Mixed Race	1 Participants n=5 Participants	0 Participants n=7 Participants	1 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	1 Participants n=8 Participants	3 Participants n=24 Participants

PRIMARY outcome

Timeframe: From Day 8 up to Day 43 of Part 2

Population: Intent-to-Treat (ITT) Population: all enrolled participants during Part 2. The ITT Population was the primary population used for assessing efficacy. Only evaluable participants were considered for analysis where participants with a Baseline platelet count \>10Gi/L was considered as evaluable.

Outcome measures

Outcome measures
Measure	Part 2 (Randomized Period) Cohort 1-Placebo n=8 Participants Participants aged between 12 and 17 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.	Part 2 (Randomized Period) Cohort 1- Eltrombopag n=16 Participants Participants aged between 12 and 17 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was 37.5 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 2-Placebo n=9 Participants Participants aged between 6 and 11 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.	Part 2 (Randomized Period) Cohort 2-Eltrombopag n=17 Participants Participants aged between 6 and 11 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was based on the body weight, participants with a weight of \<27 kg received 25 mg QD and participants with a weight of \>=27 kg received 50 mg QD. Participants of East Asian ancestry with a body weight of \<27 kg received 12.5 mg QD and participants with a weight of \>=27 kg received 25 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 3-Placebo n=5 Participants Participants aged between 1 to 5 years received eltrombopag matching placebo administered as a dry powder for oral suspension QD for 7 weeks.	Part 2 (Randomized Period) Cohort 3- Eltrombopag n=10 Participants Participants aged between 1 to 5 years received eltrombopag administered as a dry powder for oral suspension for 7 weeks. The starting dose of eltrombopag was 1.5 mg/kg QD and the dose calculations were based on the body weight. Participants of East Asian ancestry began at 0.8 mg/kg/day. The maximum dose allowed was 2 mg/kg, unless otherwise approved by the investigator, and could not exceed 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.
Percentage of Participants Achieving a Platelet Count >=50 Giga Cells Per Liter (Gi/L) at Least Once, Between Day 8 and Day 43 (Weeks 1 to 6) of the Randomized Period of the Study (Part 2)	0 Percentage of Participants	62.5 Percentage of Participants	33.3 Percentage of Participants	63.2 Percentage of Participants	80.0 Percentage of Participants	60.0 Percentage of Participants

SECONDARY outcome

Timeframe: Between Day 15 and Day 43 of Part 2

Population: Intent-to-Treat (ITT) Population, only those participants enrolled in Part 2 of this study were analyzed.

Sustained platelet response between the treatment groups was assessed by determining the number of participants who achieved a platelet count \>=50 Gi/L during treatment with eltrombopag in \>= 60% of assessments between Day 15 and Day 43 in the absence of rescue treatment were reported here.

Outcome measures

Outcome measures
Measure	Part 2 (Randomized Period) Cohort 1-Placebo n=22 Participants Participants aged between 12 and 17 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.	Part 2 (Randomized Period) Cohort 1- Eltrombopag n=45 Participants Participants aged between 12 and 17 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was 37.5 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 2-Placebo Participants aged between 6 and 11 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.	Part 2 (Randomized Period) Cohort 2-Eltrombopag Participants aged between 6 and 11 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was based on the body weight, participants with a weight of \<27 kg received 25 mg QD and participants with a weight of \>=27 kg received 50 mg QD. Participants of East Asian ancestry with a body weight of \<27 kg received 12.5 mg QD and participants with a weight of \>=27 kg received 25 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 3-Placebo Participants aged between 1 to 5 years received eltrombopag matching placebo administered as a dry powder for oral suspension QD for 7 weeks.	Part 2 (Randomized Period) Cohort 3- Eltrombopag Participants aged between 1 to 5 years received eltrombopag administered as a dry powder for oral suspension for 7 weeks. The starting dose of eltrombopag was 1.5 mg/kg QD and the dose calculations were based on the body weight. Participants of East Asian ancestry began at 0.8 mg/kg/day. The maximum dose allowed was 2 mg/kg, unless otherwise approved by the investigator, and could not exceed 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.
Percentage of Participants Achieving Platelet Counts >=50Gi/L During Treatment With Eltrombopag in >= 60% of Assessments Between Day 15 and Day 43 (Weeks 2 Through 6) of the Randomized Treatment Period (Part 2)	0 Percentage of Participants	35.6 Percentage of Participants	—	—	—	—

SECONDARY outcome

Timeframe: Baseline and Day 43 of Part 2

Population: ITT Population. Only participants during Part 2 with a value at baseline and post-baseline were considered for analysis

The weighted mean platelet count is defined as the area under the platelet-time curve divided by the duration of the treatment (12 weeks). Based on the Analysis of Covariance (ANCOVA) model, the weighted mean platelet count is the sum of the Baseline count plus the age cohort plus the treatment. Baseline was defined as the platelet count taken on Day 1 or within 48 hours prior to the first dose of treatment.

Outcome measures

Outcome measures
Measure	Part 2 (Randomized Period) Cohort 1-Placebo n=21 Participants Participants aged between 12 and 17 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.	Part 2 (Randomized Period) Cohort 1- Eltrombopag n=43 Participants Participants aged between 12 and 17 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was 37.5 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 2-Placebo Participants aged between 6 and 11 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.	Part 2 (Randomized Period) Cohort 2-Eltrombopag Participants aged between 6 and 11 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was based on the body weight, participants with a weight of \<27 kg received 25 mg QD and participants with a weight of \>=27 kg received 50 mg QD. Participants of East Asian ancestry with a body weight of \<27 kg received 12.5 mg QD and participants with a weight of \>=27 kg received 25 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 3-Placebo Participants aged between 1 to 5 years received eltrombopag matching placebo administered as a dry powder for oral suspension QD for 7 weeks.	Part 2 (Randomized Period) Cohort 3- Eltrombopag Participants aged between 1 to 5 years received eltrombopag administered as a dry powder for oral suspension for 7 weeks. The starting dose of eltrombopag was 1.5 mg/kg QD and the dose calculations were based on the body weight. Participants of East Asian ancestry began at 0.8 mg/kg/day. The maximum dose allowed was 2 mg/kg, unless otherwise approved by the investigator, and could not exceed 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.
Weighted Mean Platelet Count Baseline	12.2 Gi/L Standard Deviation 8.59	15.5 Gi/L Standard Deviation 8.03	—	—	—	—
Weighted Mean Platelet Count Day 43	30.5 Gi/L Standard Deviation 24.98	68 Gi/L Standard Deviation 56.78	—	—	—	—

SECONDARY outcome

Timeframe: From Day 1 of treatment up to Week 24 of Part 1

Population: ITT Population only those participants enrolled during Part 1 were analyzed.

The percentage of participants achieving platelet counts \>=50Gi/L at least once at any time during the 24 weeks of eltrombopag treatment were reported.

Outcome measures

Outcome measures
Measure	Part 2 (Randomized Period) Cohort 1-Placebo n=5 Participants Participants aged between 12 and 17 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.	Part 2 (Randomized Period) Cohort 1- Eltrombopag n=5 Participants Participants aged between 12 and 17 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was 37.5 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 2-Placebo n=5 Participants Participants aged between 6 and 11 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.	Part 2 (Randomized Period) Cohort 2-Eltrombopag Participants aged between 6 and 11 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was based on the body weight, participants with a weight of \<27 kg received 25 mg QD and participants with a weight of \>=27 kg received 50 mg QD. Participants of East Asian ancestry with a body weight of \<27 kg received 12.5 mg QD and participants with a weight of \>=27 kg received 25 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 3-Placebo Participants aged between 1 to 5 years received eltrombopag matching placebo administered as a dry powder for oral suspension QD for 7 weeks.	Part 2 (Randomized Period) Cohort 3- Eltrombopag Participants aged between 1 to 5 years received eltrombopag administered as a dry powder for oral suspension for 7 weeks. The starting dose of eltrombopag was 1.5 mg/kg QD and the dose calculations were based on the body weight. Participants of East Asian ancestry began at 0.8 mg/kg/day. The maximum dose allowed was 2 mg/kg, unless otherwise approved by the investigator, and could not exceed 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.
Percentage of Participants Achieving Platelet Counts >=50Gi/L at Any Time During the 24 Weeks of Eltrombopag Dosing During Part 1.	80 Percentage of Participants	80 Percentage of Participants	60 Percentage of Participants	—	—	—

SECONDARY outcome

Timeframe: Part 2/3 up to Study Week 31

Population: ITT Population. Only evaluable participants were included for this analysis, where participants with a baseline platelet count \>10 Gi/L was considered as evaluable.

The percentage of participants achieving platelet counts \>=50Gi/L at least once at any time during the 24 weeks of eltrombopag treatment during Part 2/3 of the study were reported. Participants randmoized to receive eltrombopag for 7 weeks in Part 2 continued receiving eltrombopag for an additional 17 weeks in Part 2/3 (for a total of 24 weeks of treatment) up to Study Week 24. Participants randomized to receive placebo for 7 weeks in Part 2, received 24 weeks of eltrombopag in Part 2/3 (for a total of 24 weeks of treatment) up to Study Week 31.

Outcome measures

Outcome measures
Measure	Part 2 (Randomized Period) Cohort 1-Placebo n=24 Participants Participants aged between 12 and 17 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.	Part 2 (Randomized Period) Cohort 1- Eltrombopag n=26 Participants Participants aged between 12 and 17 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was 37.5 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 2-Placebo n=15 Participants Participants aged between 6 and 11 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.	Part 2 (Randomized Period) Cohort 2-Eltrombopag Participants aged between 6 and 11 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was based on the body weight, participants with a weight of \<27 kg received 25 mg QD and participants with a weight of \>=27 kg received 50 mg QD. Participants of East Asian ancestry with a body weight of \<27 kg received 12.5 mg QD and participants with a weight of \>=27 kg received 25 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 3-Placebo Participants aged between 1 to 5 years received eltrombopag matching placebo administered as a dry powder for oral suspension QD for 7 weeks.	Part 2 (Randomized Period) Cohort 3- Eltrombopag Participants aged between 1 to 5 years received eltrombopag administered as a dry powder for oral suspension for 7 weeks. The starting dose of eltrombopag was 1.5 mg/kg QD and the dose calculations were based on the body weight. Participants of East Asian ancestry began at 0.8 mg/kg/day. The maximum dose allowed was 2 mg/kg, unless otherwise approved by the investigator, and could not exceed 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.
Percentage of Participants Achieving Platelet Counts >=50 Gi/L at Any Time During the 31 Weeks of Eltrombopag Treatment During Part 2/ 3.	75.0 Percentage of Participants	82.1 Percentage of Participants	86.7 Percentage of Participants	—	—	—

SECONDARY outcome

Timeframe: From Day 1 of treatment up to Study Week 31

Population: Pharmacokinetic (PK) population. All subjects who had received at least one dose of the investigational product and provided a PK sample were included in this analysis.

The area under the concentration-time curve over the dosing interval (AUC0-t) data was collected to estimate primary model-based PK parameters. PK samples were collected within 3 hours prior to dosing and 2, 4, 6, 8 and 24 hours after dosing. Doses were normalized to 50mg for comparison. PK samples were collected at each on-treatment visit during Part 1, Part 2, and Part 2/3. The concentration data were pooled across visits to identify population PK and variability parameter estimates and covariate effects. AUC(0-t) is defined as the area under the concentration-time curve over the dosing interval. From the final model, a single value of AUC(0-t) was estimated for each subject, and geometric mean (95% CI) values are presented for each cohort for a 50mg dose.

Outcome measures

Outcome measures
Measure	Part 2 (Randomized Period) Cohort 1-Placebo n=29 Participants Participants aged between 12 and 17 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.	Part 2 (Randomized Period) Cohort 1- Eltrombopag n=30 Participants Participants aged between 12 and 17 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was 37.5 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 2-Placebo n=19 Participants Participants aged between 6 and 11 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.	Part 2 (Randomized Period) Cohort 2-Eltrombopag Participants aged between 6 and 11 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was based on the body weight, participants with a weight of \<27 kg received 25 mg QD and participants with a weight of \>=27 kg received 50 mg QD. Participants of East Asian ancestry with a body weight of \<27 kg received 12.5 mg QD and participants with a weight of \>=27 kg received 25 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 3-Placebo Participants aged between 1 to 5 years received eltrombopag matching placebo administered as a dry powder for oral suspension QD for 7 weeks.	Part 2 (Randomized Period) Cohort 3- Eltrombopag Participants aged between 1 to 5 years received eltrombopag administered as a dry powder for oral suspension for 7 weeks. The starting dose of eltrombopag was 1.5 mg/kg QD and the dose calculations were based on the body weight. Participants of East Asian ancestry began at 0.8 mg/kg/day. The maximum dose allowed was 2 mg/kg, unless otherwise approved by the investigator, and could not exceed 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.
Population Pharmacokinetic (PK) Assessment for Eltrombopag for AUC(0-t) During Part 1, 2, and 2/3.	101 Microgramhour per milliliter (ugh/mL) Interval 87.1 to 117.0	132 Microgramhour per milliliter (ugh/mL) Interval 114.0 to 152.0	142 Microgramhour per milliliter (ugh/mL) Interval 117.0 to 173.0	—	—	—

SECONDARY outcome

Timeframe: From Day 1 of treatment up to Study Week 31

Population: Pharmacokinetic (PK) population. All subjects who had received at least one dose of the investigational product and provided a PK sample were included in this analysis.

The maximum observed concentration (Cmax) and the concentration at the end of the dosing interval (Ct) data were collected to estimate primary model-based PK parameters. PK samples were collected within 3 hours prior to dosing and 2, 4, 6, 8 and 24 hours after dosing. Doses were normalized to 50mg for comparison. PK samples were collected at each on-treatment visit during Part 1, Part 2, and Part 2/3. The concentration data were pooled across visits to identify population PK and variability parameter estimates and covariate effects. From the final model, a single value of Cmax and Ct were estimated for each subject, and geometric mean (95% CI) values are presented for each cohort for a 50mg dose.

Outcome measures

Outcome measures
Measure	Part 2 (Randomized Period) Cohort 1-Placebo n=29 Participants Participants aged between 12 and 17 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.	Part 2 (Randomized Period) Cohort 1- Eltrombopag n=30 Participants Participants aged between 12 and 17 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was 37.5 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 2-Placebo n=19 Participants Participants aged between 6 and 11 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.	Part 2 (Randomized Period) Cohort 2-Eltrombopag Participants aged between 6 and 11 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was based on the body weight, participants with a weight of \<27 kg received 25 mg QD and participants with a weight of \>=27 kg received 50 mg QD. Participants of East Asian ancestry with a body weight of \<27 kg received 12.5 mg QD and participants with a weight of \>=27 kg received 25 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 3-Placebo Participants aged between 1 to 5 years received eltrombopag matching placebo administered as a dry powder for oral suspension QD for 7 weeks.	Part 2 (Randomized Period) Cohort 3- Eltrombopag Participants aged between 1 to 5 years received eltrombopag administered as a dry powder for oral suspension for 7 weeks. The starting dose of eltrombopag was 1.5 mg/kg QD and the dose calculations were based on the body weight. Participants of East Asian ancestry began at 0.8 mg/kg/day. The maximum dose allowed was 2 mg/kg, unless otherwise approved by the investigator, and could not exceed 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.
Population Pharmacokinetic (PK) Assessments for Eltrombopag for Cmax and Ct During Part 1, 2, and 2/3. Cmax	6.65 micrograms per milliliter (ug/mL) Interval 5.87 to 7.53	9.19 micrograms per milliliter (ug/mL) Interval 8.18 to 10.3	10.7 micrograms per milliliter (ug/mL) Interval 9.24 to 12.5	—	—	—
Population Pharmacokinetic (PK) Assessments for Eltrombopag for Cmax and Ct During Part 1, 2, and 2/3. Ct	2.42 micrograms per milliliter (ug/mL) Interval 1.97 to 2.98	2.95 micrograms per milliliter (ug/mL) Interval 2.41 to 3.6	2.91 micrograms per milliliter (ug/mL) Interval 2.14 to 3.96	—	—	—

SECONDARY outcome

Timeframe: From Day 1 of treatment up to Study Week 31

Population: Pharmacokinetic (PK) population. All subjects who had received at least one dose of the investigational product and provided a PK sample were included in this analysis.

The time to maximum concentration (tmax) was collected to estimate primary model-based PK parameters. PK samples were collected within 3 hours prior to dosing and 2, 4, 6, 8 and 24 hours after dosing. PK samples were collected at each on-treatment visit during Part 1, Part 2, and Part 2/3. The concentration data were pooled across visits to identify population PK and variability parameter estimates and covariate effects. From the final model, a single value of tmax was estimated for each subject, and geometric mean (95% CI) values are presented for each cohort for a 50mg dose.

Outcome measures

Outcome measures
Measure	Part 2 (Randomized Period) Cohort 1-Placebo n=29 Participants Participants aged between 12 and 17 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.	Part 2 (Randomized Period) Cohort 1- Eltrombopag n=30 Participants Participants aged between 12 and 17 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was 37.5 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 2-Placebo n=19 Participants Participants aged between 6 and 11 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.	Part 2 (Randomized Period) Cohort 2-Eltrombopag Participants aged between 6 and 11 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was based on the body weight, participants with a weight of \<27 kg received 25 mg QD and participants with a weight of \>=27 kg received 50 mg QD. Participants of East Asian ancestry with a body weight of \<27 kg received 12.5 mg QD and participants with a weight of \>=27 kg received 25 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 3-Placebo Participants aged between 1 to 5 years received eltrombopag matching placebo administered as a dry powder for oral suspension QD for 7 weeks.	Part 2 (Randomized Period) Cohort 3- Eltrombopag Participants aged between 1 to 5 years received eltrombopag administered as a dry powder for oral suspension for 7 weeks. The starting dose of eltrombopag was 1.5 mg/kg QD and the dose calculations were based on the body weight. Participants of East Asian ancestry began at 0.8 mg/kg/day. The maximum dose allowed was 2 mg/kg, unless otherwise approved by the investigator, and could not exceed 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.
Population Pharmacokinetic (PK) Assessments for Eltrombopag for Tmax During Part 1, 2, and 2/3	4.0 hour (hr) Interval 2.0 to 6.0	4.0 hour (hr) Interval 2.0 to 6.0	2.0 hour (hr) Interval 2.0 to 4.0	—	—	—

SECONDARY outcome

Timeframe: From Day 1 of treatment up to Study Week 31

Population: Pharmacokinetic (PK) population. All subjects who had received at least one dose of the investigational product and provided a PK sample were included in this analysis.

The apparent plasma clearance following oral dosing of eltrombopag (CL/F) was collected to estimate primary model-based PK parameters. PK samples were collected within 3 hours prior to dosing and 2, 4, 6, 8 and 24 hours after dosing. PK samples were collected at each on-treatment visit during Part 1, Part 2, and Part 2/3. The concentration data were pooled across visits to identify population PK and variability parameter estimates and covariate effects. From the final model, a single value of CL/F was estimated for each subject, and geometric mean (95% CI) values are presented for each cohort for a 50mg dose.

Outcome measures

Outcome measures
Measure	Part 2 (Randomized Period) Cohort 1-Placebo n=29 Participants Participants aged between 12 and 17 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.	Part 2 (Randomized Period) Cohort 1- Eltrombopag n=30 Participants Participants aged between 12 and 17 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was 37.5 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 2-Placebo n=19 Participants Participants aged between 6 and 11 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.	Part 2 (Randomized Period) Cohort 2-Eltrombopag Participants aged between 6 and 11 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was based on the body weight, participants with a weight of \<27 kg received 25 mg QD and participants with a weight of \>=27 kg received 50 mg QD. Participants of East Asian ancestry with a body weight of \<27 kg received 12.5 mg QD and participants with a weight of \>=27 kg received 25 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 3-Placebo Participants aged between 1 to 5 years received eltrombopag matching placebo administered as a dry powder for oral suspension QD for 7 weeks.	Part 2 (Randomized Period) Cohort 3- Eltrombopag Participants aged between 1 to 5 years received eltrombopag administered as a dry powder for oral suspension for 7 weeks. The starting dose of eltrombopag was 1.5 mg/kg QD and the dose calculations were based on the body weight. Participants of East Asian ancestry began at 0.8 mg/kg/day. The maximum dose allowed was 2 mg/kg, unless otherwise approved by the investigator, and could not exceed 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.
Population Pharmacokinetic (PK) Assessments for Eltrombopag for CL/F During Part 1, 2, and 2/3	0.50 liter per hour (L/hr) Interval 0.43 to 0.57	0.38 liter per hour (L/hr) Interval 0.33 to 0.44	0.25 liter per hour (L/hr) Interval 0.2 to 0.3	—	—	—

SECONDARY outcome

Timeframe: From Baseline through Week 7 of Part 2

Population: ITT Population, only those participants enrolled in Part 2 were analyzed. The number of participants used to compute the summary statistics reflect the ITT poplation through out the analyses during Part 2.

The maximum duration for which a participant continuously maintained a platelet count \>=50 Gi/L in the absence of rescue treatment was calculated and summarized during the 24 weeks of eltrombopag treatment in Part 2. Participants with non-weekly assessments were assumed to have maintained a positive response for each week between two assessments that had positive responses. If a particpant achieved a positive response at an assessment and then achieved a negative response at the next assessment, then it was assumed that the participant had achieved a positive response for one day. Excludes periods from initiation of rescue medication until platelet count falls to below 50Gi/L, irrespective of platelet count

Outcome measures

Outcome measures
Measure	Part 2 (Randomized Period) Cohort 1-Placebo n=8 Participants Participants aged between 12 and 17 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.	Part 2 (Randomized Period) Cohort 1- Eltrombopag n=16 Participants Participants aged between 12 and 17 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was 37.5 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 2-Placebo n=9 Participants Participants aged between 6 and 11 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.	Part 2 (Randomized Period) Cohort 2-Eltrombopag n=19 Participants Participants aged between 6 and 11 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was based on the body weight, participants with a weight of \<27 kg received 25 mg QD and participants with a weight of \>=27 kg received 50 mg QD. Participants of East Asian ancestry with a body weight of \<27 kg received 12.5 mg QD and participants with a weight of \>=27 kg received 25 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 3-Placebo n=5 Participants Participants aged between 1 to 5 years received eltrombopag matching placebo administered as a dry powder for oral suspension QD for 7 weeks.	Part 2 (Randomized Period) Cohort 3- Eltrombopag n=10 Participants Participants aged between 1 to 5 years received eltrombopag administered as a dry powder for oral suspension for 7 weeks. The starting dose of eltrombopag was 1.5 mg/kg QD and the dose calculations were based on the body weight. Participants of East Asian ancestry began at 0.8 mg/kg/day. The maximum dose allowed was 2 mg/kg, unless otherwise approved by the investigator, and could not exceed 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.
Maximum Duration for Which a Participant Continuously Maintained a Platelet Count of >=50 Gi/L During the 7 Weeks of Eltrombopag Treatment in Part 2	0.0 Weeks Interval 0.0 to 0.0	1.0 Weeks Interval 0.0 to 5.0	0.0 Weeks Interval 0.0 to 2.0	2.0 Weeks Interval 0.0 to 6.0	1.0 Weeks Interval 0.0 to 2.0	1.0 Weeks Interval 0.0 to 6.0

SECONDARY outcome

Timeframe: From Baseline up to Study Week 31

Population: ITT Population only those participants enrolled in Part 2/3 were analyzed. The number of participants used to compute the summary statistics reflect the ITT poplation through out the analyses during Part 2/3.

The maximum duration for which a participant continuously maintained a platelet count \>=50 Gi/L in the absence of rescue treatment was calculated and summarized during the 24 weeks of eltrombopag treatment in Part 2/3. Participants with non-weekly assessments were assumed to have maintained a positive response for each week between two assessments that had positive responses. If a particpant achieved a positive response at an assessment and then achieved a negative response at the next assessment, then it was assumed that the participant had achieved a positive response for one day. Participants randmoized to receive eltrombopag for 7 weeks in Part 2 continued receiving eltrombopag for an additional 17 weeks in Part 2/3 (for a total of 24 weeks of treatment) up to Study Week 24. Participants randomized to receive placebo for 7 weeks in Part 2, received 24 weeks of eltrombopag in Part 2/3 (for a total of 24 weeks of treatment) up to Study Week 31.

Outcome measures

Outcome measures
Measure	Part 2 (Randomized Period) Cohort 1-Placebo n=24 Participants Participants aged between 12 and 17 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.	Part 2 (Randomized Period) Cohort 1- Eltrombopag n=28 Participants Participants aged between 12 and 17 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was 37.5 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 2-Placebo n=15 Participants Participants aged between 6 and 11 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.	Part 2 (Randomized Period) Cohort 2-Eltrombopag Participants aged between 6 and 11 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was based on the body weight, participants with a weight of \<27 kg received 25 mg QD and participants with a weight of \>=27 kg received 50 mg QD. Participants of East Asian ancestry with a body weight of \<27 kg received 12.5 mg QD and participants with a weight of \>=27 kg received 25 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 3-Placebo Participants aged between 1 to 5 years received eltrombopag matching placebo administered as a dry powder for oral suspension QD for 7 weeks.	Part 2 (Randomized Period) Cohort 3- Eltrombopag Participants aged between 1 to 5 years received eltrombopag administered as a dry powder for oral suspension for 7 weeks. The starting dose of eltrombopag was 1.5 mg/kg QD and the dose calculations were based on the body weight. Participants of East Asian ancestry began at 0.8 mg/kg/day. The maximum dose allowed was 2 mg/kg, unless otherwise approved by the investigator, and could not exceed 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.
Maximum Duration for Which a Participant Continuously Maintained a Platelet Count of >=50 Gi/L During the 24 Weeks of Eltrombopag Treatment in Part 2/ 3	2.0 Weeks Interval 0.0 to 23.0	8.0 Weeks Interval 0.0 to 24.0	4.0 Weeks Interval 0.0 to 24.0	—	—	—

SECONDARY outcome

Timeframe: From Baseline up to Week 24+ 1 day of Part 1

Population: ITT Population, only those participants enrolled during Part 1 were analyzed.

The participants who discontinued (dis) or had a sustained reduction (red) of a Baseline (BL) ITP medication for at least one day during the period of Day 1 of Part 1 to the last dose of study medication +1 day are reported. The denominator is the number of subjects taking an ITP medication at baseline. For participants in Part 1, Baseline is defined as Day 1 of Part 1. A sustained reduction is defined as reduction for 4 weeks or more. An attempted red or dis is a decrease in the dose or frequency from the BL dose or frequency of an ITP medication for at least one day during the period Part 1 Day 1 to the last dose of study medication + 1 day.

Outcome measures

Outcome measures
Measure	Part 2 (Randomized Period) Cohort 1-Placebo n=5 Participants Participants aged between 12 and 17 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.	Part 2 (Randomized Period) Cohort 1- Eltrombopag n=5 Participants Participants aged between 12 and 17 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was 37.5 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 2-Placebo n=5 Participants Participants aged between 6 and 11 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.	Part 2 (Randomized Period) Cohort 2-Eltrombopag Participants aged between 6 and 11 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was based on the body weight, participants with a weight of \<27 kg received 25 mg QD and participants with a weight of \>=27 kg received 50 mg QD. Participants of East Asian ancestry with a body weight of \<27 kg received 12.5 mg QD and participants with a weight of \>=27 kg received 25 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 3-Placebo Participants aged between 1 to 5 years received eltrombopag matching placebo administered as a dry powder for oral suspension QD for 7 weeks.	Part 2 (Randomized Period) Cohort 3- Eltrombopag Participants aged between 1 to 5 years received eltrombopag administered as a dry powder for oral suspension for 7 weeks. The starting dose of eltrombopag was 1.5 mg/kg QD and the dose calculations were based on the body weight. Participants of East Asian ancestry began at 0.8 mg/kg/day. The maximum dose allowed was 2 mg/kg, unless otherwise approved by the investigator, and could not exceed 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.
Percentage of Participants Who Reduced or Discontinued Baseline Concomitant Idiopathic Thrombocytopenic Purpura (ITP) Medications During the 24 Weeks of Eltrombopag Treatment During Part 1. Taking an ITP medication at BL	0 Percentage of Participants	20.0 Percentage of Participants	0 Percentage of Participants	—	—	—
Percentage of Participants Who Reduced or Discontinued Baseline Concomitant Idiopathic Thrombocytopenic Purpura (ITP) Medications During the 24 Weeks of Eltrombopag Treatment During Part 1. Attempted red or dis	0 Percentage of Participants	100.0 Percentage of Participants	0 Percentage of Participants	—	—	—
Percentage of Participants Who Reduced or Discontinued Baseline Concomitant Idiopathic Thrombocytopenic Purpura (ITP) Medications During the 24 Weeks of Eltrombopag Treatment During Part 1. Permanent red or dis of all BL ITP mediation	0 Percentage of Participants	100.0 Percentage of Participants	0 Percentage of Participants	—	—	—
Percentage of Participants Who Reduced or Discontinued Baseline Concomitant Idiopathic Thrombocytopenic Purpura (ITP) Medications During the 24 Weeks of Eltrombopag Treatment During Part 1. Permanent red or dis at least 1 BL ITP medcation	0 Percentage of Participants	100.0 Percentage of Participants	0 Percentage of Participants	—	—	—

SECONDARY outcome

Timeframe: From Baseline to the end of treatment up to Week 31 + 1 day of Part 2/3

Population: ITT Population, only those participants enrolled during Part 2/3 were analyzed.

Participants who discontinued (dis) or had a sustained reduction (red) of a Baseline (BL) ITP medication for at least one day during the period of Day 1 of Part 2/3 to the last dose of study medication +1 day are reported. The denominator is the number of subjects taking an ITP medication at baseline. For participants randomized to placebo in Part 2, BL is defined as Week 7 of Part 2. For participants randomized to eltrombopag in Part 2, BL is defined as Day 1 of Part 2. A sustained reduction is defined as reduction for 4 weeks or more. An attempted reduction or discontinuation is a decrease in the dose or frequency from the BL dose or frequency of an ITP medication for at least one day during the period Part 2/3 Day 1 to the last dose of study medication + 1 day.

Outcome measures

Outcome measures
Measure	Part 2 (Randomized Period) Cohort 1-Placebo n=24 Participants Participants aged between 12 and 17 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.	Part 2 (Randomized Period) Cohort 1- Eltrombopag n=28 Participants Participants aged between 12 and 17 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was 37.5 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 2-Placebo n=15 Participants Participants aged between 6 and 11 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.	Part 2 (Randomized Period) Cohort 2-Eltrombopag Participants aged between 6 and 11 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was based on the body weight, participants with a weight of \<27 kg received 25 mg QD and participants with a weight of \>=27 kg received 50 mg QD. Participants of East Asian ancestry with a body weight of \<27 kg received 12.5 mg QD and participants with a weight of \>=27 kg received 25 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 3-Placebo Participants aged between 1 to 5 years received eltrombopag matching placebo administered as a dry powder for oral suspension QD for 7 weeks.	Part 2 (Randomized Period) Cohort 3- Eltrombopag Participants aged between 1 to 5 years received eltrombopag administered as a dry powder for oral suspension for 7 weeks. The starting dose of eltrombopag was 1.5 mg/kg QD and the dose calculations were based on the body weight. Participants of East Asian ancestry began at 0.8 mg/kg/day. The maximum dose allowed was 2 mg/kg, unless otherwise approved by the investigator, and could not exceed 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.
Percentage of Participants Who Reduced or Discontinued Baseline Concomitant ITP Medications During the 24 Weeks of Eltrombopag Treatment During Part 2/ 3 Taking an ITP medication at BL	25.0 Percentage of Participants	17.9 Percentage of Participants	13.3 Percentage of Participants	—	—	—
Percentage of Participants Who Reduced or Discontinued Baseline Concomitant ITP Medications During the 24 Weeks of Eltrombopag Treatment During Part 2/ 3 Attempted red or dis	66.7 Percentage of Participants	20.0 Percentage of Participants	100.0 Percentage of Participants	—	—	—
Percentage of Participants Who Reduced or Discontinued Baseline Concomitant ITP Medications During the 24 Weeks of Eltrombopag Treatment During Part 2/ 3 Permanent (perm) dis of all BL ITP medication(med)	16.7 Percentage of Participants	20.0 Percentage of Participants	50.0 Percentage of Participants	—	—	—
Percentage of Participants Who Reduced or Discontinued Baseline Concomitant ITP Medications During the 24 Weeks of Eltrombopag Treatment During Part 2/ 3 Perm dis at least 1 BL ITP med	33.3 Percentage of Participants	20.0 Percentage of Participants	50.0 Percentage of Participants	—	—	—
Percentage of Participants Who Reduced or Discontinued Baseline Concomitant ITP Medications During the 24 Weeks of Eltrombopag Treatment During Part 2/ 3 Perm dis all BL ITP med taken prior to Part 2/3	0 Percentage of Participants	40.0 Percentage of Participants	0 Percentage of Participants	—	—	—

SECONDARY outcome

Timeframe: From Baseline to the end of treatment up to Week 31 + 1 day of Part2/3

Population: ITT Population, only those participants enrolled during Part 2/3 were analyzed.

Rescue treatment was defined as either a new immune (idiopathic) thrombocytopenic purpura (ITP) medication, an increase in the dose of a concomitant ITP medication from Baseline, a platelet transfusion, or a splenectomy. For particpants randomized to placebo in Part 2, Baseline is defined as Week 7 of Part 2. For participants randomized to eltrombopag in Part 2, Baseline is defined as Day 1 of Part 2. Participants randmoized to receive eltrombopag for 7 weeks in Part 2 continued receiving eltrombopag for an additional 17 weeks in Part 2/3 (for a total of 24 weeks of treatment) up to Study Week 24. Participants randomized to receive placebo for 7 weeks in Part 2, received 24 weeks of eltrombopag in Part 2/3 (for a total of 24 weeks of treatment) up to Study Week 31.

Outcome measures

Outcome measures
Measure	Part 2 (Randomized Period) Cohort 1-Placebo n=24 Participants Participants aged between 12 and 17 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.	Part 2 (Randomized Period) Cohort 1- Eltrombopag n=28 Participants Participants aged between 12 and 17 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was 37.5 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 2-Placebo n=15 Participants Participants aged between 6 and 11 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.	Part 2 (Randomized Period) Cohort 2-Eltrombopag Participants aged between 6 and 11 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was based on the body weight, participants with a weight of \<27 kg received 25 mg QD and participants with a weight of \>=27 kg received 50 mg QD. Participants of East Asian ancestry with a body weight of \<27 kg received 12.5 mg QD and participants with a weight of \>=27 kg received 25 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 3-Placebo Participants aged between 1 to 5 years received eltrombopag matching placebo administered as a dry powder for oral suspension QD for 7 weeks.	Part 2 (Randomized Period) Cohort 3- Eltrombopag Participants aged between 1 to 5 years received eltrombopag administered as a dry powder for oral suspension for 7 weeks. The starting dose of eltrombopag was 1.5 mg/kg QD and the dose calculations were based on the body weight. Participants of East Asian ancestry began at 0.8 mg/kg/day. The maximum dose allowed was 2 mg/kg, unless otherwise approved by the investigator, and could not exceed 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.
Number of Participants Who Required a Protocol-defined Rescue Treatment During Part 2/3 New ITP Medication	8 Participants	4 Participants	4 Participants	—	—	—
Number of Participants Who Required a Protocol-defined Rescue Treatment During Part 2/3 Increase concomitant ITP medication from Baseline	1 Participants	0 Participants	0 Participants	—	—	—
Number of Participants Who Required a Protocol-defined Rescue Treatment During Part 2/3 Platelet transfusion	0 Participants	0 Participants	0 Participants	—	—	—
Number of Participants Who Required a Protocol-defined Rescue Treatment During Part 2/3 Splenectomy	0 Participants	0 Participants	0 Participants	—	—	—

SECONDARY outcome

Timeframe: Baseline, Week 6, Week 12, and Week 24 of Part 1

Population: ITT Population. Only those participants available at the specified time points were analyzed (represented by n=X,X,X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the ITT Population.

The KIT questionnaire measures the impact on the quality of life determined by the participant and the guardian by self reported outcomes at Baseline or the Screening Visit, after 6 weeks of treatment, after 12 weeks of treatment and at the end of treatment or withdrawal from the study. The KIT total score is calculated from the scores of each of the individual questions from Q1 - Q26 (excluding any answer that is 'Not applicable'). The code list used for the individual question scores is: 1 = never, 2 = seldom, 3 = sometimes, 4 = often, 5 = always and 9 = not applicable. The range of values the total score can take is 0 (worst) to 100 (best). For subjects under the age of six, the family questionnaire (parental proxy) has been used.

Outcome measures

Outcome measures
Measure	Part 2 (Randomized Period) Cohort 1-Placebo n=5 Participants Participants aged between 12 and 17 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.	Part 2 (Randomized Period) Cohort 1- Eltrombopag n=5 Participants Participants aged between 12 and 17 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was 37.5 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 2-Placebo n=5 Participants Participants aged between 6 and 11 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.	Part 2 (Randomized Period) Cohort 2-Eltrombopag Participants aged between 6 and 11 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was based on the body weight, participants with a weight of \<27 kg received 25 mg QD and participants with a weight of \>=27 kg received 50 mg QD. Participants of East Asian ancestry with a body weight of \<27 kg received 12.5 mg QD and participants with a weight of \>=27 kg received 25 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 3-Placebo Participants aged between 1 to 5 years received eltrombopag matching placebo administered as a dry powder for oral suspension QD for 7 weeks.	Part 2 (Randomized Period) Cohort 3- Eltrombopag Participants aged between 1 to 5 years received eltrombopag administered as a dry powder for oral suspension for 7 weeks. The starting dose of eltrombopag was 1.5 mg/kg QD and the dose calculations were based on the body weight. Participants of East Asian ancestry began at 0.8 mg/kg/day. The maximum dose allowed was 2 mg/kg, unless otherwise approved by the investigator, and could not exceed 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.
Kids' ITP Tool (KIT) Questionnaire Total Score at Baseline, Week 6, Week 12, and Week 24 as Assessed Using the KIT Questionnaire During the Dose Finding Period, Part 1 Baseline, n=5, 5, 5	73.18 Score on scale Standard Deviation 15.743	53.95 Score on scale Standard Deviation 16.534	74.80 Score on scale Standard Deviation 17.199	—	—	—
Kids' ITP Tool (KIT) Questionnaire Total Score at Baseline, Week 6, Week 12, and Week 24 as Assessed Using the KIT Questionnaire During the Dose Finding Period, Part 1 Week 6, n=4, 5, 5	82.84 Score on scale Standard Deviation 9.131	61.57 Score on scale Standard Deviation 13.664	71.54 Score on scale Standard Deviation 14.798	—	—	—
Kids' ITP Tool (KIT) Questionnaire Total Score at Baseline, Week 6, Week 12, and Week 24 as Assessed Using the KIT Questionnaire During the Dose Finding Period, Part 1 Week 12, n=4, 4, 4	84.14 Score on scale Standard Deviation 11.712	66.43 Score on scale Standard Deviation 12.349	65.58 Score on scale Standard Deviation 17.887	—	—	—
Kids' ITP Tool (KIT) Questionnaire Total Score at Baseline, Week 6, Week 12, and Week 24 as Assessed Using the KIT Questionnaire During the Dose Finding Period, Part 1 Week 24, n= 3, 4, 3	76.38 Score on scale Standard Deviation 20.228	82.50 Score on scale Standard Deviation 15.995	78.87 Score on scale Standard Deviation 12.056	—	—	—

SECONDARY outcome

Timeframe: Baseline and Week 6 of Part 2

Population: ITT Population. Only those participants available at the specified time points were analyzed (represented by n=X,X,X,X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the ITT Population.

The KIT questionnaire measures the impact on the quality of life determined by the participant and the guardian by self reported outcomes at Baseline or the Screening Visit, after 6 weeks of treatment or withdrawal from the study. The KIT total score is calculated from the scores of each of the individual questions from Q1 - Q26 (excluding any answer that is 'Not applicable'). The code list used for the individual question scores is: 1 = never, 2 = seldom, 3 = sometimes, 4 = often, 5 = always and 9 = not applicable. The range of values the total score can take is 0 (worst) to 100 (best). For subjects under the age of six, the family questionnaire (parental proxy) has been used.

Outcome measures

Outcome measures
Measure	Part 2 (Randomized Period) Cohort 1-Placebo n=8 Participants Participants aged between 12 and 17 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.	Part 2 (Randomized Period) Cohort 1- Eltrombopag n=16 Participants Participants aged between 12 and 17 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was 37.5 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 2-Placebo n=9 Participants Participants aged between 6 and 11 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.	Part 2 (Randomized Period) Cohort 2-Eltrombopag n=19 Participants Participants aged between 6 and 11 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was based on the body weight, participants with a weight of \<27 kg received 25 mg QD and participants with a weight of \>=27 kg received 50 mg QD. Participants of East Asian ancestry with a body weight of \<27 kg received 12.5 mg QD and participants with a weight of \>=27 kg received 25 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 3-Placebo n=5 Participants Participants aged between 1 to 5 years received eltrombopag matching placebo administered as a dry powder for oral suspension QD for 7 weeks.	Part 2 (Randomized Period) Cohort 3- Eltrombopag n=10 Participants Participants aged between 1 to 5 years received eltrombopag administered as a dry powder for oral suspension for 7 weeks. The starting dose of eltrombopag was 1.5 mg/kg QD and the dose calculations were based on the body weight. Participants of East Asian ancestry began at 0.8 mg/kg/day. The maximum dose allowed was 2 mg/kg, unless otherwise approved by the investigator, and could not exceed 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.
Kids' ITP Tool (KIT) Questionnaire Total Score at Baseline and Week 6as Assessed Using the KIT Questionnaire During the Randomized Period, Part 2 Baseline, n=6, 11, 9, 10, 2, 8	83.94 Score on scale Standard Deviation 8.674	76.84 Score on scale Standard Deviation 15.049	71.05 Score on scale Standard Deviation 19.581	66.36 Score on scale Standard Deviation 17.321	82.61 Score on scale Standard Deviation 7.686	78.23 Score on scale Standard Deviation 9.575
Kids' ITP Tool (KIT) Questionnaire Total Score at Baseline and Week 6as Assessed Using the KIT Questionnaire During the Randomized Period, Part 2 Week 6, n= 8,11,7,13, 5, 9	79.46 Score on scale Standard Deviation 10.971	79.46 Score on scale Standard Deviation 13.899	74.65 Score on scale Standard Deviation 20.968	80.16 Score on scale Standard Deviation 13.776	88.01 Score on scale Standard Deviation 3.333	80.85 Score on scale Standard Deviation 15.082

SECONDARY outcome

Timeframe: From Baseline to end of treatment up to Study Week 31

The KIT questionnaire measures the impact on the quality of life determined by the participant and the guardian by self reported outcomes at Baseline or the Screening Visit, after 6 weeks of treatment, after 12 weeks of treatment and at the end of treatment or withdrawal from the study. The KIT total score is calculated from the scores of each of the individual questions from Q1 - Q26 (excluding any answer that is 'Not applicable'). The code list used for the individual question scores is: 1=never, 2=seldom, 3=sometimes, 4=often, 5=always and 9=not applicable. The range of values the total score can take is 0 (worst) to 100 (best). For subjects under the age of six, the family questionnaire (parental proxy) has been used.

Outcome measures

Outcome measures
Measure	Part 2 (Randomized Period) Cohort 1-Placebo n=24 Participants Participants aged between 12 and 17 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.	Part 2 (Randomized Period) Cohort 1- Eltrombopag n=28 Participants Participants aged between 12 and 17 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was 37.5 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 2-Placebo n=15 Participants Participants aged between 6 and 11 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.	Part 2 (Randomized Period) Cohort 2-Eltrombopag Participants aged between 6 and 11 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was based on the body weight, participants with a weight of \<27 kg received 25 mg QD and participants with a weight of \>=27 kg received 50 mg QD. Participants of East Asian ancestry with a body weight of \<27 kg received 12.5 mg QD and participants with a weight of \>=27 kg received 25 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 3-Placebo Participants aged between 1 to 5 years received eltrombopag matching placebo administered as a dry powder for oral suspension QD for 7 weeks.	Part 2 (Randomized Period) Cohort 3- Eltrombopag Participants aged between 1 to 5 years received eltrombopag administered as a dry powder for oral suspension for 7 weeks. The starting dose of eltrombopag was 1.5 mg/kg QD and the dose calculations were based on the body weight. Participants of East Asian ancestry began at 0.8 mg/kg/day. The maximum dose allowed was 2 mg/kg, unless otherwise approved by the investigator, and could not exceed 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.
Kids' ITP Tools (KIT) Questionnaire Total Score at Baseline, Week, 6, Week 12, and End of Treatment Visit as Assessed Using the KIT Questionnaire During the Eltrombopag Open-Label Period, Part 2/3 Baseline, n=17, 18, 10	79.34 Score on scale Standard Deviation 13.315	70.59 Score on scale Standard Deviation 16.237	79.10 Score on scale Standard Deviation 9.016	—	—	—
Kids' ITP Tools (KIT) Questionnaire Total Score at Baseline, Week, 6, Week 12, and End of Treatment Visit as Assessed Using the KIT Questionnaire During the Eltrombopag Open-Label Period, Part 2/3 Week 6, n=11, 13, 9	79.46 Score on scale Standard Deviation 13.899	80.16 Score on scale Standard Deviation 13.776	80.85 Score on scale Standard Deviation 15.082	—	—	—
Kids' ITP Tools (KIT) Questionnaire Total Score at Baseline, Week, 6, Week 12, and End of Treatment Visit as Assessed Using the KIT Questionnaire During the Eltrombopag Open-Label Period, Part 2/3 Week 12, n=9, 7, 2	84.25 Score on scale Standard Deviation 7.531	76.48 Score on scale Standard Deviation 19.948	88.10 Score on scale Standard Deviation 11.166	—	—	—
Kids' ITP Tools (KIT) Questionnaire Total Score at Baseline, Week, 6, Week 12, and End of Treatment Visit as Assessed Using the KIT Questionnaire During the Eltrombopag Open-Label Period, Part 2/3 Week 24, n=17, 11, 8	82.16 Score on scale Standard Deviation 16.926	83.93 Score on scale Standard Deviation 13.327	77.93 Score on scale Standard Deviation 22.971	—	—	—

SECONDARY outcome

Timeframe: From Baseline through Week 7 of Part 2

The WHO Bleeding Scale is a measure of bleeding severity with the following grades: Grade 0 = no bleeding, Grade 1 = petechiae, Grade 2 = mild blood loss, Grade 3 = gross bleeding and Grade 4 = debilitating blood loss. The WHO grades were dichotomized into the following categories: no bleeding=Grade 0; any bleeding=Grades 1 to 4; no clinically significant bleeding=Grades 0 to 1; clinically significant bleeding=Grades 2 to 4. For participants randomized to Placebo in Part 2, Baseline defined as Week 7 of Part 2. For participants randomized to Eltrombopag in Part 2, Baseline defined as Day 1 of Part 2.

Outcome measures

Outcome measures
Measure	Part 2 (Randomized Period) Cohort 1-Placebo n=8 Participants Participants aged between 12 and 17 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.	Part 2 (Randomized Period) Cohort 1- Eltrombopag n=16 Participants Participants aged between 12 and 17 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was 37.5 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 2-Placebo n=9 Participants Participants aged between 6 and 11 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.	Part 2 (Randomized Period) Cohort 2-Eltrombopag n=19 Participants Participants aged between 6 and 11 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was based on the body weight, participants with a weight of \<27 kg received 25 mg QD and participants with a weight of \>=27 kg received 50 mg QD. Participants of East Asian ancestry with a body weight of \<27 kg received 12.5 mg QD and participants with a weight of \>=27 kg received 25 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 3-Placebo n=5 Participants Participants aged between 1 to 5 years received eltrombopag matching placebo administered as a dry powder for oral suspension QD for 7 weeks.	Part 2 (Randomized Period) Cohort 3- Eltrombopag n=10 Participants Participants aged between 1 to 5 years received eltrombopag administered as a dry powder for oral suspension for 7 weeks. The starting dose of eltrombopag was 1.5 mg/kg QD and the dose calculations were based on the body weight. Participants of East Asian ancestry began at 0.8 mg/kg/day. The maximum dose allowed was 2 mg/kg, unless otherwise approved by the investigator, and could not exceed 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2 Week 7, Grades 1-4, n=8, 16, 9, 17, 5, 9	7 Participants	5 Participants	7 Participants	5 Participants	4 Participants	4 Participants
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2 Week 7, Grades 0-1, n=8, 16, 9, 17, 5, 9	4 Participants	15 Participants	8 Participants	16 Participants	3 Participants	7 Participants
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2 Baseline, Grades 1-4, n=8, 16, 9, 19, 5, 10	6 Participants	16 Participants	7 Participants	11 Participants	5 Participants	8 Participants
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2 Baseline, Grades 0-1, n=8, 16, 9, 19, 5, 10	6 Participants	13 Participants	6 Participants	17 Participants	4 Participants	6 Participants
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2 Baseline, Grades 2-4, n=8, 16, 9, 19, 5, 10	2 Participants	3 Participants	3 Participants	2 Participants	1 Participants	4 Participants
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2 Week 1, Grades 1-4, n=8, 16, 9, 17, 5, 10	7 Participants	9 Participants	6 Participants	7 Participants	3 Participants	7 Participants
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2 Week 1, Grades 0-1, n=8, 16, 9, 17, 5, 10	3 Participants	14 Participants	6 Participants	17 Participants	5 Participants	5 Participants
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2 Week 1, Grades 2-4, n=8, 16, 9, 17, 5, 10	5 Participants	2 Participants	3 Participants	0 Participants	0 Participants	5 Participants
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2 Week 2, Grades 1-4, n=8, 16, 9, 17, 5, 10	7 Participants	11 Participants	6 Participants	6 Participants	2 Participants	5 Participants
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2 Week 2, Grades 0-1, n=8, 16, 9, 17, 5, 10	5 Participants	13 Participants	7 Participants	16 Participants	3 Participants	7 Participants
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2 Week 2, Grades 2-4, n=8, 16, 9, 17, 5, 10	3 Participants	3 Participants	2 Participants	1 Participants	2 Participants	3 Participants
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2 Week 3, Grades 1-4, n=8, 16, 9, 16, 5, 9	6 Participants	10 Participants	7 Participants	6 Participants	2 Participants	5 Participants
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2 Week 3, Grades 0-1, n=8, 16, 9, 16, 5, 9	5 Participants	14 Participants	7 Participants	14 Participants	3 Participants	7 Participants
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2 Week 3, Grades 2-4, n=8, 16, 9, 16, 5, 9	3 Participants	2 Participants	2 Participants	2 Participants	2 Participants	2 Participants
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2 Week 4, Grades 1-4, n=8, 16, 9, 17, 5, 9	6 Participants	7 Participants	7 Participants	7 Participants	2 Participants	6 Participants
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2 Week 4, Grades 0-1, n=8, 16, 9, 17, 5, 9	6 Participants	16 Participants	8 Participants	17 Participants	3 Participants	7 Participants
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2 Week 4, Grades 2-4, n=8, 16, 9, 17, 5, 9	2 Participants	0 Participants	1 Participants	0 Participants	2 Participants	2 Participants
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2 Week 5, Grades 1-4, n=8, 16, 9, 16, 5, 9	6 Participants	8 Participants	7 Participants	3 Participants	4 Participants	5 Participants
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2 Week 5, Grades 0-1, n=8, 16, 9, 16, 5, 9	4 Participants	14 Participants	8 Participants	16 Participants	4 Participants	8 Participants
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2 Week 5, Grades 2-4, n=8, 16, 9, 16, 5, 9	4 Participants	2 Participants	1 Participants	0 Participants	1 Participants	1 Participants
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2 Week 6, Grades 1-4, n=8, 16, 9, 17, 5, 9	5 Participants	2 Participants	7 Participants	4 Participants	4 Participants	4 Participants
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2 Week 6, Grades 0-1, n=8, 16, 9, 17, 5, 9	7 Participants	16 Participants	7 Participants	16 Participants	4 Participants	9 Participants
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2 Week 6, Grades 2-4, n=8, 16, 9, 17, 5, 9	1 Participants	0 Participants	2 Participants	1 Participants	1 Participants	0 Participants
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2 Week 7, Grades 2-4, n=8, 16, 9, 17, 5, 9	4 Participants	1 Participants	1 Participants	1 Participants	2 Participants	2 Participants

SECONDARY outcome

Timeframe: From Baseline of Part 2/3 through Follow-up

Outcome measures

Outcome measures
Measure	Part 2 (Randomized Period) Cohort 1-Placebo n=24 Participants Participants aged between 12 and 17 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.	Part 2 (Randomized Period) Cohort 1- Eltrombopag n=28 Participants Participants aged between 12 and 17 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was 37.5 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 2-Placebo n=15 Participants Participants aged between 6 and 11 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.	Part 2 (Randomized Period) Cohort 2-Eltrombopag Participants aged between 6 and 11 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was based on the body weight, participants with a weight of \<27 kg received 25 mg QD and participants with a weight of \>=27 kg received 50 mg QD. Participants of East Asian ancestry with a body weight of \<27 kg received 12.5 mg QD and participants with a weight of \>=27 kg received 25 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 3-Placebo Participants aged between 1 to 5 years received eltrombopag matching placebo administered as a dry powder for oral suspension QD for 7 weeks.	Part 2 (Randomized Period) Cohort 3- Eltrombopag Participants aged between 1 to 5 years received eltrombopag administered as a dry powder for oral suspension for 7 weeks. The starting dose of eltrombopag was 1.5 mg/kg QD and the dose calculations were based on the body weight. Participants of East Asian ancestry began at 0.8 mg/kg/day. The maximum dose allowed was 2 mg/kg, unless otherwise approved by the investigator, and could not exceed 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Week 5, Grades 1-4, n=24, 24, 13	11 Participants	4 Participants	9 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Week 5, Grades 0-1, n=24, 24, 13	21 Participants	24 Participants	12 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Week 5, Grades 2-4, n=24, 24, 13	3 Participants	0 Participants	1 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Week 6, Grades 1-4, n=23, 24, 12	6 Participants	6 Participants	4 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Baseline, Grades 1-4, n=24, 28, 15	23 Participants	18 Participants	12 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Baseline, Grades 0-1, n=24, 28, 15	17 Participants	25 Participants	9 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Baseline, Grades 2-4, n=24, 28, 15	7 Participants	3 Participants	6 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Week 1, Grades 1-4, n=24, 26, 15	14 Participants	13 Participants	9 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Week 1, Grades 0-1, n=24, 26, 15	20 Participants	24 Participants	9 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Week 1, Grades 2-4, n=24, 26, 15	4 Participants	2 Participants	6 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Week 2, Grades 1-4, n=24, 26, 14	15 Participants	12 Participants	8 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Week 2, Grades 0-1, n=24, 26, 14	21 Participants	23 Participants	10 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Week 2, Grades 2-4, n=24, 26, 14	3 Participants	3 Participants	4 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Week 3, Grades 1-4, n=24, 25, 14	13 Participants	9 Participants	6 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Week 3, Grades 0-1, n=24, 25, 14	21 Participants	23 Participants	12 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Week 3, Grades 2-4, n=24, 25, 14	3 Participants	2 Participants	2 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Week 4, Grades 1-4, n=24, 26, 13	10 Participants	11 Participants	8 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Week 4, Grades 0-1, n=24, 26, 13	24 Participants	26 Participants	10 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Week 4, Grades 2-4, n=24, 26, 13	0 Participants	0 Participants	3 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Week 6, Grades 0-1, n=23, 24, 12	23 Participants	22 Participants	12 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Week 6, Grades 2-4, n=23, 24, 12	0 Participants	2 Participants	0 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Week 7, Grades 1-4, n=22, 25, 14	8 Participants	7 Participants	4 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Week 7, Grades 0-1, n=22, 25, 14	20 Participants	24 Participants	12 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Week 7, Grades 2-4, n=22, 25, 14	2 Participants	1 Participants	2 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Week 8, Grades 1-4, n=19, 21, 11	10 Participants	6 Participants	5 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Week 8, Grades 0-1, n=19, 21, 11	19 Participants	19 Participants	9 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Week 8, Grades 2-4, n=19, 21, 11	0 Participants	2 Participants	2 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Week 9, Grades 1-4, n=17, 16, 12	8 Participants	5 Participants	6 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Week 9, Grades 0-1, n=17, 16, 12	13 Participants	16 Participants	10 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Week 9, Grades 2-4, n=17, 16, 12	4 Participants	0 Participants	2 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Week 10, Grades 1-4, n=16, 14, 11	5 Participants	5 Participants	7 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Week 10, Grades 0-1, n=16, 14, 11	16 Participants	12 Participants	11 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Week 10, Grades 2-4, n=16, 14, 11	0 Participants	2 Participants	0 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Week 11, Grades 1-4, n=16, 15, 12	15 Participants	5 Participants	7 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Week 11, Grades 0-1, n=16, 15, 12	16 Participants	13 Participants	10 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Week 11, Grades 2-4, n=16, 15, 12	0 Participants	2 Participants	2 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Week 12, Grades 1-4, n=19, 16, 9	6 Participants	7 Participants	4 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Week 12, Grades 0-1, n=19, 16, 9	18 Participants	14 Participants	7 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Week 12, Grades 2-4, n=19, 16, 9	1 Participants	2 Participants	2 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Week 13, Grades 1-4, n=12, 14, 10	6 Participants	5 Participants	6 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Week 13, Grades 0-1, n=12, 14, 10	12 Participants	13 Participants	10 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Week 13, Grades 2-4, n=12, 14, 10	0 Participants	1 Participants	0 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Week 14, Grades 1-4, n=15, 11, 17	3 Participants	2 Participants	3 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Week 14, Grades 0-1, n=15, 11, 17	15 Participants	11 Participants	5 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Week 14, Grades 2-4, n=15, 11, 17	0 Participants	0 Participants	2 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Week 15, Grades 1-4, n=12, 14, 6	6 Participants	3 Participants	3 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Week 15, Grades 0-1, n=12, 14, 6	10 Participants	14 Participants	5 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Week 15, Grades 2-4, n=12, 14, 6	2 Participants	0 Participants	1 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Week 16, Grades 1-4, n=17, 15, 9	7 Participants	8 Participants	4 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Week 16, Grades 0-1, n=17, 15, 9	17 Participants	14 Participants	9 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Week 16, Grades 2-4, n=17, 15, 9	0 Participants	1 Participants	0 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Week 17, Grades 1-4, n=13, 11, 5	5 Participants	3 Participants	4 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Week 17, Grades 0-1, n=13, 11, 5	13 Participants	11 Participants	5 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Week 17, Grades 2-4, n=13, 11, 5	0 Participants	0 Participants	0 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Week 18, Grades 1-4, n=16, 12 ,4	3 Participants	2 Participants	3 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Week 18, Grades 0-1, n=16, 12 ,4	16 Participants	11 Participants	4 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Week 18, Grades 2-4, n=16, 12 ,4	0 Participants	1 Participants	0 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Week 19, Grades 1-4, n=14, 15, 7	3 Participants	4 Participants	1 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Week 19, Grades 0-1, n=14, 15, 7	14 Participants	14 Participants	7 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Week 19, Grades 2-4, n=14, 15, 7	0 Participants	1 Participants	0 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Week 20, Grades 1-4, n=13, 13, 8	2 Participants	3 Participants	2 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Week 20, Grades 0-1, n=13, 13, 8	13 Participants	13 Participants	6 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Week 20, Grades 2-4, n=13, 13, 8	0 Participants	0 Participants	2 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Week 21, Grades 1-4, n=4, 10, 3	1 Participants	0 Participants	0 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Week 21, Grades 0-1, n=4, 10, 3	4 Participants	10 Participants	3 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Week 21, Grades 2-4, n=4, 10, 3	0 Participants	0 Participants	0 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Week 22, Grades 1-4, n=12,7, 5	2 Participants	2 Participants	2 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Week 22 Grades 0-1, n=12,7, 5	12 Participants	6 Participants	5 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Week 22 Grades 2-4, n=12,7, 5	0 Participants	1 Participants	0 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Week 23, Grades 1-4, n=8, 7,6	1 Participants	1 Participants	2 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Week 23, Grades 0-1, n=8, 7,6	8 Participants	7 Participants	6 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Week 23, Grades 2-4, n=8, 7,6	0 Participants	0 Participants	0 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Week 24, Grades 1-4, n=23, 24, 13	5 Participants	5 Participants	4 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Week 24, Grades 0-1, n=23, 14, 13	21 Participants	24 Participants	12 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Week 24, Grades 2-4, n=23, 14, 13	2 Participants	0 Participants	1 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Follow Up Week 1, Grades 1-4, n=8, 5, 3	5 Participants	1 Participants	3 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Follow Up Week 1, Grades 0-1, n=8, 5, 3	8 Participants	4 Participants	2 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Follow Up Week 1, Grades 2-4, n=8, 5, 3	0 Participants	1 Participants	1 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Follow Up Week 2, Grades 1-4, n=7, 7, 7	2 Participants	6 Participants	2 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Follow Up Week 2, Grades 0-1, n=7, 7, 7	7 Participants	6 Participants	6 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Follow Up Week 2, Grades 2-4, n=7, 7, 7	0 Participants	1 Participants	1 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Follow Up Week 3, Grades 1-4, n=5, 5, 5	1 Participants	2 Participants	4 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Follow Up Week 3, Grades 0-1, n=5, 5, 5	5 Participants	5 Participants	4 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Follow Up Week 3, Grades 2-4, n=5, 5, 5	0 Participants	0 Participants	1 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Follow Up Week 4, Grades 1-4, n=9, 14, 8	5 Participants	4 Participants	3 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Follow Up Week 4, Grades 0-1, n=9, 14, 8	8 Participants	13 Participants	7 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Follow Up Week 4, Grades 2-4, n=9, 14, 8	1 Participants	1 Participants	1 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Any Follow Up Visit, Grades 1, n=15, 18, 10	7 Participants	10 Participants	5 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Any Follow Up Visit, Grades 0-1, n=15, 18, 10	15 Participants	18 Participants	9 Participants	—	—	—
Number of Participants With Any Bleeding, no Clinically Significant Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 2/3 Any Follow Up Visit, Grades 2-4, n=15, 18, 10	1 Participants	3 Participants	3 Participants	—	—	—

SECONDARY outcome

Timeframe: Post-Baseline from Week 1 through Follow-up up to Study Week 35

Population: Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X,X,X,X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the Safety Population.

Clinical chemistry parameters included: aspartate amino transferase (AST, reference range \[RR\]: 0-38 International Units per Liter \[IU/L\]), alkaline phosphatase (ALP: RR: 50 - 375 IU/L), total bilirubin (RR: 3.42 - 22.23 micromoles \[umol\]/L), albumin grams \[g/L\], alanine amino transferase (ALT, RR: 5-30 IU/L), prothrombin international normalized ratio (PT INR, RR-0.9 - 1.2), activated partial thromboplastin time (APTT, RR: 24.2 - 32.9 seconds), glucose (RR: 4.107- 6.55018 millimoles \[mmol\]/L), potassium (3 - 5 mmol/L), and sodium (135 - 143 mmol/L). Baseline values were obtained at Day 1. The number of participants with the indicated clinical chemistry data outside of the reference range (with high and low) any time post-Baseline are presented. Anytime post-Baseline assesments included any scheduled and unscheduled post-Baseline assessment

Outcome measures

Outcome measures
Measure	Part 2 (Randomized Period) Cohort 1-Placebo n=15 Participants Participants aged between 12 and 17 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.	Part 2 (Randomized Period) Cohort 1- Eltrombopag n=21 Participants Participants aged between 12 and 17 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was 37.5 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 2-Placebo n=44 Participants Participants aged between 6 and 11 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.	Part 2 (Randomized Period) Cohort 2-Eltrombopag n=65 Participants Participants aged between 6 and 11 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was based on the body weight, participants with a weight of \<27 kg received 25 mg QD and participants with a weight of \>=27 kg received 50 mg QD. Participants of East Asian ancestry with a body weight of \<27 kg received 12.5 mg QD and participants with a weight of \>=27 kg received 25 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 3-Placebo Participants aged between 1 to 5 years received eltrombopag matching placebo administered as a dry powder for oral suspension QD for 7 weeks.	Part 2 (Randomized Period) Cohort 3- Eltrombopag Participants aged between 1 to 5 years received eltrombopag administered as a dry powder for oral suspension for 7 weeks. The starting dose of eltrombopag was 1.5 mg/kg QD and the dose calculations were based on the body weight. Participants of East Asian ancestry began at 0.8 mg/kg/day. The maximum dose allowed was 2 mg/kg, unless otherwise approved by the investigator, and could not exceed 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.
Number of Participants With the Indicated Clinical Chemistry Parameter Falling Outside of the Reference Range Any Time Post-Baseline During Part 1, Part 2, and Part 2/3 Potassium, high, n=15, 21, 44, 65	7 Participants	0 Participants	3 Participants	9 Participants	—	—
Number of Participants With the Indicated Clinical Chemistry Parameter Falling Outside of the Reference Range Any Time Post-Baseline During Part 1, Part 2, and Part 2/3 Potassium, low, n=15, 21, 44, 65,	3 Participants	4 Participants	8 Participants	14 Participants	—	—
Number of Participants With the Indicated Clinical Chemistry Parameter Falling Outside of the Reference Range Any Time Post-Baseline During Part 1, Part 2, and Part 2/3 Sodium, high, n=15, 21, 44, 65	2 Participants	1 Participants	2 Participants	6 Participants	—	—
Number of Participants With the Indicated Clinical Chemistry Parameter Falling Outside of the Reference Range Any Time Post-Baseline During Part 1, Part 2, and Part 2/3 Sodium, low, n=15, 21, 44, 65	2 Participants	1 Participants	4 Participants	9 Participants	—	—
Number of Participants With the Indicated Clinical Chemistry Parameter Falling Outside of the Reference Range Any Time Post-Baseline During Part 1, Part 2, and Part 2/3 AST high, n=15, 21, 44, 65	5 Participants	4 Participants	7 Participants	17 Participants	—	—
Number of Participants With the Indicated Clinical Chemistry Parameter Falling Outside of the Reference Range Any Time Post-Baseline During Part 1, Part 2, and Part 2/3 AST low, n=15, 21, 44, 65	1 Participants	1 Participants	3 Participants	7 Participants	—	—
Number of Participants With the Indicated Clinical Chemistry Parameter Falling Outside of the Reference Range Any Time Post-Baseline During Part 1, Part 2, and Part 2/3 ALT, high, n= 15, 21, 44, 65	2 Participants	3 Participants	3 Participants	14 Participants	—	—
Number of Participants With the Indicated Clinical Chemistry Parameter Falling Outside of the Reference Range Any Time Post-Baseline During Part 1, Part 2, and Part 2/3 ALT, low, n= 15, 21, 44, 65	2 Participants	3 Participants	4 Participants	11 Participants	—	—
Number of Participants With the Indicated Clinical Chemistry Parameter Falling Outside of the Reference Range Any Time Post-Baseline During Part 1, Part 2, and Part 2/3 Total Bilirubin, high, n=15, 21, 44, 65	5 Participants	2 Participants	2 Participants	9 Participants	—	—
Number of Participants With the Indicated Clinical Chemistry Parameter Falling Outside of the Reference Range Any Time Post-Baseline During Part 1, Part 2, and Part 2/3 Total Bilirubin, low, n=15, 21, 44, 65	6 Participants	0 Participants	16 Participants	31 Participants	—	—
Number of Participants With the Indicated Clinical Chemistry Parameter Falling Outside of the Reference Range Any Time Post-Baseline During Part 1, Part 2, and Part 2/3 Direct Bilirubin, high, n=10, 16, 34, 55	0 Participants	1 Participants	1 Participants	3 Participants	—	—
Number of Participants With the Indicated Clinical Chemistry Parameter Falling Outside of the Reference Range Any Time Post-Baseline During Part 1, Part 2, and Part 2/3 Direct Bilirubin, low, n=10, 16, 34, 55	1 Participants	0 Participants	6 Participants	8 Participants	—	—
Number of Participants With the Indicated Clinical Chemistry Parameter Falling Outside of the Reference Range Any Time Post-Baseline During Part 1, Part 2, and Part 2/3 Albumin, high, n=15, 21, 24, 65	3 Participants	3 Participants	2 Participants	9 Participants	—	—
Number of Participants With the Indicated Clinical Chemistry Parameter Falling Outside of the Reference Range Any Time Post-Baseline During Part 1, Part 2, and Part 2/3 Albumin, low, n=15, 21, 24, 65	1 Participants	3 Participants	5 Participants	11 Participants	—	—
Number of Participants With the Indicated Clinical Chemistry Parameter Falling Outside of the Reference Range Any Time Post-Baseline During Part 1, Part 2, and Part 2/3 ALP, high, n=15, 21, 24, 65	4 Participants	1 Participants	6 Participants	13 Participants	—	—
Number of Participants With the Indicated Clinical Chemistry Parameter Falling Outside of the Reference Range Any Time Post-Baseline During Part 1, Part 2, and Part 2/3 ALP, low, n=15, 21, 24, 65	2 Participants	2 Participants	4 Participants	11 Participants	—	—
Number of Participants With the Indicated Clinical Chemistry Parameter Falling Outside of the Reference Range Any Time Post-Baseline During Part 1, Part 2, and Part 2/3 PT INR, high, n=15, 20, 42, 64	2 Participants	1 Participants	4 Participants	12 Participants	—	—
Number of Participants With the Indicated Clinical Chemistry Parameter Falling Outside of the Reference Range Any Time Post-Baseline During Part 1, Part 2, and Part 2/3 PT INR, low, n=15, 20, 42, 64	0 Participants	0 Participants	0 Participants	1 Participants	—	—
Number of Participants With the Indicated Clinical Chemistry Parameter Falling Outside of the Reference Range Any Time Post-Baseline During Part 1, Part 2, and Part 2/3 PT, high, n=13, 20, 36, 61	5 Participants	5 Participants	8 Participants	24 Participants	—	—
Number of Participants With the Indicated Clinical Chemistry Parameter Falling Outside of the Reference Range Any Time Post-Baseline During Part 1, Part 2, and Part 2/3 PT, low, n=13, 20, 36, 61	0 Participants	1 Participants	0 Participants	3 Participants	—	—
Number of Participants With the Indicated Clinical Chemistry Parameter Falling Outside of the Reference Range Any Time Post-Baseline During Part 1, Part 2, and Part 2/3 PTT, high, n=15, 21, 41, 63	4 Participants	2 Participants	1 Participants	11 Participants	—	—
Number of Participants With the Indicated Clinical Chemistry Parameter Falling Outside of the Reference Range Any Time Post-Baseline During Part 1, Part 2, and Part 2/3 PTT, low, n=15, 21, 41, 63	0 Participants	1 Participants	1 Participants	9 Participants	—	—
Number of Participants With the Indicated Clinical Chemistry Parameter Falling Outside of the Reference Range Any Time Post-Baseline During Part 1, Part 2, and Part 2/3 Glucose, high, n=15, 21, 44, 65	5 Participants	5 Participants	7 Participants	27 Participants	—	—
Number of Participants With the Indicated Clinical Chemistry Parameter Falling Outside of the Reference Range Any Time Post-Baseline During Part 1, Part 2, and Part 2/3 Glucose, low, n=15, 21, 44, 65	7 Participants	6 Participants	16 Participants	29 Participants	—	—

SECONDARY outcome

Timeframe: Post-Baseline from Week 1 through Follow-up up to Study Week 35

Hematology parameters included: erythrocytes (RR: 4.2 - 6.1 teragrams per liter \[TI/L\]), hemoglobin (RR: 125 - 165 g/L), hematocrit (RR: 0.36 - 0.46), platelets (RR: 170 - 430 gigagrams per liter \[GI/L\]), mean platelet volume (MPV, RR: 4 - 14 femotoliter \[fL\]), leukocytes (RR: 3.4 - 11.2 GI/L), total neutrophils (RR: 2.1 - 4.9 GI/L), lymphocytes (RR: 1.4 - 2.9 GI/L), monocytes (RR: 0.2 - 0.9 GI/L), eosinophils (RR: 0.2 - 0.7 GI/L), and basophils (RR: 0.02 - 0.12 GI/L). Baseline values were obtained at Day 1. The number of participants with the indicated hematology parameters data outside of the reference range (with high and low) any time post-baseline are presented. Anytime post-Baseline assesments included any scheduled and unscheduled post-Baseline assessment

Outcome measures

Outcome measures
Measure	Part 2 (Randomized Period) Cohort 1-Placebo n=15 Participants Participants aged between 12 and 17 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.	Part 2 (Randomized Period) Cohort 1- Eltrombopag n=21 Participants Participants aged between 12 and 17 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was 37.5 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 2-Placebo n=44 Participants Participants aged between 6 and 11 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.	Part 2 (Randomized Period) Cohort 2-Eltrombopag n=65 Participants Participants aged between 6 and 11 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was based on the body weight, participants with a weight of \<27 kg received 25 mg QD and participants with a weight of \>=27 kg received 50 mg QD. Participants of East Asian ancestry with a body weight of \<27 kg received 12.5 mg QD and participants with a weight of \>=27 kg received 25 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 3-Placebo Participants aged between 1 to 5 years received eltrombopag matching placebo administered as a dry powder for oral suspension QD for 7 weeks.	Part 2 (Randomized Period) Cohort 3- Eltrombopag Participants aged between 1 to 5 years received eltrombopag administered as a dry powder for oral suspension for 7 weeks. The starting dose of eltrombopag was 1.5 mg/kg QD and the dose calculations were based on the body weight. Participants of East Asian ancestry began at 0.8 mg/kg/day. The maximum dose allowed was 2 mg/kg, unless otherwise approved by the investigator, and could not exceed 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.
Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline During Part 1, Part 2, and Part 2/3 Mean Platelet Volume, high, n=12, 17, 40, 59	10 Participants	10 Participants	23 Participants	47 Participants	—	—
Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline During Part 1, Part 2, and Part 2/3 Erythrocytes high, n=15, 21, 44, 65	5 Participants	0 Participants	7 Participants	15 Participants	—	—
Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline During Part 1, Part 2, and Part 2/3 Erythrocytes low, n=15, 21, 44, 65	2 Participants	8 Participants	13 Participants	24 Participants	—	—
Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline During Part 1, Part 2, and Part 2/3 Hemoglobin, high, n= 15, 21, 44, 65	2 Participants	2 Participants	2 Participants	8 Participants	—	—
Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline During Part 1, Part 2, and Part 2/3 Hemoglobin low, n= 15, 21, 44, 65	10 Participants	5 Participants	15 Participants	32 Participants	—	—
Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline During Part 1, Part 2, and Part 2/3 Hematocrit, high, n=15, 21, 44, 65	1 Participants	0 Participants	0 Participants	5 Participants	—	—
Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline During Part 1, Part 2, and Part 2/3 Hematocrit, low, n=15, 21, 44, 65	10 Participants	11 Participants	22 Participants	39 Participants	—	—
Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline During Part 1, Part 2, and Part 2/3 Platelets, high, n=15, 21, 44, 65	9 Participants	0 Participants	6 Participants	14 Participants	—	—
Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline During Part 1, Part 2, and Part 2/3 Platelets, low, n=15, 21, 44, 65	15 Participants	21 Participants	44 Participants	65 Participants	—	—
Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline During Part 1, Part 2, and Part 2/3 Leukocytes, high, n=15, 21, 44, 65	6 Participants	5 Participants	8 Participants	27 Participants	—	—
Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline During Part 1, Part 2, and Part 2/3 Leukocytes, low, n=15, 21, 44, 65	4 Participants	5 Participants	10 Participants	19 Participants	—	—
Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline During Part 1, Part 2, and Part 2/3 Neutrophils, high, n=15, 21, 44, 65	7 Participants	5 Participants	11 Participants	33 Participants	—	—
Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline During Part 1, Part 2, and Part 2/3 Neutrophils, low, n=15, 21, 44, 65	3 Participants	4 Participants	10 Participants	21 Participants	—	—
Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline During Part 1, Part 2, and Part 2/3 Lymphocytes, high, n=15, 21, 44, 65	1 Participants	3 Participants	5 Participants	11 Participants	—	—
Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline During Part 1, Part 2, and Part 2/3 Lymphocytes, low, n=15, 21, 44, 65	5 Participants	6 Participants	10 Participants	25 Participants	—	—
Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline During Part 1, Part 2, and Part 2/3 Monocytes, high, n=15, 21, 44, 65	3 Participants	3 Participants	7 Participants	15 Participants	—	—
Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline During Part 1, Part 2, and Part 2/3 Monocytes, low, n=15, 21, 44, 65	4 Participants	7 Participants	10 Participants	23 Participants	—	—
Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline During Part 1, Part 2, and Part 2/3 Eosinophils, high, n=15, 21, 44, 65	5 Participants	3 Participants	11 Participants	24 Participants	—	—
Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline During Part 1, Part 2, and Part 2/3 Eosinophils, low, n=15, 21, 44, 65	4 Participants	2 Participants	5 Participants	9 Participants	—	—
Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline During Part 1, Part 2, and Part 2/3 Basophils, high, n=15, 21, 44, 65	6 Participants	5 Participants	10 Participants	20 Participants	—	—
Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline During Part 1, Part 2, and Part 2/3 Basophils, low, n=15, 21, 44, 65	2 Participants	0 Participants	1 Participants	1 Participants	—	—
Number of Participants With the Indicated Hematology Parameters Falling Outside of the Reference Range at Any Time Post-Baseline During Part 1, Part 2, and Part 2/3 Mean Platelet Volume, low, n=12, 17, 40, 59	4 Participants	6 Participants	10 Participants	16 Participants	—	—

SECONDARY outcome

Timeframe: Post-Baseline from Week 1 through Follow-up up to Study Week 35

Renal parameters included: creatinine (RR: 44.2 - 88.4 umol/L), creatinine clearance derived (RR: 89.0 - 165.0 milliliter per minute \[ ml/min\]), protein/creatinine (RR: 0.113- 18.0992 microgram per millimoles \[mg/mmol\]), and urea (RR: 1.785- 8.925 mmol/L). Baseline values were obtained at Day 1. The number of participants with the indicated renal parameters data outside the reference range (with high and low) any time post-Baseline are presented. Anytime post-Baseline assesments included any scheduled and unscheduled post-baseline assessment

Outcome measures

Outcome measures
Measure	Part 2 (Randomized Period) Cohort 1-Placebo n=15 Participants Participants aged between 12 and 17 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.	Part 2 (Randomized Period) Cohort 1- Eltrombopag n=21 Participants Participants aged between 12 and 17 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was 37.5 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 2-Placebo n=44 Participants Participants aged between 6 and 11 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.	Part 2 (Randomized Period) Cohort 2-Eltrombopag n=65 Participants Participants aged between 6 and 11 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was based on the body weight, participants with a weight of \<27 kg received 25 mg QD and participants with a weight of \>=27 kg received 50 mg QD. Participants of East Asian ancestry with a body weight of \<27 kg received 12.5 mg QD and participants with a weight of \>=27 kg received 25 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 3-Placebo Participants aged between 1 to 5 years received eltrombopag matching placebo administered as a dry powder for oral suspension QD for 7 weeks.	Part 2 (Randomized Period) Cohort 3- Eltrombopag Participants aged between 1 to 5 years received eltrombopag administered as a dry powder for oral suspension for 7 weeks. The starting dose of eltrombopag was 1.5 mg/kg QD and the dose calculations were based on the body weight. Participants of East Asian ancestry began at 0.8 mg/kg/day. The maximum dose allowed was 2 mg/kg, unless otherwise approved by the investigator, and could not exceed 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.
Number of Participants With the Indicated Renal Parameters Falling Outside of the Reference Range Any Time Post-Baseline During Part 1, Part 2, and Part 2/3 Creatinine, high, n=15, 21, 44, 65	1 Participants	3 Participants	6 Participants	13 Participants	—	—
Number of Participants With the Indicated Renal Parameters Falling Outside of the Reference Range Any Time Post-Baseline During Part 1, Part 2, and Part 2/3 Creatinine, low, n=15, 21, 44, 65	5 Participants	4 Participants	4 Participants	12 Participants	—	—
Number of Participants With the Indicated Renal Parameters Falling Outside of the Reference Range Any Time Post-Baseline During Part 1, Part 2, and Part 2/3 Creatinine Clearance Derived, high, n=15, 21,44,65	11 Participants	17 Participants	28 Participants	46 Participants	—	—
Number of Participants With the Indicated Renal Parameters Falling Outside of the Reference Range Any Time Post-Baseline During Part 1, Part 2, and Part 2/3 Creatinine Clearance Derived, low, n=15, 21,44,65	0 Participants	2 Participants	3 Participants	4 Participants	—	—
Number of Participants With the Indicated Renal Parameters Falling Outside of the Reference Range Any Time Post-Baseline During Part 1, Part 2, and Part 2/3 Protein/Creatinine, high, n=12, 19, 38, 58	1 Participants	2 Participants	4 Participants	18 Participants	—	—
Number of Participants With the Indicated Renal Parameters Falling Outside of the Reference Range Any Time Post-Baseline During Part 1, Part 2, and Part 2/3 Protein/Creatinine, low, n=12, 19, 38, 58	1 Participants	0 Participants	0 Participants	0 Participants	—	—
Number of Participants With the Indicated Renal Parameters Falling Outside of the Reference Range Any Time Post-Baseline During Part 1, Part 2, and Part 2/3 Urea, high, n=15, 21, 44, 65	1 Participants	2 Participants	2 Participants	5 Participants	—	—
Number of Participants With the Indicated Renal Parameters Falling Outside of the Reference Range Any Time Post-Baseline During Part 1, Part 2, and Part 2/3 Urea, low, n=15, 21, 44, 65	5 Participants	1 Participants	9 Participants	11 Participants	—	—

SECONDARY outcome

Timeframe: From Baseline up to Study Week 24 of Part 1

Population: Safety Population, only those participants enrolled during Part 1 were analyzed.

Outcome measures

Outcome measures
Measure	Part 2 (Randomized Period) Cohort 1-Placebo n=5 Participants Participants aged between 12 and 17 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.	Part 2 (Randomized Period) Cohort 1- Eltrombopag n=5 Participants Participants aged between 12 and 17 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was 37.5 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 2-Placebo n=5 Participants Participants aged between 6 and 11 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.	Part 2 (Randomized Period) Cohort 2-Eltrombopag Participants aged between 6 and 11 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was based on the body weight, participants with a weight of \<27 kg received 25 mg QD and participants with a weight of \>=27 kg received 50 mg QD. Participants of East Asian ancestry with a body weight of \<27 kg received 12.5 mg QD and participants with a weight of \>=27 kg received 25 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 3-Placebo Participants aged between 1 to 5 years received eltrombopag matching placebo administered as a dry powder for oral suspension QD for 7 weeks.	Part 2 (Randomized Period) Cohort 3- Eltrombopag Participants aged between 1 to 5 years received eltrombopag administered as a dry powder for oral suspension for 7 weeks. The starting dose of eltrombopag was 1.5 mg/kg QD and the dose calculations were based on the body weight. Participants of East Asian ancestry began at 0.8 mg/kg/day. The maximum dose allowed was 2 mg/kg, unless otherwise approved by the investigator, and could not exceed 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.
Number of Participants With a Positive Urine Microscopy Parameters Any Time Post-Baseline During Part 1 WBC Casts	0 Participants	0 Participants	0 Participants	—	—	—
Number of Participants With a Positive Urine Microscopy Parameters Any Time Post-Baseline During Part 1 Epithelial Renal Cell Casts	0 Participants	0 Participants	2 Participants	—	—	—
Number of Participants With a Positive Urine Microscopy Parameters Any Time Post-Baseline During Part 1 RBC Casts	0 Participants	0 Participants	0 Participants	—	—	—

SECONDARY outcome

Timeframe: From Baseline and post-Baseline up to Study Week 7 of Part 2

Population: Safety Population, only those participants enrolled during Part 2 were analyzed.

Outcome measures

Outcome measures
Measure	Part 2 (Randomized Period) Cohort 1-Placebo n=8 Participants Participants aged between 12 and 17 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.	Part 2 (Randomized Period) Cohort 1- Eltrombopag n=16 Participants Participants aged between 12 and 17 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was 37.5 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 2-Placebo n=9 Participants Participants aged between 6 and 11 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.	Part 2 (Randomized Period) Cohort 2-Eltrombopag n=17 Participants Participants aged between 6 and 11 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was based on the body weight, participants with a weight of \<27 kg received 25 mg QD and participants with a weight of \>=27 kg received 50 mg QD. Participants of East Asian ancestry with a body weight of \<27 kg received 12.5 mg QD and participants with a weight of \>=27 kg received 25 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 3-Placebo n=4 Participants Participants aged between 1 to 5 years received eltrombopag matching placebo administered as a dry powder for oral suspension QD for 7 weeks.	Part 2 (Randomized Period) Cohort 3- Eltrombopag n=11 Participants Participants aged between 1 to 5 years received eltrombopag administered as a dry powder for oral suspension for 7 weeks. The starting dose of eltrombopag was 1.5 mg/kg QD and the dose calculations were based on the body weight. Participants of East Asian ancestry began at 0.8 mg/kg/day. The maximum dose allowed was 2 mg/kg, unless otherwise approved by the investigator, and could not exceed 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.
Number of Participants With a Positive Urine Microscopy Parameters Any Time Post-Baseline During Part 2 Pre-trt Epithelial Renal Tubular Cell Casts	0 Participants	2 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With a Positive Urine Microscopy Parameters Any Time Post-Baseline During Part 2 Pre-trt RBC Casts	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With a Positive Urine Microscopy Parameters Any Time Post-Baseline During Part 2 Pre-trt WBC Casts	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With a Positive Urine Microscopy Parameters Any Time Post-Baseline During Part 2 Post-BL Epithelial Renal Tubular Cell Casts	1 Participants	3 Participants	0 Participants	0 Participants	1 Participants	0 Participants
Number of Participants With a Positive Urine Microscopy Parameters Any Time Post-Baseline During Part 2 Post-BL RBC Casts	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With a Positive Urine Microscopy Parameters Any Time Post-Baseline During Part 2 Post-BL WBC Casts	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants

SECONDARY outcome

Timeframe: From Baseline and post-Baseline up to Study Week 31 of Part 2/3

Population: Safety Population, only those participants enrolled during Part 2/3 were analyzed.

Urine microscopy included Red Blood Cell (RBC) casts, white blood cell (WBC) casts, and epithelial renal tubular cell casts. Urine microscopy data was reviewed by the Medical Monitor in order to classify the results as positive or negative. The number of participants with positive finding at Baseline and at anytime post-Baseline (Post-BL) were reported. Baseline was defined as the value obtained at the first visit before treatment (Pre-trt). A positive result indicated if the result was positive for at least one of RBC casts, WBC casts, or epithelial renal tubular cell casts. Participants randomized to receive eltrombopag for 7 weeks in Part 2 continued receiving eltrombopag for an additional 17 weeks in Part 2/3 (for a total of 24 weeks of treatment) up to Study Week 24. Participants randomized to receive placebo for 7 weeks in Part 2, received 24 weeks of eltrombopag in Part 2/3 (for a total of 24 weeks of treatment) up to Study Week 31.

Outcome measures

Outcome measures
Measure	Part 2 (Randomized Period) Cohort 1-Placebo n=24 Participants Participants aged between 12 and 17 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.	Part 2 (Randomized Period) Cohort 1- Eltrombopag n=26 Participants Participants aged between 12 and 17 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was 37.5 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 2-Placebo n=15 Participants Participants aged between 6 and 11 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.	Part 2 (Randomized Period) Cohort 2-Eltrombopag Participants aged between 6 and 11 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was based on the body weight, participants with a weight of \<27 kg received 25 mg QD and participants with a weight of \>=27 kg received 50 mg QD. Participants of East Asian ancestry with a body weight of \<27 kg received 12.5 mg QD and participants with a weight of \>=27 kg received 25 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 3-Placebo Participants aged between 1 to 5 years received eltrombopag matching placebo administered as a dry powder for oral suspension QD for 7 weeks.	Part 2 (Randomized Period) Cohort 3- Eltrombopag Participants aged between 1 to 5 years received eltrombopag administered as a dry powder for oral suspension for 7 weeks. The starting dose of eltrombopag was 1.5 mg/kg QD and the dose calculations were based on the body weight. Participants of East Asian ancestry began at 0.8 mg/kg/day. The maximum dose allowed was 2 mg/kg, unless otherwise approved by the investigator, and could not exceed 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.
Number of Participants With a Positive Urine Microscopy Parameters Any Time Post-Baseline During Part 2/3 Pre-trt Epithelial Renal Tubular Cell Casts	3 Participants	0 Participants	1 Participants	—	—	—
Number of Participants With a Positive Urine Microscopy Parameters Any Time Post-Baseline During Part 2/3 Pre-trt RBC Casts	1 Participants	0 Participants	0 Participants	—	—	—
Number of Participants With a Positive Urine Microscopy Parameters Any Time Post-Baseline During Part 2/3 Pre-trt WBC Casts	0 Participants	0 Participants	0 Participants	—	—	—
Number of Participants With a Positive Urine Microscopy Parameters Any Time Post-Baseline During Part 2/3 Post-BL Epithelial Renal Tubular Cell Casts	3 Participants	2 Participants	1 Participants	—	—	—
Number of Participants With a Positive Urine Microscopy Parameters Any Time Post-Baseline During Part 2/3 Post-BL RBC Casts	0 Participants	0 Participants	1 Participants	—	—	—
Number of Participants With a Positive Urine Microscopy Parameters Any Time Post-Baseline During Part 2/3 Post-BL WBC Casts	1 Participants	0 Participants	1 Participants	—	—	—

SECONDARY outcome

Timeframe: From Baseline through Study Week 35

Population: Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X,X,X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the Safety Population.

Vital sign assessments included systolic blood pressure (SBP) and diastolic blood pressure (DBP) measurements that were measured before any blood draw at the following scheduled time points: Screening, Day 1, each week from Week 1 to Week 24, at each Follow-up week (Week 1-4) and the maximum post- Baseline (BL) visit. BL is defined as the value obtained on Day 1of treatment. The maximum post-BL visit (MPB) included any scheduled and unscheduled post-BL assessment. Reference ranges (RR) for SBP (mmHg) (Lower limit of normal, normal, Upper limit of normal) for Cohort 1: \<85, 85-115, \>115; for Cohort 2: \<85, 85-120,\>120; and Cohort 3: \<95, 95-135, \>135. RR for DBP (mmHg) for Cohort 1: \<45, 45-70,\>70; for Cohort 2: \<50, 50-75, \>75; and Cohort 3: \<55, 55-85, \>85.

Outcome measures

Outcome measures
Measure	Part 2 (Randomized Period) Cohort 1-Placebo n=15 Participants Participants aged between 12 and 17 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.	Part 2 (Randomized Period) Cohort 1- Eltrombopag n=21 Participants Participants aged between 12 and 17 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was 37.5 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 2-Placebo n=44 Participants Participants aged between 6 and 11 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.	Part 2 (Randomized Period) Cohort 2-Eltrombopag n=65 Participants Participants aged between 6 and 11 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was based on the body weight, participants with a weight of \<27 kg received 25 mg QD and participants with a weight of \>=27 kg received 50 mg QD. Participants of East Asian ancestry with a body weight of \<27 kg received 12.5 mg QD and participants with a weight of \>=27 kg received 25 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 3-Placebo Participants aged between 1 to 5 years received eltrombopag matching placebo administered as a dry powder for oral suspension QD for 7 weeks.	Part 2 (Randomized Period) Cohort 3- Eltrombopag Participants aged between 1 to 5 years received eltrombopag administered as a dry powder for oral suspension for 7 weeks. The starting dose of eltrombopag was 1.5 mg/kg QD and the dose calculations were based on the body weight. Participants of East Asian ancestry began at 0.8 mg/kg/day. The maximum dose allowed was 2 mg/kg, unless otherwise approved by the investigator, and could not exceed 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Screening, DBP, high, n=15 ,20 ,41 ,40	1 Participants	4 Participants	3 Participants	3 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Screening, DBP, low, n=15, 20, 41, 40	0 Participants	2 Participants	6 Participants	5 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Day 1, DBP, high, n=14, 18, 38, 59	2 Participants	4 Participants	3 Participants	7 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Day 1, DBP, low, n=14, 18, 38, 59	1 Participants	1 Participants	3 Participants	4 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 1, DBP, high, n=14, 19, 42, 63	1 Participants	3 Participants	4 Participants	5 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 1, DBP, low, n=14, 19, 42, 63	1 Participants	1 Participants	4 Participants	5 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 2, DBP, high, n=15, 20, 42, 61	3 Participants	2 Participants	2 Participants	3 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 2, DBP, low, n=15, 20, 42, 61	2 Participants	3 Participants	4 Participants	5 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 3, DBP, high,n=15, 21, 41, 60	1 Participants	3 Participants	3 Participants	6 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 3, DBP, low,n=15, 21, 41, 60	2 Participants	3 Participants	5 Participants	5 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 4, DBP,high, n=15, 21, 42, 62	0 Participants	3 Participants	3 Participants	6 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 4, DBP,low, n=15, 21, 42, 62	4 Participants	4 Participants	3 Participants	5 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 5, DBP, high, n=15, 19, 40, 59	1 Participants	2 Participants	4 Participants	8 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 5, DBP, low, n=15, 19, 40, 59	1 Participants	1 Participants	5 Participants	5 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 6, DBP, high, n=14, 21, 42, 58	1 Participants	2 Participants	3 Participants	5 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 6, DBP, low, n=14, 21, 42, 58	0 Participants	0 Participants	3 Participants	4 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 7, DBP, high, n=15, 21, 42, 58	1 Participants	4 Participants	6 Participants	7 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 7, DBP, low, n=15, 21, 42, 58	0 Participants	1 Participants	2 Participants	4 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 8, DBP,high,n=15, 0, 0, 49	0 Participants	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	4 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 8, DBP,low,n=15, 0, 0, 49	1 Participants	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	6 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 9, DBP, high, n=15, 0, 0, 45	2 Participants	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	4 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 9, DBP, low, n=15, 0, 0, 45	1 Participants	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	6 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 10, DBP, high, n=15, 0, 0, 40	0 Participants	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	6 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 10, DBP, low, n=15, 0, 0, 40	0 Participants	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	3 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 11, DBP, high, n=13, 0, 0, 41	0 Participants	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	4 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 11, DBP, low, n=13, 0, 0, 41	2 Participants	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	3 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 12, DBP, high, n=13, 0, 0, 42	0 Participants	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	5 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 12, DBP, low, n=13, 0, 0, 42	3 Participants	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	3 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 13, DBP, high, n=12, 0, 0, 32	0 Participants	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	0 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 13, DBP, low, n=12, 0, 0, 32	0 Participants	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	5 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 14, DBP, high, n=9, 0, 0, 32	0 Participants	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	3 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 14, DBP, low, n=9, 0, 0, 32	1 Participants	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	3 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 15, DBP, high, n=11, 0, 0, 31	1 Participants	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	3 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 15, DBP, low, n=11, 0, 0, 31	2 Participants	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	0 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 16, DBP,high,n=12, 0, 0, 39	0 Participants	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	2 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 16, DBP,low,n=12, 0, 0, 39	0 Participants	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	3 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 17, DBP,high,n=5, 0, 0, 29	0 Participants	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	2 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 17, DBP,low,n=5, 0, 0, 29	1 Participants	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	1 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 18, DBP,high,n=9, 0, 0, 32	0 Participants	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	3 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 18, DBP,low,n=9, 0, 0, 32	1 Participants	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	1 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 19, DBP,high,n=5, 0, 0, 34	0 Participants	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	1 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 19, DBP,low,n=5, 0, 0, 34	0 Participants	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	2 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 20, DBP,high,n=13, 0, 0, 33	0 Participants	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	0 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 20, DBP,low,n=13, 0, 0, 33	0 Participants	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	1 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 21, DBP,high,n=10, 0, 0, 17	1 Participants	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	1 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 21, DBP,low,n=10, 0, 0, 17	1 Participants	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	1 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 22, DBP,high,n=11, 0, 0, 23	1 Participants	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	1 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 22, DBP,low,n=11, 0, 0, 23	1 Participants	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	0 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 23, DBP,high,n=11, 0, 0, 21	0 Participants	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	1 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 23, DBP,low,n=11, 0, 0, 21	2 Participants	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	2 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 24 DBP,high,n=15, 0, 0, 58	0 Participants	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	5 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 24, DBP,low,n=15, 0, 0, 58	3 Participants	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	3 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 FU Week 1, DBP,high,n=5, 0, 0, 13	1 Participants	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	2 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 FU Week 1, DBP,low,n=5, 0, 0, 13	1 Participants	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	1 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 FU Week 2, DBP,high,n=5, 0, 0, 21	0 Participants	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	2 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 FU Week 2, DBP,low,n=5, 0, 0, 21	0 Participants	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	1 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 FU Week 3, DBP,high,n=5, 0, 0, 14	0 Participants	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	2 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 FU Week 3, DBP,low,n=5, 0, 0, 14	0 Participants	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	0 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 FU Week 4, DBP,high,n=3, 0, 0, 31	0 Participants	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	7 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 FU Week 4, DBP,low,n=3, 0, 0, 31	1 Participants	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	5 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Screening, SBP, high, n=15, 20, 41, 40	4 Participants	4 Participants	10 Participants	10 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Screening, SBP, low, n=15, 20, 41, 40	3 Participants	0 Participants	3 Participants	2 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Day 1, SBP,high,n=14, 18, 38, 59	4 Participants	5 Participants	9 Participants	14 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Day 1, SBP,low,n=14, 18, 38, 59	0 Participants	1 Participants	4 Participants	4 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 1, SBP,high,n=14, 19, 42, 63	3 Participants	6 Participants	14 Participants	18 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 1, SBP,low,n=14, 19, 42, 63	2 Participants	0 Participants	4 Participants	8 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 2, SBP,high,n=15, 20, 43, 62	4 Participants	7 Participants	7 Participants	15 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 2, SBP,low,n=15, 20, 43, 62	1 Participants	2 Participants	5 Participants	6 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 3, SBP,high,n=15, 21, 41, 60	3 Participants	4 Participants	12 Participants	17 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 3, SBP,low,n=15, 21, 41, 60	1 Participants	2 Participants	2 Participants	3 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 4, SBP,high,n=15, 21, 42, 62	4 Participants	6 Participants	10 Participants	16 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 4, SBP,low,n=15, 21, 42, 62	4 Participants	1 Participants	3 Participants	2 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 5, SBP,high,n=15, 19, 40, 59	5 Participants	5 Participants	13 Participants	17 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 5, SBP, low, n=15, 19, 40, 59	2 Participants	1 Participants	3 Participants	3 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 6, SBP,high,n=14, 21, 42, 58	4 Participants	8 Participants	11 Participants	16 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 6, SBP,low,n=14, 21, 42, 58	2 Participants	1 Participants	3 Participants	5 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 7, SBP,high,n=15, 21, 42, 58	5 Participants	5 Participants	9 Participants	13 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 7, SBP,low,n=15, 21, 42, 58	1 Participants	0 Participants	2 Participants	5 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 8, SBP,high,n=15, 0, 0, 49	3 Participants	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	16 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 8, SBP,low,n=15, 0, 0, 49	4 Participants	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	4 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 9, SBP,high,n=15, 0, 0, 45	4 Participants	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	15 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 9, SBP,low,n=15, 0, 0, 45	3 Participants	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	2 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 10, SBP,high,n=15, 0, 0, 40	2 Participants	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	10 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 10, SBP,low,n=15, 0, 0, 40	2 Participants	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	3 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 11, SBP,high,n=13, 0, 0, 41	4 Participants	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	9 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 11, SBP,low,n=13, 0, 0, 41	2 Participants	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	2 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 12, SBP,high,n=13, 0, 0, 42	3 Participants	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	10 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 12, SBP,low,n=13, 0, 0, 42	3 Participants	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	3 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 13, SBP,high,n=12, 0, 0, 32	3 Participants	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	8 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 13, SBP,low,n=12, 0, 0, 32	2 Participants	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	3 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 14, SBP,high,n=9, 0, 0, 32	4 Participants	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	10 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 14, SBP,low,n=9, 0, 0, 32	0 Participants	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	3 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 15, SBP,high,n=11, 0, 0, 31	3 Participants	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	9 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 15, SBP,low,n=11, 0, 0, 31	2 Participants	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	1 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 16 SBP,high,n=12, 0, 0, 39	5 Participants	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	14 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 16, SBP,low,n=12, 0, 0, 39	1 Participants	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	1 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 17, SBP,high,n=5, 0, 0, 29	1 Participants	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	9 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 17, SBP,low,n=5, 0, 0, 29	1 Participants	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	0 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 18, SBP,high,n=9, 0, 0, 32	2 Participants	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	10 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 18, SBP,low,n=9, 0, 0, 32	0 Participants	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	1 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 19, SBP,high,n=5, 0, 0, 34	2 Participants	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	9 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 19, SBP,low,n=5, 0, 0, 34	0 Participants	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	2 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 20, SBP,high,n=13, 0, 0, 33	6 Participants	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	10 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 20, SBP,low,n=13, 0, 0, 33	2 Participants	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	1 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 21, SBP,high,n=10, 0, 0, 17	2 Participants	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	0 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 21, SBP,low,n=10, 0, 0, 17	3 Participants	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	0 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 22, SBP,high,n=11, 0, 0, 23	2 Participants	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	8 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 22, SBP,low,n=11, 0, 0, 23	3 Participants	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	0 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 23, SBP,high,n=11, 0, 0, 21	2 Participants	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	6 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 23, SBP,low,n=11, 0, 0, 21	2 Participants	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	1 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 24, SBP,high,n=15, 0, 0, 58	4 Participants	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	19 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 Week 24, SBP, low, n=15, 0, 0, 58	2 Participants	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	2 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 FU Week 1, SBP, high,n=5, 0, 0, 13	0 Participants	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	4 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 FU Week 1, SBP, low,n=5, 0, 0, 13	2 Participants	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	0 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 FU Week 2, SBP, high,n=5, 0, 0, 21	2 Participants	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	3 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 FU Week 2, SBP, low,n=5, 0, 0, 21	0 Participants	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	3 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 FU Week 3, SBP, high,n=5, 0, 0, 14	1 Participants	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	4 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 FU Week 3, SBP, low,n=5, 0, 0, 14	0 Participants	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	0 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 FU Week 4, SBP, high,n=3, 0, 0, 31	1 Participants	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	10 Participants	—	—
Number of Participants With the Indicated Vital Signs Falling Outside of the Reference Range During Part 1, Part 2, and Part 2/3 FU Week 4, SBP,low,n=3, 0, 0, 31	1 Participants	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	NA Participants Part 2 ended at Week 7 so no participants were analyzed for this parameter at this time point.	3 Participants	—	—

SECONDARY outcome

Timeframe: From Baseline through Week 24

Outcome measures

Outcome measures
Measure	Part 2 (Randomized Period) Cohort 1-Placebo n=5 Participants Participants aged between 12 and 17 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.	Part 2 (Randomized Period) Cohort 1- Eltrombopag n=5 Participants Participants aged between 12 and 17 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was 37.5 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 2-Placebo n=5 Participants Participants aged between 6 and 11 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.	Part 2 (Randomized Period) Cohort 2-Eltrombopag Participants aged between 6 and 11 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was based on the body weight, participants with a weight of \<27 kg received 25 mg QD and participants with a weight of \>=27 kg received 50 mg QD. Participants of East Asian ancestry with a body weight of \<27 kg received 12.5 mg QD and participants with a weight of \>=27 kg received 25 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 3-Placebo Participants aged between 1 to 5 years received eltrombopag matching placebo administered as a dry powder for oral suspension QD for 7 weeks.	Part 2 (Randomized Period) Cohort 3- Eltrombopag Participants aged between 1 to 5 years received eltrombopag administered as a dry powder for oral suspension for 7 weeks. The starting dose of eltrombopag was 1.5 mg/kg QD and the dose calculations were based on the body weight. Participants of East Asian ancestry began at 0.8 mg/kg/day. The maximum dose allowed was 2 mg/kg, unless otherwise approved by the investigator, and could not exceed 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.
Mean Respiratory Rate at Baseline and the Maximum Post-Baseline Value Recorded During the Dose-Finding Period, Part 1 FU Week 1, n=1,1,3	20.0 Breaths per min Standard Deviation NA There were too few participants available to collect data at this time point to calculate a standard deviation.	20.0 Breaths per min Standard Deviation NA There were too few participants available to collect data at this time point to calculate a standard deviation.	22.0 Breaths per min Standard Deviation 2.00	—	—	—
Mean Respiratory Rate at Baseline and the Maximum Post-Baseline Value Recorded During the Dose-Finding Period, Part 1 BL, n=4, 5, 4	20.0 Breaths per min Standard Deviation 0.00	21.4 Breaths per min Standard Deviation 4.10	25.5 Breaths per min Standard Deviation 4.43	—	—	—
Mean Respiratory Rate at Baseline and the Maximum Post-Baseline Value Recorded During the Dose-Finding Period, Part 1 Week 1, n=4,5,4	21.5 Breaths per min Standard Deviation 4.43	22.0 Breaths per min Standard Deviation 6.00	26.5 Breaths per min Standard Deviation 6.40	—	—	—
Mean Respiratory Rate at Baseline and the Maximum Post-Baseline Value Recorded During the Dose-Finding Period, Part 1 Week 2, n=5,5,4	20.6 Breaths per min Standard Deviation 3.44	19.4 Breaths per min Standard Deviation 4.98	24.0 Breaths per min Standard Deviation 5.42	—	—	—
Mean Respiratory Rate at Baseline and the Maximum Post-Baseline Value Recorded During the Dose-Finding Period, Part 1 Week 3, n=5,5,5	22.0 Breaths per min Standard Deviation 5.66	17.0 Breaths per min Standard Deviation 5.10	23.6 Breaths per min Standard Deviation 6.07	—	—	—
Mean Respiratory Rate at Baseline and the Maximum Post-Baseline Value Recorded During the Dose-Finding Period, Part 1 Week 4, n=5,5,5	18.8 Breaths per min Standard Deviation 1.79	17.2 Breaths per min Standard Deviation 4.82	25.4 Breaths per min Standard Deviation 5.98	—	—	—
Mean Respiratory Rate at Baseline and the Maximum Post-Baseline Value Recorded During the Dose-Finding Period, Part 1 Week 5, n=5,5,4	20.4 Breaths per min Standard Deviation 2.19	20.2 Breaths per min Standard Deviation 6.87	24.3 Breaths per min Standard Deviation 5.56	—	—	—
Mean Respiratory Rate at Baseline and the Maximum Post-Baseline Value Recorded During the Dose-Finding Period, Part 1 Week 6, n=5,5,4	18.4 Breaths per min Standard Deviation 2.61	20.2 Breaths per min Standard Deviation 5.02	24.5 Breaths per min Standard Deviation 2.52	—	—	—
Mean Respiratory Rate at Baseline and the Maximum Post-Baseline Value Recorded During the Dose-Finding Period, Part 1 Week 7, n=5,5,5	19.2 Breaths per min Standard Deviation 1.10	23.4 Breaths per min Standard Deviation 9.15	24.4 Breaths per min Standard Deviation 6.69	—	—	—
Mean Respiratory Rate at Baseline and the Maximum Post-Baseline Value Recorded During the Dose-Finding Period, Part 1 Week 8, n=5,5,5	19.8 Breaths per min Standard Deviation 3.03	20.4 Breaths per min Standard Deviation 3.05	23.8 Breaths per min Standard Deviation 4.82	—	—	—
Mean Respiratory Rate at Baseline and the Maximum Post-Baseline Value Recorded During the Dose-Finding Period, Part 1 Week 9, n=5,4,5	19.2 Breaths per min Standard Deviation 2.28	22.5 Breaths per min Standard Deviation 3.79	22.0 Breaths per min Standard Deviation 2.00	—	—	—
Mean Respiratory Rate at Baseline and the Maximum Post-Baseline Value Recorded During the Dose-Finding Period, Part 1 Week 10, n=5,5,5	19.6 Breaths per min Standard Deviation 2.61	18.0 Breaths per min Standard Deviation 4.00	22.4 Breaths per min Standard Deviation 1.67	—	—	—
Mean Respiratory Rate at Baseline and the Maximum Post-Baseline Value Recorded During the Dose-Finding Period, Part 1 Week 11, n=5,3,4	19.6 Breaths per min Standard Deviation 1.67	20.3 Breaths per min Standard Deviation 3.21	25.0 Breaths per min Standard Deviation 5.03	—	—	—
Mean Respiratory Rate at Baseline and the Maximum Post-Baseline Value Recorded During the Dose-Finding Period, Part 1 Week 12, n=4,3,4	19.5 Breaths per min Standard Deviation 1.00	20.0 Breaths per min Standard Deviation 0.00	27.6 Breaths per min Standard Deviation 11.52	—	—	—
Mean Respiratory Rate at Baseline and the Maximum Post-Baseline Value Recorded During the Dose-Finding Period, Part 1 Week 13, n=4,4,4	19.5 Breaths per min Standard Deviation 1.00	21.0 Breaths per min Standard Deviation 2.16	23.0 Breaths per min Standard Deviation 3.46	—	—	—
Mean Respiratory Rate at Baseline and the Maximum Post-Baseline Value Recorded During the Dose-Finding Period, Part 1 Week 14, n=3,3,3	18.7 Breaths per min Standard Deviation 1.15	22.7 Breaths per min Standard Deviation 1.15	27.3 Breaths per min Standard Deviation 7.57	—	—	—
Mean Respiratory Rate at Baseline and the Maximum Post-Baseline Value Recorded During the Dose-Finding Period, Part 1 Week 15, n=3,3,3	18.0 Breaths per min Standard Deviation 2.00	21.3 Breaths per min Standard Deviation 1.15	24.0 Breaths per min Standard Deviation 2.00	—	—	—
Mean Respiratory Rate at Baseline and the Maximum Post-Baseline Value Recorded During the Dose-Finding Period, Part 1 Week 16, n=5,3,4	18.8 Breaths per min Standard Deviation 3.35	20.0 Breaths per min Standard Deviation 4.00	30.8 Breaths per min Standard Deviation 16.88	—	—	—
Mean Respiratory Rate at Baseline and the Maximum Post-Baseline Value Recorded During the Dose-Finding Period, Part 1 Week 17, n=2,0,3	18.0 Breaths per min Standard Deviation 0.00	NA Breaths per min Standard Deviation NA No participants were analyzed for this parameter at this time point.	24.0 Breaths per min Standard Deviation 4.00	—	—	—
Mean Respiratory Rate at Baseline and the Maximum Post-Baseline Value Recorded During the Dose-Finding Period, Part 1 Week 18, n=3,3,4	19.3 Breaths per min Standard Deviation 1.15	21.3 Breaths per min Standard Deviation 3.06	29.0 Breaths per min Standard Deviation 13.22	—	—	—
Mean Respiratory Rate at Baseline and the Maximum Post-Baseline Value Recorded During the Dose-Finding Period, Part 1 Week 19, n=3,0,2	19.3 Breaths per min Standard Deviation 1.15	NA Breaths per min Standard Deviation NA No participants were analyzed for this parameter at this time point.	28.0 Breaths per min Standard Deviation 11.31	—	—	—
Mean Respiratory Rate at Baseline and the Maximum Post-Baseline Value Recorded During the Dose-Finding Period, Part 1 Week 20, n=5,4,4	19.6 Breaths per min Standard Deviation 1.67	21.5 Breaths per min Standard Deviation 3.00	23.5 Breaths per min Standard Deviation 3.42	—	—	—
Mean Respiratory Rate at Baseline and the Maximum Post-Baseline Value Recorded During the Dose-Finding Period, Part 1 Week 21, n=3,2,5	19.3 Breaths per min Standard Deviation 1.15	19.00 Breaths per min Standard Deviation 1.41	23.6 Breaths per min Standard Deviation 3.51	—	—	—
Mean Respiratory Rate at Baseline and the Maximum Post-Baseline Value Recorded During the Dose-Finding Period, Part 1 Week 22, n=3,4,3	19.3 Breaths per min Standard Deviation 2.31	21.0 Breaths per min Standard Deviation 2.00	27.3 Breaths per min Standard Deviation 7.57	—	—	—
Mean Respiratory Rate at Baseline and the Maximum Post-Baseline Value Recorded During the Dose-Finding Period, Part 1 Week 23, n=4,2,4	20.0 Breaths per min Standard Deviation 1.63	20.0 Breaths per min Standard Deviation 0.00	21.5 Breaths per min Standard Deviation 1.91	—	—	—
Mean Respiratory Rate at Baseline and the Maximum Post-Baseline Value Recorded During the Dose-Finding Period, Part 1 Week 24, n=5,5,4	19.6 Breaths per min Standard Deviation 0.89	23.0 Breaths per min Standard Deviation 3.16	24.8 Breaths per min Standard Deviation 7.09	—	—	—
Mean Respiratory Rate at Baseline and the Maximum Post-Baseline Value Recorded During the Dose-Finding Period, Part 1 FU Week 2, n=3,2,0	19.3 Breaths per min Standard Deviation 1.15	26.5 Breaths per min Standard Deviation 9.19	NA Breaths per min Standard Deviation NA No participants were analyzed for this parameter at this time point.	—	—	—
Mean Respiratory Rate at Baseline and the Maximum Post-Baseline Value Recorded During the Dose-Finding Period, Part 1 FU Week 3, n=2,1,2	21.0 Breaths per min Standard Deviation 4.24	28.0 Breaths per min Standard Deviation NA There were too few participants available to collect data at this time point to calculate a standard deviation.	24.5 Breaths per min Standard Deviation 4.95	—	—	—
Mean Respiratory Rate at Baseline and the Maximum Post-Baseline Value Recorded During the Dose-Finding Period, Part 1 FU Week 4, n=1,0,1	18.0 Breaths per min Standard Deviation NA There were too few participants available to collect data at this time point to calculate a standard deviation.	NA Breaths per min Standard Deviation NA No participants were analyzed for this parameter at this time point.	24.0 Breaths per min Standard Deviation NA There were too few participants available to collect data at this time point to calculate a standard deviation.	—	—	—
Mean Respiratory Rate at Baseline and the Maximum Post-Baseline Value Recorded During the Dose-Finding Period, Part 1 MPB, n=5, 5, 5	24.4 Breaths per min Standard Deviation 4.56	29.8 Breaths per min Standard Deviation 6.02	32.2 Breaths per min Standard Deviation 13.90	—	—	—

SECONDARY outcome

Timeframe: From Week 1 to Week 7 of Part 2

Population: Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X,X,X,X,X,X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety Population

Outcome measures

Outcome measures
Measure	Part 2 (Randomized Period) Cohort 1-Placebo n=8 Participants Participants aged between 12 and 17 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.	Part 2 (Randomized Period) Cohort 1- Eltrombopag n=16 Participants Participants aged between 12 and 17 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was 37.5 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 2-Placebo n=9 Participants Participants aged between 6 and 11 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.	Part 2 (Randomized Period) Cohort 2-Eltrombopag n=17 Participants Participants aged between 6 and 11 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was based on the body weight, participants with a weight of \<27 kg received 25 mg QD and participants with a weight of \>=27 kg received 50 mg QD. Participants of East Asian ancestry with a body weight of \<27 kg received 12.5 mg QD and participants with a weight of \>=27 kg received 25 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 3-Placebo n=4 Participants Participants aged between 1 to 5 years received eltrombopag matching placebo administered as a dry powder for oral suspension QD for 7 weeks.	Part 2 (Randomized Period) Cohort 3- Eltrombopag n=11 Participants Participants aged between 1 to 5 years received eltrombopag administered as a dry powder for oral suspension for 7 weeks. The starting dose of eltrombopag was 1.5 mg/kg QD and the dose calculations were based on the body weight. Participants of East Asian ancestry began at 0.8 mg/kg/day. The maximum dose allowed was 2 mg/kg, unless otherwise approved by the investigator, and could not exceed 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.
Mean Respiratory Rate at Baseline and the Maximum Post-Baseline Value Recorded During the Randomized Period, Part 2 BL, n= 5, 14, 9, 12, 3, 10	19.6 Breaths per min Standard Deviation 1.67	18.4 Breaths per min Standard Deviation 2.38	19.4 Breaths per min Standard Deviation 3.13	21.5 Breaths per min Standard Deviation 10.03	18.7 Breaths per min Standard Deviation 1.15	21.4 Breaths per min Standard Deviation 2.12
Mean Respiratory Rate at Baseline and the Maximum Post-Baseline Value Recorded During the Randomized Period, Part 2 Week 1, n=7, 16 ,9, 17, 2, 10	19.0 Breaths per min Standard Deviation 1.00	18.8 Breaths per min Standard Deviation 1.76	19.9 Breaths per min Standard Deviation 2.26	20.7 Breaths per min Standard Deviation 4.48	19.0 Breaths per min Standard Deviation 1.41	28.2 Breaths per min Standard Deviation 9.54
Mean Respiratory Rate at Baseline and the Maximum Post-Baseline Value Recorded During the Randomized Period, Part 2 Week 2, n=6, 15, 9, 16, 4, 10	19.3 Breaths per min Standard Deviation 2.73	18.9 Breaths per min Standard Deviation 2.70	19.8 Breaths per min Standard Deviation 2.33	23.0 Breaths per min Standard Deviation 8.01	21.5 Breaths per min Standard Deviation 5.00	27.1 Breaths per min Standard Deviation 11.70
Mean Respiratory Rate at Baseline and the Maximum Post-Baseline Value Recorded During the Randomized Period, Part 2 Week 3, n=8, 16, 9, 16, 4, 9	18.8 Breaths per min Standard Deviation 1.83	18.9 Breaths per min Standard Deviation 1.93	20.1 Breaths per min Standard Deviation 2.76	22.3 Breaths per min Standard Deviation 4.78	21.0 Breaths per min Standard Deviation 2.58	25.8 Breaths per min Standard Deviation 7.17
Mean Respiratory Rate at Baseline and the Maximum Post-Baseline Value Recorded During the Randomized Period, Part 2 Week 4, n=7, 16, 8, 14, 4, 10	19.4 Breaths per min Standard Deviation 2.51	18.6 Breaths per min Standard Deviation 2.80	19.8 Breaths per min Standard Deviation 2.49	21.4 Breaths per min Standard Deviation 4.29	21.5 Breaths per min Standard Deviation 1.00	25.4 Breaths per min Standard Deviation 7.18
Mean Respiratory Rate at Baseline and the Maximum Post-Baseline Value Recorded During the Randomized Period, Part 2 Week 5, n=8, 16, 8, 15, 3, 8	19.3 Breaths per min Standard Deviation 1.04	18.5 Breaths per min Standard Deviation 2.10	20.5 Breaths per min Standard Deviation 2.98	19.7 Breaths per min Standard Deviation 2.74	20.0 Breaths per min Standard Deviation 2.00	29.0 Breaths per min Standard Deviation 14.77
Mean Respiratory Rate at Baseline and the Maximum Post-Baseline Value Recorded During the Randomized Period, Part 2 Week 6, n=8, 16, 9, 15, 4, 9	20.3 Breaths per min Standard Deviation 2.25	19.4 Breaths per min Standard Deviation 2.16	20.6 Breaths per min Standard Deviation 2.19	20.6 Breaths per min Standard Deviation 4.12	21.0 Breaths per min Standard Deviation 1.15	24.4 Breaths per min Standard Deviation 6.69
Mean Respiratory Rate at Baseline and the Maximum Post-Baseline Value Recorded During the Randomized Period, Part 2 Week 7, n=7, 16, 9, 17, 4, 8	20.9 Breaths per min Standard Deviation 2.27	18.4 Breaths per min Standard Deviation 1.50	20.9 Breaths per min Standard Deviation 3.33	20.7 Breaths per min Standard Deviation 7.87	18.5 Breaths per min Standard Deviation 1.91	23.5 Breaths per min Standard Deviation 6.12
Mean Respiratory Rate at Baseline and the Maximum Post-Baseline Value Recorded During the Randomized Period, Part 2 MPB, n=8, 16, 9, 17, 4, 11	21.5 Breaths per min Standard Deviation 2.33	21.3 Breaths per min Standard Deviation 21.8	22.7 Breaths per min Standard Deviation 2.45	26.6 Breaths per min Standard Deviation 7.87	23.5 Breaths per min Standard Deviation 3.42	30.0 Breaths per min Standard Deviation 13.39

SECONDARY outcome

Timeframe: From Week 1 to Follow-up Week 4 of Part 2/3 up to Study Week 35

Respiratory rate was measured at the following scheduled time points: Screening, Day 1, each week from Week 1 to Week 24, and at each Follow-up Weeks 1-4. Baseline is defined as the value obtained on Day 1 of treatment. The maximum post-Baseline visit included any scheduled and unscheduled post-Baseline assessment. Participants randomized to receive eltrombopag for 7 weeks in Part 2 continued receiving eltrombopag for an additional 17 weeks in Part 2/3 (for a total of 24 weeks of treatment) up to Study Week 24. Participants randomized to receive placebo for 7 weeks in Part 2, received 24 weeks of eltrombopag in Part 2/3 (for a total of 24 weeks of treatment) up to Study Week 31.

Outcome measures

Outcome measures
Measure	Part 2 (Randomized Period) Cohort 1-Placebo n=24 Participants Participants aged between 12 and 17 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.	Part 2 (Randomized Period) Cohort 1- Eltrombopag n=26 Participants Participants aged between 12 and 17 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was 37.5 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 2-Placebo n=15 Participants Participants aged between 6 and 11 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.	Part 2 (Randomized Period) Cohort 2-Eltrombopag Participants aged between 6 and 11 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was based on the body weight, participants with a weight of \<27 kg received 25 mg QD and participants with a weight of \>=27 kg received 50 mg QD. Participants of East Asian ancestry with a body weight of \<27 kg received 12.5 mg QD and participants with a weight of \>=27 kg received 25 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 3-Placebo Participants aged between 1 to 5 years received eltrombopag matching placebo administered as a dry powder for oral suspension QD for 7 weeks.	Part 2 (Randomized Period) Cohort 3- Eltrombopag Participants aged between 1 to 5 years received eltrombopag administered as a dry powder for oral suspension for 7 weeks. The starting dose of eltrombopag was 1.5 mg/kg QD and the dose calculations were based on the body weight. Participants of East Asian ancestry began at 0.8 mg/kg/day. The maximum dose allowed was 2 mg/kg, unless otherwise approved by the investigator, and could not exceed 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.
Mean Respiratory Rate at Baseline and Maximum Post-Baseline Visit During Part 2/3 Screening, n=16, 14, 10	18.5 Breaths per minute Standard Deviation 1.75	21.2 Breaths per minute Standard Deviation 6.57	21.5 Breaths per minute Standard Deviation 2.56	—	—	—
Mean Respiratory Rate at Baseline and Maximum Post-Baseline Visit During Part 2/3 Day 1 , n=21, 21, 15	19.2 Breaths per minute Standard Deviation 2.57	2.12 Breaths per minute Standard Deviation 7.74	21.7 Breaths per minute Standard Deviation 4.76	—	—	—
Mean Respiratory Rate at Baseline and Maximum Post-Baseline Visit During Part 2/3 Week 1, n=24, 25, 14	19.1 Breaths per minute Standard Deviation 1.74	20.4 Breaths per minute Standard Deviation 3.93	25.1 Breaths per minute Standard Deviation 7.63	—	—	—
Mean Respiratory Rate at Baseline and Maximum Post-Baseline Visit During Part 2/3 Week 2, n=22, 24, 13	19.4 Breaths per minute Standard Deviation 2.56	21.8 Breaths per minute Standard Deviation 6.85	25.2 Breaths per minute Standard Deviation 10.83	—	—	—
Mean Respiratory Rate at Baseline and Maximum Post-Baseline Visit During Part 2/3 Week 3, n=24, 23, 12	18.8 Breaths per minute Standard Deviation 1.73	21.2 Breaths per minute Standard Deviation 4.40	24.0 Breaths per minute Standard Deviation 6.09	—	—	—
Mean Respiratory Rate at Baseline and Maximum Post-Baseline Visit During Part 2/3 Week 4, n=23, 23, 13	19.0 Breaths per minute Standard Deviation 2.59	20.9 Breaths per minute Standard Deviation 3.82	24.3 Breaths per minute Standard Deviation 6.37	—	—	—
Mean Respiratory Rate at Baseline and Maximum Post-Baseline Visit During Part 2/3 Week 5, n=23, 23, 11	18.9 Breaths per minute Standard Deviation 2.13	19.8 Breaths per minute Standard Deviation 3.19	26.9 Breaths per minute Standard Deviation 12.91	—	—	—
Mean Respiratory Rate at Baseline and Maximum Post-Baseline Visit During Part 2/3 Week 6, n=23, 22, 11	19.3 Breaths per minute Standard Deviation 2.30	20.6 Breaths per minute Standard Deviation 4.11	23.3 Breaths per minute Standard Deviation 4.92	—	—	—
Mean Respiratory Rate at Baseline and Maximum Post-Baseline Visit During Part 2/3 Week 7, n=22, 25, 11	18.8 Breaths per minute Standard Deviation 1.99	20.1 Breaths per minute Standard Deviation 4.46	22.4 Breaths per minute Standard Deviation 4.60	—	—	—
Mean Respiratory Rate at Baseline and Maximum Post-Baseline Visit During Part 2/3 Week 8, n=19, 19, 10	19.2 Breaths per minute Standard Deviation 2.32	23.4 Breaths per minute Standard Deviation 6.23	22.0 Breaths per minute Standard Deviation 1.79	—	—	—
Mean Respiratory Rate at Baseline and Maximum Post-Baseline Visit During Part 2/3 Week 9, n=17, 16, 12	19.5 Breaths per minute Standard Deviation 2.96	22.0 Breaths per minute Standard Deviation 3.95	22.5 Breaths per minute Standard Deviation 4.48	—	—	—
Mean Respiratory Rate at Baseline and Maximum Post-Baseline Visit During Part 2/3 Week 10, n=16, 13, 11	18.7 Breaths per minute Standard Deviation 2.27	22.8 Breaths per minute Standard Deviation 3.83	23.3 Breaths per minute Standard Deviation 6.83	—	—	—
Mean Respiratory Rate at Baseline and Maximum Post-Baseline Visit During Part 2/3 Week 11, n=15, 13, 12	18.9 Breaths per minute Standard Deviation 1.28	22.8 Breaths per minute Standard Deviation 3.11	22.2 Breaths per minute Standard Deviation 5.29	—	—	—
Mean Respiratory Rate at Baseline and Maximum Post-Baseline Visit During Part 2/3 Week 12, n=17, 16, 9	18.6 Breaths per minute Standard Deviation 1.90	22.2 Breaths per minute Standard Deviation 3.76	23.6 Breaths per minute Standard Deviation 4.98	—	—	—
Mean Respiratory Rate at Baseline and Maximum Post-Baseline Visit During Part 2/3 Week 13, n=11, 13, 8	19.3 Breaths per minute Standard Deviation 1.56	23.4 Breaths per minute Standard Deviation 7.68	21.0 Breaths per minute Standard Deviation 2.62	—	—	—
Mean Respiratory Rate at Baseline and Maximum Post-Baseline Visit During Part 2/3 Week 14, n=13, 11, 7	18.7 Breaths per minute Standard Deviation 2.98	19.9 Breaths per minute Standard Deviation 5.49	23.4 Breaths per minute Standard Deviation 4.86	—	—	—
Mean Respiratory Rate at Baseline and Maximum Post-Baseline Visit During Part 2/3 Week 15, n=12, 13, 5	18.7 Breaths per minute Standard Deviation 1.76	21.1 Breaths per minute Standard Deviation 2.53	24.4 Breaths per minute Standard Deviation 8.76	—	—	—
Mean Respiratory Rate at Baseline and Maximum Post-Baseline Visit During Part 2/3 Week 16, n=16, 14, 8	18.6 Breaths per minute Standard Deviation 1.26	22.9 Breaths per minute Standard Deviation 7.97	24.3 Breaths per minute Standard Deviation 6.88	—	—	—
Mean Respiratory Rate at Baseline and Maximum Post-Baseline Visit During Part 2/3 Week 17, n=13, 10, 5	19.0 Breaths per minute Standard Deviation 2.08	22.4 Breaths per minute Standard Deviation 6.45	25.2 Breaths per minute Standard Deviation 9.65	—	—	—
Mean Respiratory Rate at Baseline and Maximum Post-Baseline Visit During Part 2/3 Week 18, n=16, 12, 4	19.1 Breaths per minute Standard Deviation 3.79	22.0 Breaths per minute Standard Deviation 4.53	29.0 Breaths per minute Standard Deviation 10.52	—	—	—
Mean Respiratory Rate at Baseline and Maximum Post-Baseline Visit During Part 2/3 Week 19, n=14, 13, 6	18.1 Breaths per minute Standard Deviation 1.49	24.5 Breaths per minute Standard Deviation 19.33	24.0 Breaths per minute Standard Deviation 6.45	—	—	—
Mean Respiratory Rate at Baseline and Maximum Post-Baseline Visit During Part 2/3 Week 20, n=13, 13, 7	17.4 Breaths per minute Standard Deviation 1.94	20.9 Breaths per minute Standard Deviation 3.52	33.00 Breaths per minute Standard Deviation 16.77	—	—	—
Mean Respiratory Rate at Baseline and Maximum Post-Baseline Visit During Part 2/3 Week 21, n=4, 10, 3	18.8 Breaths per minute Standard Deviation 3.40	20.2 Breaths per minute Standard Deviation 3.55	28.0 Breaths per minute Standard Deviation 10.58	—	—	—
Mean Respiratory Rate at Baseline and Maximum Post-Baseline Visit During Part 2/3 Week 22, n=11, 7, 5	19.7 Breaths per minute Standard Deviation 2.94	19.1 Breaths per minute Standard Deviation 2.79	26.0 Breaths per minute Standard Deviation 4.90	—	—	—
Mean Respiratory Rate at Baseline and Maximum Post-Baseline Visit During Part 2/3 Week 23, n=8, 7, 6	20.4 Breaths per minute Standard Deviation 2.72	21.1 Breaths per minute Standard Deviation 3.24	23.7 Breaths per minute Standard Deviation 5.13	—	—	—
Mean Respiratory Rate at Baseline and Maximum Post-Baseline Visit During Part 2/3 Week 24, n=22, 23, 11	19.1 Breaths per minute Standard Deviation 2.03	20.2 Breaths per minute Standard Deviation 3.11	23.8 Breaths per minute Standard Deviation 5.47	—	—	—
Mean Respiratory Rate at Baseline and Maximum Post-Baseline Visit During Part 2/3 FU Week 1, n=6, 6, 3	18.8 Breaths per minute Standard Deviation 1.60	20.0 Breaths per minute Standard Deviation 3.41	26.0 Breaths per minute Standard Deviation 10.39	—	—	—
Mean Respiratory Rate at Baseline and Maximum Post-Baseline Visit During Part 2/3 FU Week 2, n=6, 5, 7	18.7 Breaths per minute Standard Deviation 1.63	20.8 Breaths per minute Standard Deviation 4.15	22.2 Breaths per minute Standard Deviation 4.02	—	—	—
Mean Respiratory Rate at Baseline and Maximum Post-Baseline Visit During Part 2/3 FU Week 3, n=6, 4, 4	19.0 Breaths per minute Standard Deviation 1.67	23.0 Breaths per minute Standard Deviation 4.16	24.8 Breaths per minute Standard Deviation 5.50	—	—	—
Mean Respiratory Rate at Baseline and Maximum Post-Baseline Visit During Part 2/3 FU Week 4, n=10, 12, 7	19.4 Breaths per minute Standard Deviation 0.97	20.8 Breaths per minute Standard Deviation 1.86	21.0 Breaths per minute Standard Deviation 3.74	—	—	—
Mean Respiratory Rate at Baseline and Maximum Post-Baseline Visit During Part 2/3 MPB, n=24, 26, 15	23.0 Breaths per minute Standard Deviation 2.78	27.7 Breaths per minute Standard Deviation 13.00	27.7 Breaths per minute Standard Deviation 11.54	—	—	—

SECONDARY outcome

Timeframe: From Week 1 to Follow-up Week 4 of Part 1, up to Study Week 28

Outcome measures

Outcome measures
Measure	Part 2 (Randomized Period) Cohort 1-Placebo n=5 Participants Participants aged between 12 and 17 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.	Part 2 (Randomized Period) Cohort 1- Eltrombopag n=5 Participants Participants aged between 12 and 17 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was 37.5 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 2-Placebo n=5 Participants Participants aged between 6 and 11 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.	Part 2 (Randomized Period) Cohort 2-Eltrombopag Participants aged between 6 and 11 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was based on the body weight, participants with a weight of \<27 kg received 25 mg QD and participants with a weight of \>=27 kg received 50 mg QD. Participants of East Asian ancestry with a body weight of \<27 kg received 12.5 mg QD and participants with a weight of \>=27 kg received 25 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 3-Placebo Participants aged between 1 to 5 years received eltrombopag matching placebo administered as a dry powder for oral suspension QD for 7 weeks.	Part 2 (Randomized Period) Cohort 3- Eltrombopag Participants aged between 1 to 5 years received eltrombopag administered as a dry powder for oral suspension for 7 weeks. The starting dose of eltrombopag was 1.5 mg/kg QD and the dose calculations were based on the body weight. Participants of East Asian ancestry began at 0.8 mg/kg/day. The maximum dose allowed was 2 mg/kg, unless otherwise approved by the investigator, and could not exceed 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.
Mean Pulse Rate at Baseline and the Maximum Post-Baseline Visit Recorded During the Dose-Finding Period, Part 1 Week 16, n=5, 3, 4	86.4 Beats per minute Standard Deviation 18.60	103.0 Beats per minute Standard Deviation 5.57	93.0 Beats per minute Standard Deviation 18.96	—	—	—
Mean Pulse Rate at Baseline and the Maximum Post-Baseline Visit Recorded During the Dose-Finding Period, Part 1 Week 17, n=2, 0, 3	67.5 Beats per minute Standard Deviation 20.51	NA Beats per minute Standard Deviation NA There were no participants analyzed at this time point, therefore there is no calculated standard deviation.	97.7 Beats per minute Standard Deviation 12.01	—	—	—
Mean Pulse Rate at Baseline and the Maximum Post-Baseline Visit Recorded During the Dose-Finding Period, Part 1 Week 18, n=3, 3, 4	88.0 Beats per minute Standard Deviation 10.44	86.7 Beats per minute Standard Deviation 17.01	102.8 Beats per minute Standard Deviation 16.88	—	—	—
Mean Pulse Rate at Baseline and the Maximum Post-Baseline Visit Recorded During the Dose-Finding Period, Part 1 Week 19, n=3, 0, 2	88.0 Beats per minute Standard Deviation 20.81	NA Beats per minute Standard Deviation NA There were no participants analyzed at this time point, therefore there is no calculated standard deviation.	94.0 Beats per minute Standard Deviation 8.49	—	—	—
Mean Pulse Rate at Baseline and the Maximum Post-Baseline Visit Recorded During the Dose-Finding Period, Part 1 Week 20, n=5, 4, 4	79.8 Beats per minute Standard Deviation 13.03	96.8 Beats per minute Standard Deviation 12.58	111.8 Beats per minute Standard Deviation 14.97	—	—	—
Mean Pulse Rate at Baseline and the Maximum Post-Baseline Visit Recorded During the Dose-Finding Period, Part 1 Week 21, n=3, 2, 5	79.0 Beats per minute Standard Deviation 6.93	75.5 Beats per minute Standard Deviation 3.54	101.0 Beats per minute Standard Deviation 18.63	—	—	—
Mean Pulse Rate at Baseline and the Maximum Post-Baseline Visit Recorded During the Dose-Finding Period, Part 1 Week 22, n=3, 4, 4	70.3 Beats per minute Standard Deviation 14.36	86.5 Beats per minute Standard Deviation 9.04	100.0 Beats per minute Standard Deviation 18.63	—	—	—
Mean Pulse Rate at Baseline and the Maximum Post-Baseline Visit Recorded During the Dose-Finding Period, Part 1 Week 23, n=4, 2, 5	71.5 Beats per minute Standard Deviation 13.03	82.5 Beats per minute Standard Deviation 3.54	100.0 Beats per minute Standard Deviation 13.14	—	—	—
Mean Pulse Rate at Baseline and the Maximum Post-Baseline Visit Recorded During the Dose-Finding Period, Part 1 Week 24, n=5, 5, 5	79.6 Beats per minute Standard Deviation 7.86	85.8 Beats per minute Standard Deviation 6.91	96.0 Beats per minute Standard Deviation 4.74	—	—	—
Mean Pulse Rate at Baseline and the Maximum Post-Baseline Visit Recorded During the Dose-Finding Period, Part 1 FU Week 1, n=1, 1, 3	81.0 Beats per minute Standard Deviation NA There were too few participants available to collect data at this time point to calculate a standard deviation.	125.0 Beats per minute Standard Deviation NA There were too few participants available to collect data at this time point to calculate a standard deviation.	107.7 Beats per minute Standard Deviation 10.79	—	—	—
Mean Pulse Rate at Baseline and the Maximum Post-Baseline Visit Recorded During the Dose-Finding Period, Part 1 FU Week 2, n=3, 2, 0	77.7 Beats per minute Standard Deviation 8.74	84.5 Beats per minute Standard Deviation 28.99	NA Beats per minute Standard Deviation NA There were no participants analyzed at this time point, therefore there is no calculated standard deviation.	—	—	—
Mean Pulse Rate at Baseline and the Maximum Post-Baseline Visit Recorded During the Dose-Finding Period, Part 1 FU Week 3, n=2, 1, 2	87.0 Beats per minute Standard Deviation 2.83	78.0 Beats per minute Standard Deviation NA There were too few participants available to collect data at this time point to calculate a standard deviation.	98.0 Beats per minute Standard Deviation 8.49	—	—	—
Mean Pulse Rate at Baseline and the Maximum Post-Baseline Visit Recorded During the Dose-Finding Period, Part 1 FU Week 4, n=1, 0, 2	89.0 Beats per minute Standard Deviation NA There were too few participants available to collect data at this time point to calculate a standard deviation.	NA Beats per minute Standard Deviation NA There were no participants analyzed at this time point, therefore there is no calculated standard deviation.	99.0 Beats per minute Standard Deviation 26.87	—	—	—
Mean Pulse Rate at Baseline and the Maximum Post-Baseline Visit Recorded During the Dose-Finding Period, Part 1 MBP, n=5, 5, 5	108.8 Beats per minute Standard Deviation 24.01	109.8 Beats per minute Standard Deviation 14.17	119.6 Beats per minute Standard Deviation 5.73	—	—	—
Mean Pulse Rate at Baseline and the Maximum Post-Baseline Visit Recorded During the Dose-Finding Period, Part 1 Screening, n=5, 5, 5	85.2 Beats per minute Standard Deviation 15.71	88.4 Beats per minute Standard Deviation 8.50	102.0 Beats per minute Standard Deviation 7.97	—	—	—
Mean Pulse Rate at Baseline and the Maximum Post-Baseline Visit Recorded During the Dose-Finding Period, Part 1 Day 1, n=4, 5, 5,	84.3 Beats per minute Standard Deviation 11.32	88.2 Beats per minute Standard Deviation 12.89	102.4 Beats per minute Standard Deviation 13.22	—	—	—
Mean Pulse Rate at Baseline and the Maximum Post-Baseline Visit Recorded During the Dose-Finding Period, Part 1 Week 1, n= 4, 5, 5	85.3 Beats per minute Standard Deviation 4.79	90.8 Beats per minute Standard Deviation 11.19	103.8 Beats per minute Standard Deviation 8.47	—	—	—
Mean Pulse Rate at Baseline and the Maximum Post-Baseline Visit Recorded During the Dose-Finding Period, Part 1 Week 2, n=5, 5, 5	80.4 Beats per minute Standard Deviation 12.97	84.4 Beats per minute Standard Deviation 16.77	96.8 Beats per minute Standard Deviation 10.66	—	—	—
Mean Pulse Rate at Baseline and the Maximum Post-Baseline Visit Recorded During the Dose-Finding Period, Part 1 Week 3, n=5, 5, 5	92.8 Beats per minute Standard Deviation 31.16	91.4 Beats per minute Standard Deviation 11.04	106.2 Beats per minute Standard Deviation 11.10	—	—	—
Mean Pulse Rate at Baseline and the Maximum Post-Baseline Visit Recorded During the Dose-Finding Period, Part 1 Week 4, n=5, 5, 5	86.4 Beats per minute Standard Deviation 10.92	84.0 Beats per minute Standard Deviation 7.62	98.6 Beats per minute Standard Deviation 14.29	—	—	—
Mean Pulse Rate at Baseline and the Maximum Post-Baseline Visit Recorded During the Dose-Finding Period, Part 1 Week 5, n=5, 5, 5	84.6 Beats per minute Standard Deviation 9.48	88.4 Beats per minute Standard Deviation 9.58	107.8 Beats per minute Standard Deviation 9.58	—	—	—
Mean Pulse Rate at Baseline and the Maximum Post-Baseline Visit Recorded During the Dose-Finding Period, Part 1 Week 6, n=5, 5, 4	76.4 Beats per minute Standard Deviation 10.50	89.8 Beats per minute Standard Deviation 13.79	103.0 Beats per minute Standard Deviation 8.29	—	—	—
Mean Pulse Rate at Baseline and the Maximum Post-Baseline Visit Recorded During the Dose-Finding Period, Part 1 Week 7, n=5, 5, 5	82.0 Beats per minute Standard Deviation 9.46	96.2 Beats per minute Standard Deviation 17.84	103.2 Beats per minute Standard Deviation 8.93	—	—	—
Mean Pulse Rate at Baseline and the Maximum Post-Baseline Visit Recorded During the Dose-Finding Period, Part 1 Week 8, n=5, 5, 5	83.0 Beats per minute Standard Deviation 5.20	89.4 Beats per minute Standard Deviation 15.04	111.8 Beats per minute Standard Deviation 10.62	—	—	—
Mean Pulse Rate at Baseline and the Maximum Post-Baseline Visit Recorded During the Dose-Finding Period, Part 1 Week 9, n=5, 5, 5	80.4 Beats per minute Standard Deviation 13.35	79.2 Beats per minute Standard Deviation 11.34	101.6 Beats per minute Standard Deviation 5.59	—	—	—
Mean Pulse Rate at Baseline and the Maximum Post-Baseline Visit Recorded During the Dose-Finding Period, Part 1 Week 10, n=5, 5, 5	80.6 Beats per minute Standard Deviation 14.93	84.4 Beats per minute Standard Deviation 10.31	105.4 Beats per minute Standard Deviation 9.29	—	—	—
Mean Pulse Rate at Baseline and the Maximum Post-Baseline Visit Recorded During the Dose-Finding Period, Part 1 Week 11, n=5, 3, 5	86.6 Beats per minute Standard Deviation 11.04	97.7 Beats per minute Standard Deviation 16.50	106.6 Beats per minute Standard Deviation 11.19	—	—	—
Mean Pulse Rate at Baseline and the Maximum Post-Baseline Visit Recorded During the Dose-Finding Period, Part 1 Week 12, n=4, 4, 5	80.5 Beats per minute Standard Deviation 12.07	92.0 Beats per minute Standard Deviation 12.83	101.4 Beats per minute Standard Deviation 16.62	—	—	—
Mean Pulse Rate at Baseline and the Maximum Post-Baseline Visit Recorded During the Dose-Finding Period, Part 1 Week 13, n=4, 4, 4	90.8 Beats per minute Standard Deviation 15.52	86.5 Beats per minute Standard Deviation 7.05	103.8 Beats per minute Standard Deviation 3.50	—	—	—
Mean Pulse Rate at Baseline and the Maximum Post-Baseline Visit Recorded During the Dose-Finding Period, Part 1 Week 14, n=3, 3, 3	81.0 Beats per minute Standard Deviation 9.85	87.0 Beats per minute Standard Deviation 8.66	101.0 Beats per minute Standard Deviation 11.00	—	—	—
Mean Pulse Rate at Baseline and the Maximum Post-Baseline Visit Recorded During the Dose-Finding Period, Part 1 Week 15, n=3, 4, 4	77.3 Beats per minute Standard Deviation 6.66	86.8 Beats per minute Standard Deviation 11.87	102.5 Beats per minute Standard Deviation 3.87	—	—	—

SECONDARY outcome

Timeframe: From Week 1 to Week 7 of Part 2

Outcome measures

Outcome measures
Measure	Part 2 (Randomized Period) Cohort 1-Placebo n=8 Participants Participants aged between 12 and 17 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.	Part 2 (Randomized Period) Cohort 1- Eltrombopag n=16 Participants Participants aged between 12 and 17 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was 37.5 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 2-Placebo n=9 Participants Participants aged between 6 and 11 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.	Part 2 (Randomized Period) Cohort 2-Eltrombopag n=17 Participants Participants aged between 6 and 11 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was based on the body weight, participants with a weight of \<27 kg received 25 mg QD and participants with a weight of \>=27 kg received 50 mg QD. Participants of East Asian ancestry with a body weight of \<27 kg received 12.5 mg QD and participants with a weight of \>=27 kg received 25 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 3-Placebo n=4 Participants Participants aged between 1 to 5 years received eltrombopag matching placebo administered as a dry powder for oral suspension QD for 7 weeks.	Part 2 (Randomized Period) Cohort 3- Eltrombopag n=11 Participants Participants aged between 1 to 5 years received eltrombopag administered as a dry powder for oral suspension for 7 weeks. The starting dose of eltrombopag was 1.5 mg/kg QD and the dose calculations were based on the body weight. Participants of East Asian ancestry began at 0.8 mg/kg/day. The maximum dose allowed was 2 mg/kg, unless otherwise approved by the investigator, and could not exceed 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.
Mean Pulse Rate at Baseline and the Maximum Post-Baseline Visit Recorded During the Randomized Period, Part 2 Screening, n=8, 16, 9, 15	80.1 Beats per minute Standard Deviation 10.11	82.8 Beats per minute Standard Deviation 17.28	86.9 Beats per minute Standard Deviation 16.10	94.3 Beats per minute Standard Deviation 17.53	91.5 Beats per minute Standard Deviation 6.56	101.5 Beats per minute Standard Deviation 23.48
Mean Pulse Rate at Baseline and the Maximum Post-Baseline Visit Recorded During the Randomized Period, Part 2 Day 1, n=6, 14, 9, 13	77.2 Beats per minute Standard Deviation 12.32	81.3 Beats per minute Standard Deviation 8.70	93.0 Beats per minute Standard Deviation 14.04	88.8 Beats per minute Standard Deviation 12.84	98.7 Beats per minute Standard Deviation 5.69	99.6 Beats per minute Standard Deviation 15.84
Mean Pulse Rate at Baseline and the Maximum Post-Baseline Visit Recorded During the Randomized Period, Part 2 Week 1, n=8, 16, 9, 17	76.4 Beats per minute Standard Deviation 8.50	80.1 Beats per minute Standard Deviation 12.04	89.9 Beats per minute Standard Deviation 18.48	98.4 Beats per minute Standard Deviation 19.76	98.5 Beats per minute Standard Deviation 13.44	96.4 Beats per minute Standard Deviation 17.08
Mean Pulse Rate at Baseline and the Maximum Post-Baseline Visit Recorded During the Randomized Period, Part 2 Week 2, n=7, 15, 9, 17	79.4 Beats per minute Standard Deviation 8.75	81.7 Beats per minute Standard Deviation 9.79	89.0 Beats per minute Standard Deviation 12.44	91.8 Beats per minute Standard Deviation 16.96	95.3 Beats per minute Standard Deviation 7.09	102.5 Beats per minute Standard Deviation 11.81
Mean Pulse Rate at Baseline and the Maximum Post-Baseline Visit Recorded During the Randomized Period, Part 2 Week 3, n=8, 16, 9, 16	81.5 Beats per minute Standard Deviation 12.21	84.0 Beats per minute Standard Deviation 10.93	86.6 Beats per minute Standard Deviation 13.39	95.8 Beats per minute Standard Deviation 13.57	97.0 Beats per minute Standard Deviation 14.67	102.6 Beats per minute Standard Deviation 17.44
Mean Pulse Rate at Baseline and the Maximum Post-Baseline Visit Recorded During the Randomized Period, Part 2 Week 4, n=8, 16, 9, 16	76.3 Beats per minute Standard Deviation 6.96	82.4 Beats per minute Standard Deviation 10.39	84.4 Beats per minute Standard Deviation 15.91	91.5 Beats per minute Standard Deviation 14.45	93.5 Beats per minute Standard Deviation 17.00	116.1 Beats per minute Standard Deviation 23.26
Mean Pulse Rate at Baseline and the Maximum Post-Baseline Visit Recorded During the Randomized Period, Part 2 Week 5, n=8, 16, 9, 16	79.3 Beats per minute Standard Deviation 9.44	82.5 Beats per minute Standard Deviation 13.87	95.3 Beats per minute Standard Deviation 14.96	92.4 Beats per minute Standard Deviation 15.18	89.0 Beats per minute Standard Deviation 15.52	99.8 Beats per minute Standard Deviation 19.51
Mean Pulse Rate at Baseline and the Maximum Post-Baseline Visit Recorded During the Randomized Period, Part 2 Week 6, n=8, 16, 9, 17	77.0 Beats per minute Standard Deviation 9.50	83.2 Beats per minute Standard Deviation 11.01	86.8 Beats per minute Standard Deviation 11.62	90.1 Beats per minute Standard Deviation 17.74	84.8 Beats per minute Standard Deviation 13.15	103.0 Beats per minute Standard Deviation 23.14
Mean Pulse Rate at Baseline and the Maximum Post-Baseline Visit Recorded During the Randomized Period, Part 2 Week 7, n=8, 16, 9, 17	74.1 Beats per minute Standard Deviation 6.92	82.8 Beats per minute Standard Deviation 11.68	96.7 Beats per minute Standard Deviation 15.39	91.6 Beats per minute Standard Deviation 17.68	101.5 Beats per minute Standard Deviation 16.60	105.3 Beats per minute Standard Deviation 15.18
Mean Pulse Rate at Baseline and the Maximum Post-Baseline Visit Recorded During the Randomized Period, Part 2 MBP, n=8, 16, 9, 17	88.3 Beats per minute Standard Deviation 7.72	97.6 Beats per minute Standard Deviation 7.51	106.1 Beats per minute Standard Deviation 11.92	108.6 Beats per minute Standard Deviation 17.08	106.8 Beats per minute Standard Deviation 12.28	117.5 Beats per minute Standard Deviation 21.68

SECONDARY outcome

Timeframe: From Week 1to Follow-up Week 4 of Part 2/3, up to Study Week 35

Pulse rate was measured at the following scheduled time points: Screening, Day 1, each week from Week 1 to Week 24, and at each Follow-up Weeks 1-4. Baseline is defined as the value obtained on Day 1 of treatment. The maximum post-Baseline visit included any scheduled and unscheduled post-Baseline assessment. Participants randomized to receive eltrombopag for 7 weeks in Part 2 continued receiving eltrombopag for an additional 17 weeks in Part 2/3 (for a total of 24 weeks of treatment) up to Study Week 24. Participants randomized to receive placebo for 7 weeks in Part 2, received 24 weeks of eltrombopag in Part 2/3 (for a total of 24 weeks of treatment) up to Study Week 31.

Outcome measures

Outcome measures
Measure	Part 2 (Randomized Period) Cohort 1-Placebo n=24 Participants Participants aged between 12 and 17 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.	Part 2 (Randomized Period) Cohort 1- Eltrombopag n=26 Participants Participants aged between 12 and 17 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was 37.5 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 2-Placebo n=15 Participants Participants aged between 6 and 11 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.	Part 2 (Randomized Period) Cohort 2-Eltrombopag Participants aged between 6 and 11 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was based on the body weight, participants with a weight of \<27 kg received 25 mg QD and participants with a weight of \>=27 kg received 50 mg QD. Participants of East Asian ancestry with a body weight of \<27 kg received 12.5 mg QD and participants with a weight of \>=27 kg received 25 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 3-Placebo Participants aged between 1 to 5 years received eltrombopag matching placebo administered as a dry powder for oral suspension QD for 7 weeks.	Part 2 (Randomized Period) Cohort 3- Eltrombopag Participants aged between 1 to 5 years received eltrombopag administered as a dry powder for oral suspension for 7 weeks. The starting dose of eltrombopag was 1.5 mg/kg QD and the dose calculations were based on the body weight. Participants of East Asian ancestry began at 0.8 mg/kg/day. The maximum dose allowed was 2 mg/kg, unless otherwise approved by the investigator, and could not exceed 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.
Mean Pulse Rate at Baseline and the Maximum Post-Baseline Visit Recorded During the Eltrombopag Only Period Part 2/3 Week 11, n=15, 14, 12	81.5 Beats per minute Standard Deviation 10.20	89.3 Beats per minute Standard Deviation 16.28	99.3 Beats per minute Standard Deviation 15.39	—	—	—
Mean Pulse Rate at Baseline and the Maximum Post-Baseline Visit Recorded During the Eltrombopag Only Period Part 2/3 Week 12, n=17, 16, 9	81.1 Beats per minute Standard Deviation 11.98	91.1 Beats per minute Standard Deviation 16.39	105.3 Beats per minute Standard Deviation 19.58	—	—	—
Mean Pulse Rate at Baseline and the Maximum Post-Baseline Visit Recorded During the Eltrombopag Only Period Part 2/3 Week 13, n=11, 13, 8	78.1 Beats per minute Standard Deviation 8.47	97.0 Beats per minute Standard Deviation 21.79	99.5 Beats per minute Standard Deviation 20.57	—	—	—
Mean Pulse Rate at Baseline and the Maximum Post-Baseline Visit Recorded During the Eltrombopag Only Period Part 2/3 Week 14, n=13, 12, 7	74.5 Beats per minute Standard Deviation 11.15	94.8 Beats per minute Standard Deviation 18.07	95.6 Beats per minute Standard Deviation 12.09	—	—	—
Mean Pulse Rate at Baseline and the Maximum Post-Baseline Visit Recorded During the Eltrombopag Only Period Part 2/3 Week 15, n=12, 14, 5	82.5 Beats per minute Standard Deviation 9.41	94.4 Beats per minute Standard Deviation 18.94	98.0 Beats per minute Standard Deviation 8.72	—	—	—
Mean Pulse Rate at Baseline and the Maximum Post-Baseline Visit Recorded During the Eltrombopag Only Period Part 2/3 Screening, n=16, 15, 10	82.8 Beats per minute Standard Deviation 17.28	94.3 Beats per minute Standard Deviation 17.53	104.8 Beats per minute Standard Deviation 21.82	—	—	—
Mean Pulse Rate at Baseline and the Maximum Post-Baseline Visit Recorded During the Eltrombopag Only Period Part 2/3 Day 1 , n=22, 22, 15	78.7 Beats per minute Standard Deviation 8.67	92.0 Beats per minute Standard Deviation 14.14	100.8 Beats per minute Standard Deviation 15.71	—	—	—
Mean Pulse Rate at Baseline and the Maximum Post-Baseline Visit Recorded During the Eltrombopag Only Period Part 2/3 Week 1, n=24, 26, 14	79.9 Beats per minute Standard Deviation 10.82	94.8 Beats per minute Standard Deviation 17.54	97.8 Beats per minute Standard Deviation 15.67	—	—	—
Mean Pulse Rate at Baseline and the Maximum Post-Baseline Visit Recorded During the Eltrombopag Only Period Part 2/3 Week 2, n=23, 26, 13	79.9 Beats per minute Standard Deviation 10.02	92.5 Beats per minute Standard Deviation 16.91	99.8 Beats per minute Standard Deviation 12.64	—	—	—
Mean Pulse Rate at Baseline and the Maximum Post-Baseline Visit Recorded During the Eltrombopag Only Period Part 2/3 Week 3, n=24, 24, 12	83.3 Beats per minute Standard Deviation 10.63	95.4 Beats per minute Standard Deviation 12.31	99.4 Beats per minute Standard Deviation 16.56	—	—	—
Mean Pulse Rate at Baseline and the Maximum Post-Baseline Visit Recorded During the Eltrombopag Only Period Part 2/3 Week 4, n=24, 25, 13	81.9 Beats per minute Standard Deviation 9.81	91.7 Beats per minute Standard Deviation 13.42	110.6 Beats per minute Standard Deviation 22.55	—	—	—
Mean Pulse Rate at Baseline and the Maximum Post-Baseline Visit Recorded During the Eltrombopag Only Period Part 2/3 Week 5, n=24, 24, 11	80.8 Beats per minute Standard Deviation 13.00	91.7 Beats per minute Standard Deviation 14.72	97.4 Beats per minute Standard Deviation 17.92	—	—	—
Mean Pulse Rate at Baseline and the Maximum Post-Baseline Visit Recorded During the Eltrombopag Only Period Part 2/3 Week 6, n=23, 24, 11	82.2 Beats per minute Standard Deviation 10.45	91.6 Beats per minute Standard Deviation 16.82	102.8 Beats per minute Standard Deviation 20.31	—	—	—
Mean Pulse Rate at Baseline and the Maximum Post-Baseline Visit Recorded During the Eltrombopag Only Period Part 2/3 Week 7, n=22, 25, 11	82.1 Beats per minute Standard Deviation 11.47	91.1 Beats per minute Standard Deviation 16.61	101.5 Beats per minute Standard Deviation 16.91	—	—	—
Mean Pulse Rate at Baseline and the Maximum Post-Baseline Visit Recorded During the Eltrombopag Only Period Part 2/3 Week 8, n=19, 20, 10	79.9 Beats per minute Standard Deviation 11.85	90.8 Beats per minute Standard Deviation 16.68	94.2 Beats per minute Standard Deviation 25.71	—	—	—
Mean Pulse Rate at Baseline and the Maximum Post-Baseline Visit Recorded During the Eltrombopag Only Period Part 2/3 Week 9, n=17, 16, 12	87.4 Beats per minute Standard Deviation 15.75	91.9 Beats per minute Standard Deviation 17.79	100.9 Beats per minute Standard Deviation 15.19	—	—	—
Mean Pulse Rate at Baseline and the Maximum Post-Baseline Visit Recorded During the Eltrombopag Only Period Part 2/3 Week 10, n=16, 13, 11	87.9 Beats per minute Standard Deviation 11.74	94.3 Beats per minute Standard Deviation 17.82	97.8 Beats per minute Standard Deviation 18.77	—	—	—
Mean Pulse Rate at Baseline and the Maximum Post-Baseline Visit Recorded During the Eltrombopag Only Period Part 2/3 Week 16, n=17, 14, 8v	81.3 Beats per minute Standard Deviation 11.24	91.4 Beats per minute Standard Deviation 15.08	99.8 Beats per minute Standard Deviation 17.16	—	—	—
Mean Pulse Rate at Baseline and the Maximum Post-Baseline Visit Recorded During the Eltrombopag Only Period Part 2/3 Week 17, n=13, 11, 5	79.7 Beats per minute Standard Deviation 11.69	96.1 Beats per minute Standard Deviation 20.80	102.2 Beats per minute Standard Deviation 22.61	—	—	—
Mean Pulse Rate at Baseline and the Maximum Post-Baseline Visit Recorded During the Eltrombopag Only Period Part 2/3 Week 18, n=16, 12, 4	81.1 Beats per minute Standard Deviation 8.79	95.8 Beats per minute Standard Deviation 23.01	99.8 Beats per minute Standard Deviation 5.56	—	—	—
Mean Pulse Rate at Baseline and the Maximum Post-Baseline Visit Recorded During the Eltrombopag Only Period Part 2/3 Week 19, n=14, 14, 6	82.1 Beats per minute Standard Deviation 12.33	96.5 Beats per minute Standard Deviation 20.24	104.2 Beats per minute Standard Deviation 18.88	—	—	—
Mean Pulse Rate at Baseline and the Maximum Post-Baseline Visit Recorded During the Eltrombopag Only Period Part 2/3 Week 20, n=13, 13, 7	79.0 Beats per minute Standard Deviation 10.98	95.9 Beats per minute Standard Deviation 17.44	91.6 Beats per minute Standard Deviation 17.18	—	—	—
Mean Pulse Rate at Baseline and the Maximum Post-Baseline Visit Recorded During the Eltrombopag Only Period Part 2/3 Week 21, n=4, 10, 3	82.3 Beats per minute Standard Deviation 10.53	90.3 Beats per minute Standard Deviation 10.71	99.7 Beats per minute Standard Deviation 15.28	—	—	—
Mean Pulse Rate at Baseline and the Maximum Post-Baseline Visit Recorded During the Eltrombopag Only Period Part 2/3 Week 22, n=11, 6, 5	83.2 Beats per minute Standard Deviation 10.57	99.7 Beats per minute Standard Deviation 5.50	98.6 Beats per minute Standard Deviation 18.20	—	—	—
Mean Pulse Rate at Baseline and the Maximum Post-Baseline Visit Recorded During the Eltrombopag Only Period Part 2/3 Week 23, n=8, 7, 6	80.4 Beats per minute Standard Deviation 11.25	89.0 Beats per minute Standard Deviation 22.38	96.2 Beats per minute Standard Deviation 10.68	—	—	—
Mean Pulse Rate at Baseline and the Maximum Post-Baseline Visit Recorded During the Eltrombopag Only Period Part 2/3 Week 24, n=23, 23, 11	81.2 Beats per minute Standard Deviation 9.70	93.5 Beats per minute Standard Deviation 12.59	95.3 Beats per minute Standard Deviation 17.75	—	—	—
Mean Pulse Rate at Baseline and the Maximum Post-Baseline Visit Recorded During the Eltrombopag Only Period Part 2/3 FU Week 1, n=6, 6, 3	86.3 Beats per minute Standard Deviation 5.85	94.2 Beats per minute Standard Deviation 18.03	100.0 Beats per minute Standard Deviation 20.07	—	—	—
Mean Pulse Rate at Baseline and the Maximum Post-Baseline Visit Recorded During the Eltrombopag Only Period Part 2/3 FU Week 2, n=8, 7, 7	83.0 Beats per minute Standard Deviation 8.54	87.9 Beats per minute Standard Deviation 12.77	110.0 Beats per minute Standard Deviation 27.47	—	—	—
Mean Pulse Rate at Baseline and the Maximum Post-Baseline Visit Recorded During the Eltrombopag Only Period Part 2/3 FU Week 3, n=6, 5, 4	83.7 Beats per minute Standard Deviation 13.03	92.4 Beats per minute Standard Deviation 11.55	92.0 Beats per minute Standard Deviation 12.19	—	—	—
Mean Pulse Rate at Baseline and the Maximum Post-Baseline Visit Recorded During the Eltrombopag Only Period Part 2/3 FU Week 4, n=11, 13, 7	81.6 Beats per minute Standard Deviation 11.89	92.3 Beats per minute Standard Deviation 16.10	102.3 Beats per minute Standard Deviation 18.87	—	—	—
Mean Pulse Rate at Baseline and the Maximum Post-Baseline Visit Recorded During the Eltrombopag Only Period Part 2/3 MPB, n=24, 26, 15	102.2 Beats per minute Standard Deviation 9.35	110.9 Beats per minute Standard Deviation 15.03	121.2 Beats per minute Standard Deviation 20.42	—	—	—

SECONDARY outcome

Timeframe: Baseline and Week 24 of Part 1

Population: Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety Population.

Urinalysis parameters included: urine protein (UP), urine glucose (UG), urine ketones (UK), urine occult blood (UOB), and pH. The dipstick test gives results in a semi-quantitative manner. UP was categorized as missing (MS), no result (NR), negative (Neg), Trace, 1+, 2+, 3+ and 4+. UG results were categorized as MS, NR, Neg, normal, 5, 15(1+), 30(2+), 60(3+), 110(4+)UK parameters were categorized as as MS, NR, Neg, Trace(5), Small(15), Moderate(40), Large(80), Large(160). UOB parameters were categorized as MS, NR, Neg, 1+, 2+, 3+, Non haemolysed trace, and haemolysed trace. PH results were categorized as MS. NR, normalresult, Neg, and range of pH (from 5-9in increments of 0.5). Data for indicated parameters was reported at Baseline (BL) and Week 24 (W24). The Baseline value was the measurement taken at Day 1.

Outcome measures

Outcome measures
Measure	Part 2 (Randomized Period) Cohort 1-Placebo n=15 Participants Participants aged between 12 and 17 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.	Part 2 (Randomized Period) Cohort 1- Eltrombopag Participants aged between 12 and 17 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was 37.5 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 2-Placebo Participants aged between 6 and 11 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.	Part 2 (Randomized Period) Cohort 2-Eltrombopag Participants aged between 6 and 11 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was based on the body weight, participants with a weight of \<27 kg received 25 mg QD and participants with a weight of \>=27 kg received 50 mg QD. Participants of East Asian ancestry with a body weight of \<27 kg received 12.5 mg QD and participants with a weight of \>=27 kg received 25 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 3-Placebo Participants aged between 1 to 5 years received eltrombopag matching placebo administered as a dry powder for oral suspension QD for 7 weeks.	Part 2 (Randomized Period) Cohort 3- Eltrombopag Participants aged between 1 to 5 years received eltrombopag administered as a dry powder for oral suspension for 7 weeks. The starting dose of eltrombopag was 1.5 mg/kg QD and the dose calculations were based on the body weight. Participants of East Asian ancestry began at 0.8 mg/kg/day. The maximum dose allowed was 2 mg/kg, unless otherwise approved by the investigator, and could not exceed 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 UP, MS, BL, n=3	1 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 UP, NR, BL, n=3	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 UP, Neg, BL, n=3	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 UP, Trace, BL, n=3	2 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 UP, 1+, BL, n=3	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 UP, 2+, BL, n=3	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 UP, 3+, BL, n=3	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 UP, 4+, BL, n=3	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 UG, MS, BL, n=3	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 UG, NR, BL, n=3	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 UG, Neg, BL, n=3	3 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 UG, normal, BL, n=3	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 UG, 5, BL, n=3	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 UG, 15(1+), BL, n=3	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 UG, 30(2+), BL, n=3	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 UG, 60(3+), BL, n=3	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 UG, 110(4+), BL, n=3	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 UK, MS, BL, n=3	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 UK, NR, BL, n=3	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 UK, Neg, BL, n=3	3 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 UK, Trace(5), BL, n=3	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 UK, Small(15), BL, n=3	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 UK, Moderate(40), BL, n=3	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 UK, Large(80), BL, n=3	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 UK, Large(160), BL, n=3	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 UOB, MS, BL,n=3	1 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 UOB, NR, BL,n=3	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 UOB, Neg, BL,n=3	2 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 UOB, 1+, BL,n=3	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 UOB, 2+, BL,n=3	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 UOB, 3+, BL,n=3	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 UOB, Non haemolysed trace, BL,n=3	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 UOB, haemolysed trace, BL,n=3	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 pH, MS, BL, n=3	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 pH, NR, BL, n=3	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 pH, normal result, BL, n=3	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 pH, Neg, BL, n=3	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 pH, 5, BL, n=3	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 pH, 5.5, BL, n=3	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 pH, 6, BL, n=3	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 pH, 6.5, BL, n=3	1 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 pH, 7, BL, n=3	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 pH, 7.5,BL, n=3	1 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 pH, 8, BL, n=3	1 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 pH, 8.5, BL, n=3	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 pH, 9, BL, n=3	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 UP, MS, W24, n=4	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 UP, NR, W24, n=4	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 UP, Neg, W24, n=4	3 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 UP, Trace, W24, n=4	1 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 UP, 1+, W24, n=4	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 UP, 2+, W24, n=4	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 UP, 3+, W24, n=4	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 UP, 4+, W24, n=4	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 UG, MS, W24, n=4	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 UG, NR, W24, n=4	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 UG, Neg, W24, n=4	4 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 UG, normal, W24, n=4	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 UG, 5, W24, n=4	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 UG, 15(1+), W24, n=4	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 UG, 30(2+), W24, n=4	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 UG, 60(3+), W24, n=4	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 UG, 110(4+), W24, n=4	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 UK, MS, W24, n=4	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 UK, NR, W24, n=4	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 UK, Neg, W24, n=4	3 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 UK, Trace(5), W24, n=4	1 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 UK, Small(15), W24, n=4	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 UK, Moderate(40), W24, n=4	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 UK, Large(80), W24, n=4	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 UK, Large(160), W24, n=4	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 UOB, MS, W24, n=4	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 UOB, NR, W24, n=4	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 UOB, Neg, W24, n=4	3 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 UOB, 1+, W24, n=4	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 UOB, 2+, W24, n=4	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 UOB, 3+, W24, n=4	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 UOB, Non haemolysed trace, W24, n=4	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 UOB, haemolysed trace, W24, n=4	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 pH, MS, W24, n=4	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 pH, NR, W24, n=4	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 pH, normal result, W24, n=4	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 pH, Neg, W24, n=4	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 pH, 5, W24, n=4	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 pH, 5.5, W24, n=4	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 pH, 6, W24, n=4	2 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 pH, 6.5, W24, n=4	2 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 pH, 7, W24, n=4	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 pH, 7.5,W24, n=4	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 pH, 8, W24, n=4	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 pH, 8.5, W24, n=4	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Dose-Finding Period, Part 1 pH, 9, W24, n=4	0 Participants	—	—	—	—	—

SECONDARY outcome

Timeframe: Baseline and Week 7 of Part 2

Population: Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X,X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety Population

Urinalysis parameters included: urine protein (UP), urine glucose (UG), urine ketones (UK), urine occult blood (UOB), and pH. The dipstick test gives results in a semi-quantitative manner. UP was categorized as missing (MS), no result (NR), negative (Neg), Trace, 1+, 2+, 3+ and 4+. UG results were categorized as MS, NR, Neg, normal, 5, 15(1+), 30(2+), 60(3+), 110(4+)UK parameters were categorized as as MS, NR, Neg, Trace(5), Small(15), Moderate(40), Large(80), Large(160). UOB parameters were categorized as MS, NR, Neg, 1+, 2+, 3+, Non haemolysed trace, and haemolysed trace. PH results were categorized as MS. NR, normalresult, Neg, and range of pH (from 5-9in increments of 0.5). Data for indicated parameters was reported at Baseline (BL) and Week 7 (W7). The Baseline value was the measurement taken at Day 1.

Outcome measures

Outcome measures
Measure	Part 2 (Randomized Period) Cohort 1-Placebo n=21 Participants Participants aged between 12 and 17 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.	Part 2 (Randomized Period) Cohort 1- Eltrombopag n=44 Participants Participants aged between 12 and 17 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was 37.5 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 2-Placebo Participants aged between 6 and 11 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.	Part 2 (Randomized Period) Cohort 2-Eltrombopag Participants aged between 6 and 11 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was based on the body weight, participants with a weight of \<27 kg received 25 mg QD and participants with a weight of \>=27 kg received 50 mg QD. Participants of East Asian ancestry with a body weight of \<27 kg received 12.5 mg QD and participants with a weight of \>=27 kg received 25 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 3-Placebo Participants aged between 1 to 5 years received eltrombopag matching placebo administered as a dry powder for oral suspension QD for 7 weeks.	Part 2 (Randomized Period) Cohort 3- Eltrombopag Participants aged between 1 to 5 years received eltrombopag administered as a dry powder for oral suspension for 7 weeks. The starting dose of eltrombopag was 1.5 mg/kg QD and the dose calculations were based on the body weight. Participants of East Asian ancestry began at 0.8 mg/kg/day. The maximum dose allowed was 2 mg/kg, unless otherwise approved by the investigator, and could not exceed 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 UP, MS, BL, n=10, 9	2 Participants	0 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 UP, NR, BL, n=10, 9	0 Participants	1 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 UP, Neg, BL, n=10, 9	7 Participants	8 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 UP, Trace, BL, n=10, 9	1 Participants	0 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 UP, 1+, BL, n=10, 9	0 Participants	0 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 UP, 2+, BL, n=10, 9	0 Participants	0 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 UP, 3+, BL, n=10, 9	0 Participants	0 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 UP, 4+, BL, n=10, 9	0 Participants	0 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 UG, MS, BL, n=10, 9	2 Participants	0 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 UG, NR, BL, n=10, 9	0 Participants	1 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 UG, Neg, BL, n=10, 9	6 Participants	8 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 UG, normal, BL, n=10, 9	2 Participants	0 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 UG, 5, BL, n=10, 9	0 Participants	0 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 UG, 15(1+), BL, n=10, 9	0 Participants	0 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 UG, 30(2+), BL, n=10, 9	0 Participants	0 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 UG, 60(3+), BL, n=10, 9	0 Participants	0 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 UG, 110(4+), BL, n=10, 9	0 Participants	0 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 UK, MS, BL, n=10, 9	2 Participants	0 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 UK, NR, BL, n=10, 9	0 Participants	1 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 UK, Neg, BL, n=10, 9	8 Participants	8 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 UK, Trace(5), BL, n=10, 9	0 Participants	0 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 UK, Small(15), BL, n=10, 9	0 Participants	0 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 UK, Moderate(40), BL, n=10, 9	0 Participants	0 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 UK, Large(80), BL, n=10, 9	0 Participants	0 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 UK, Large(160), BL, n=10, 9	0 Participants	0 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 UOB, MS, BL, n=9, 9	2 Participants	1 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 UOB, NR, BL, n=9, 9	0 Participants	1 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 UOB, Neg, BL, n=9, 9	6 Participants	4 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 UOB, 1+, BL,n=9, 9	0 Participants	1 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 UOB, 2+, BL,n=9, 9	1 Participants	0 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 UOB, 3+, BL, n=9, 9	0 Participants	0 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 UOB, Non haemolysed trace, BL,n=9, 9	0 Participants	0 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 UOB, haemolysed trace, BL, n=9, 9	0 Participants	0 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 pH, MS, BL, n=10, 9	0 Participants	0 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 pH, NR, BL, n=10, 9	0 Participants	1 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 pH, normal result, BL, n=10, 9	0 Participants	0 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 pH, Neg, BL, n=10, 9	0 Participants	0 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 pH, 5, BL, n=10, 9	1 Participants	1 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 pH, 5.5, BL, n=10, 9	1 Participants	1 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 pH, 6, BL, n=10, 9	3 Participants	4 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 pH, 6.5, BL, n=10, 9	2 Participants	1 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 pH, 7, BL, n=10, 9	1 Participants	0 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 pH, 7.5,BL, n=10, 9	1 Participants	1 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 pH, 8, BL, n=10, 9	1 Participants	0 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 pH, 8.5, BL, n=10, 9	0 Participants	0 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 pH, 9, BL, n=10, 9	0 Participants	0 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 UP, MS, W7, n=2, 3	0 Participants	0 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 UP, NR, W7, n=2, 3	0 Participants	0 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 UP, Neg, W7, n=2, 3	2 Participants	3 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 UP, Trace, W7, n=2, 3	0 Participants	0 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 UP, 1+, W7, n=2, 3	0 Participants	0 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 UP, 2+, W7, n=2, 3	0 Participants	0 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 UP, 3+, W7, n=2, 3	0 Participants	0 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 UP, 4+, W7, n=2, 3	0 Participants	0 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 UG, MS, W7, n=2, 3	0 Participants	0 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 UG, NR, W7, n=2, 3	0 Participants	0 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 UG, Neg, W7, n=2, 3	2 Participants	3 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 UG, normal, W7, n=2, 3	0 Participants	0 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 UG, 5, W7, n=2, 3	0 Participants	0 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 UG, 15(1+), W7, n=2, 3	0 Participants	0 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 UG, 30(2+), W7, n=2, 3	0 Participants	0 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 UG, 60(3+), W7, n=2, 3	0 Participants	0 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 UG, 110(4+), W7, n=2, 3	0 Participants	0 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 UK, MS, W7, n=2, 3	0 Participants	0 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 UK, NR, W7, n=2, 3	0 Participants	0 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 UK, Neg, W7, n=2, 3	2 Participants	3 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 UK, Trace(5), W7, n=2, 3	0 Participants	0 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 UK, Small(15), W7, n=2, 3	0 Participants	0 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 UK, Moderate(40), W7, n=2, 3	0 Participants	0 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 UK, Large(80), W7, n=2, 3	0 Participants	0 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 UK, Large(160), W7, n=2, 3	0 Participants	0 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 UOB, MS, W7, n=2, 3	1 Participants	0 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 UOB, NR, W7, n=2, 3	0 Participants	0 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 UOB, Neg, W7, n=2, 3	1 Participants	3 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 UOB, 1+, W7, n=2, 3	0 Participants	0 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 UOB, 2+, W7, n=2, 3	0 Participants	0 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 UOB, 3+, W7, n=2, 3	0 Participants	0 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 UOB, Non haemolysed trace, W7, n=2, 3	0 Participants	0 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 UOB, haemolysed trace, W7, n=2, 3	0 Participants	0 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 pH, MS, W7, n=2, 3	0 Participants	0 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 pH, NR, W7, n=2, 3	0 Participants	0 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 pH, normal result, W7, n=2, 3	0 Participants	0 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 pH, Neg, W7, n=2, 3	0 Participants	0 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 pH, 5, W7, n=2, 3	1 Participants	0 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 pH, 5.5, W7, n=2, 3	0 Participants	0 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 pH, 6, W7, n=2, 3	0 Participants	1 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 pH, 6.5, W7, n=2, 3	0 Participants	1 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 pH, 7, W7, n=2, 3	1 Participants	1 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 pH, 7.5, W7, n=2, 3	0 Participants	0 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 pH, 8, W7, n=2, 3	0 Participants	0 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 pH, 8.5, W7, n=2, 3	0 Participants	0 Participants	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 7 During the Randomized Period,Part 2 pH, 9, W7, n=2, 3	0 Participants	0 Participants	—	—	—	—

SECONDARY outcome

Timeframe: Baseline and Week 24 of Part 2/3 up to Study Week 31

Outcome measures

Outcome measures
Measure	Part 2 (Randomized Period) Cohort 1-Placebo n=44 Participants Participants aged between 12 and 17 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.	Part 2 (Randomized Period) Cohort 1- Eltrombopag Participants aged between 12 and 17 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was 37.5 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 2-Placebo Participants aged between 6 and 11 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.	Part 2 (Randomized Period) Cohort 2-Eltrombopag Participants aged between 6 and 11 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was based on the body weight, participants with a weight of \<27 kg received 25 mg QD and participants with a weight of \>=27 kg received 50 mg QD. Participants of East Asian ancestry with a body weight of \<27 kg received 12.5 mg QD and participants with a weight of \>=27 kg received 25 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 3-Placebo Participants aged between 1 to 5 years received eltrombopag matching placebo administered as a dry powder for oral suspension QD for 7 weeks.	Part 2 (Randomized Period) Cohort 3- Eltrombopag Participants aged between 1 to 5 years received eltrombopag administered as a dry powder for oral suspension for 7 weeks. The starting dose of eltrombopag was 1.5 mg/kg QD and the dose calculations were based on the body weight. Participants of East Asian ancestry began at 0.8 mg/kg/day. The maximum dose allowed was 2 mg/kg, unless otherwise approved by the investigator, and could not exceed 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 UP, MS, BL, n=11	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 UP, NR, BL, n=11	1 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 UP, Neg, BL, n=11	10 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 UP, Trace, BL, n=11	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 UP, 1+, BL, n=11	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 UP, 2+, BL, n=11	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 UP, 3+, BL, n=11	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 UP, 4+, BL, n=11	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 UG, MS, BL, n=11	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 UG, NR, BL, n=11	1 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 UG, Neg, BL, n=11	10 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 UG, normal, BL, n=11	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 UG, 5, BL, n=11	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 UG, 15(1+), BL, n=11	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 UG, 30(2+), BL, n=11	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 UG, 60(3+), BL, n=11	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 UG, 110(4+), BL, n=11	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 UK, MS, BL, n=11	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 UK, NR, BL, n=11	1 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 UK, Neg, BL, n=11	10 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 UK, Trace(5), BL, n=11	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 UK, Small(15), BL, n=11	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 UK, Moderate(40), BL, n=11	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 UK, Large(80), BL, n=11	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 UK, Large(160), BL, n=11	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 UOB, MS, BL,n=11	2 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 UOB, NR, BL,n=11	1 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 UOB, Neg, BL,n=11	5 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 UOB, 1+, BL,n=11	1 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 UOB, 2+, BL,n=11	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 UOB, 3+, BL,n=11	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 UOB, Non haemolysed trace, BL,n=11	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 UOB, haemolysed trace, BL,n=11	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 pH, MS, BL, n=11	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 pH, NR, BL, n=11	1 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 pH, normal result, BL, n=11	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 pH, Neg, BL, n=11	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 pH, 5, BL, n=11	2 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 pH, 5.5, BL, n=11	1 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 pH, 6, BL, n=11	4 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 pH, 6.5, BL, n=11	1 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 pH, 7, BL, n=11	1 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 pH, 7.5,BL, n=11	1 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 pH, 8, BL, n=11	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 pH, 8.5, BL, n=11	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 pH, 9, BL, n=11	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 UP, MS, W24, n=34	2 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 UP, NR, W24, n=34	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 UP, Neg, W24, n=34	32 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 UP, Trace, W24, n=34	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 UP, 1+, W24, n=34	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 UP, 2+, W24, n=34	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 UP, 3+, W24, n=34	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 UP, 4+, W24, n=34	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 UG, MS, W24, n=4	1 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 UG, NR, W24, n=4	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 UG, Neg, W24, n=33	29 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 UG, normal, W24, n=33	3 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 UG, 5, W24, n=33	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 UG, 15(1+), W24, n=33	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 UG, 30(2+), W24, n=33	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 UG, 60(3+), W24, n=33	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 UG, 110(4+), W24, n=33	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 UK, MS, W24, n=33	1 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 UK, NR, W24, n=33	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 UK, Neg, W24, n=33	32 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 UK, Trace(5), W24, n=33	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 UK, Small(15), W24, n=33	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 UK, Moderate(40), W24, n=33	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 UK, Large(80), W24, n=33	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 UK, Large(160), W24, n=33	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 UOB, MS, W24, n=33	1 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 UOB, NR, W24, n=33	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 UOB, Neg, W24, n=33	31 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 UOB, 1+, W24, n=33	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 UOB, 2+, W24, n=33	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 UOB, 3+, W24, n=33	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 UOB, Non haemolysed trace, W24, n=33	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 UOB, haemolysed trace, W24, n=33	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 pH, MS, W24, n=34	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 pH, NR, W24, n=34	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 pH, normal result, W24, n=34	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 pH, Neg, W24, n=34	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 pH, 5, W24, n=34	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 pH, 5.5, W24, n=34	4 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 pH, 6, W24, n=34	10 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 pH, 6.5, W24, n=34	4 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 pH, 7, W24, n=34	11 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 pH, 7.5,W24, n=34	3 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 pH, 8, W24, n=34	2 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 pH, 8.5, W24, n=34	0 Participants	—	—	—	—	—
Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline and Week 24 During the Eltrombopag Open-label Period, Part 2/3 pH, 9, W24, n=34	0 Participants	—	—	—	—	—

SECONDARY outcome

Timeframe: From Treatment + 1 day up to Week 24 of Part1

Population: Safety Population: all participants who received at least one dose of the investigational product during Part 1 were analyzed.

An adverse event (AE) is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose: results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability or incapacity, or is a congenital anomaly or birth defect. Medical or scientific judgment should be exercised in other situations.

Outcome measures

Outcome measures
Measure	Part 2 (Randomized Period) Cohort 1-Placebo n=5 Participants Participants aged between 12 and 17 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.	Part 2 (Randomized Period) Cohort 1- Eltrombopag n=5 Participants Participants aged between 12 and 17 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was 37.5 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 2-Placebo n=5 Participants Participants aged between 6 and 11 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.	Part 2 (Randomized Period) Cohort 2-Eltrombopag Participants aged between 6 and 11 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was based on the body weight, participants with a weight of \<27 kg received 25 mg QD and participants with a weight of \>=27 kg received 50 mg QD. Participants of East Asian ancestry with a body weight of \<27 kg received 12.5 mg QD and participants with a weight of \>=27 kg received 25 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 3-Placebo Participants aged between 1 to 5 years received eltrombopag matching placebo administered as a dry powder for oral suspension QD for 7 weeks.	Part 2 (Randomized Period) Cohort 3- Eltrombopag Participants aged between 1 to 5 years received eltrombopag administered as a dry powder for oral suspension for 7 weeks. The starting dose of eltrombopag was 1.5 mg/kg QD and the dose calculations were based on the body weight. Participants of East Asian ancestry began at 0.8 mg/kg/day. The maximum dose allowed was 2 mg/kg, unless otherwise approved by the investigator, and could not exceed 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.
Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE) During Part 1 Any AE	5 Participants	5 Participants	5 Participants	—	—	—
Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE) During Part 1 Any SAE	1 Participants	1 Participants	0 Participants	—	—	—

SECONDARY outcome

Timeframe: From Treatment + 1 day up to Week 7 of Part 2

Population: Safety Population: all participants who received at least one dose of the investigational product during Part 2 were analyzed.

Outcome measures

Outcome measures
Measure	Part 2 (Randomized Period) Cohort 1-Placebo n=8 Participants Participants aged between 12 and 17 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.	Part 2 (Randomized Period) Cohort 1- Eltrombopag n=16 Participants Participants aged between 12 and 17 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was 37.5 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 2-Placebo n=9 Participants Participants aged between 6 and 11 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.	Part 2 (Randomized Period) Cohort 2-Eltrombopag n=17 Participants Participants aged between 6 and 11 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was based on the body weight, participants with a weight of \<27 kg received 25 mg QD and participants with a weight of \>=27 kg received 50 mg QD. Participants of East Asian ancestry with a body weight of \<27 kg received 12.5 mg QD and participants with a weight of \>=27 kg received 25 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 3-Placebo n=4 Participants Participants aged between 1 to 5 years received eltrombopag matching placebo administered as a dry powder for oral suspension QD for 7 weeks.	Part 2 (Randomized Period) Cohort 3- Eltrombopag n=11 Participants Participants aged between 1 to 5 years received eltrombopag administered as a dry powder for oral suspension for 7 weeks. The starting dose of eltrombopag was 1.5 mg/kg QD and the dose calculations were based on the body weight. Participants of East Asian ancestry began at 0.8 mg/kg/day. The maximum dose allowed was 2 mg/kg, unless otherwise approved by the investigator, and could not exceed 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.
Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE) During Part 2 Any AE	8 Participants	13 Participants	9 Participants	14 Participants	3 Participants	9 Participants
Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE) During Part 2 Any SAE	1 Participants	1 Participants	1 Participants	3 Participants	0 Participants	0 Participants

SECONDARY outcome

Timeframe: From Treatment + 1 day up to Week 31 of Part2/3

Population: Safety Population: all participants who received at least one dose of the investigational product during Part 2/3 were analyzed

Outcome measures

Outcome measures
Measure	Part 2 (Randomized Period) Cohort 1-Placebo n=24 Participants Participants aged between 12 and 17 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.	Part 2 (Randomized Period) Cohort 1- Eltrombopag n=26 Participants Participants aged between 12 and 17 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was 37.5 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 2-Placebo n=15 Participants Participants aged between 6 and 11 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.	Part 2 (Randomized Period) Cohort 2-Eltrombopag Participants aged between 6 and 11 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was based on the body weight, participants with a weight of \<27 kg received 25 mg QD and participants with a weight of \>=27 kg received 50 mg QD. Participants of East Asian ancestry with a body weight of \<27 kg received 12.5 mg QD and participants with a weight of \>=27 kg received 25 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 3-Placebo Participants aged between 1 to 5 years received eltrombopag matching placebo administered as a dry powder for oral suspension QD for 7 weeks.	Part 2 (Randomized Period) Cohort 3- Eltrombopag Participants aged between 1 to 5 years received eltrombopag administered as a dry powder for oral suspension for 7 weeks. The starting dose of eltrombopag was 1.5 mg/kg QD and the dose calculations were based on the body weight. Participants of East Asian ancestry began at 0.8 mg/kg/day. The maximum dose allowed was 2 mg/kg, unless otherwise approved by the investigator, and could not exceed 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.
Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE) During Part 2/3 Any AE	22 Participants	26 Participants	14 Participants	—	—	—
Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE) During Part 2/3 Any SAE	3 Participants	5 Participants	0 Participants	—	—	—

SECONDARY outcome

Timeframe: Baseline, 3and 6-mo Follow-up of Part 1

Population: Safety Population: all subjects who have received at least one dose of the investigational product during Part 1 were analyzed.

The visual acuity assessment was performed by an ophthalmologist or an optometrist under the guidance of an ophthalmologist. Visual acuity is defined as acuteness or clearness of vision. The number of participants with a change in visual acuity and worsening visual acuity due to cataracts since Baseline are presented for Part 1 Follow-up Visits at 3-months (FU3) and at 6-months (FU6). Change in visual acuity since Baseline is displayed under the left eye but applies to both eyes. Change in visual acuity (VA) is categorized as "yes" or "no". Change due to cataracts is categorized as "yes" or "no".

Outcome measures

Outcome measures
Measure	Part 2 (Randomized Period) Cohort 1-Placebo n=5 Participants Participants aged between 12 and 17 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.	Part 2 (Randomized Period) Cohort 1- Eltrombopag n=5 Participants Participants aged between 12 and 17 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was 37.5 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 2-Placebo n=5 Participants Participants aged between 6 and 11 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.	Part 2 (Randomized Period) Cohort 2-Eltrombopag Participants aged between 6 and 11 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was based on the body weight, participants with a weight of \<27 kg received 25 mg QD and participants with a weight of \>=27 kg received 50 mg QD. Participants of East Asian ancestry with a body weight of \<27 kg received 12.5 mg QD and participants with a weight of \>=27 kg received 25 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 3-Placebo Participants aged between 1 to 5 years received eltrombopag matching placebo administered as a dry powder for oral suspension QD for 7 weeks.	Part 2 (Randomized Period) Cohort 3- Eltrombopag Participants aged between 1 to 5 years received eltrombopag administered as a dry powder for oral suspension for 7 weeks. The starting dose of eltrombopag was 1.5 mg/kg QD and the dose calculations were based on the body weight. Participants of East Asian ancestry began at 0.8 mg/kg/day. The maximum dose allowed was 2 mg/kg, unless otherwise approved by the investigator, and could not exceed 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.
Number of Participants With a Change in Visual Acuity and a Change Due to Worsening of Cataracts During Part 1 Change in VA at FU3, no	1 Participants	1 Participants	2 Participants	—	—	—
Number of Participants With a Change in Visual Acuity and a Change Due to Worsening of Cataracts During Part 1 Change in VA at FU3, yes	0 Participants	0 Participants	1 Participants	—	—	—
Number of Participants With a Change in Visual Acuity and a Change Due to Worsening of Cataracts During Part 1 Change in VA at FU6, no	4 Participants	4 Participants	5 Participants	—	—	—
Number of Participants With a Change in Visual Acuity and a Change Due to Worsening of Cataracts During Part 1 Change in VA at FU6, yes	0 Participants	0 Participants	0 Participants	—	—	—
Number of Participants With a Change in Visual Acuity and a Change Due to Worsening of Cataracts During Part 1 Change due to cataracts at FU3, no	0 Participants	0 Participants	1 Participants	—	—	—
Number of Participants With a Change in Visual Acuity and a Change Due to Worsening of Cataracts During Part 1 Change due to cataracts at FU3, yes	0 Participants	0 Participants	0 Participants	—	—	—
Number of Participants With a Change in Visual Acuity and a Change Due to Worsening of Cataracts During Part 1 Change due to cataracts at FU6, no	0 Participants	0 Participants	0 Participants	—	—	—
Number of Participants With a Change in Visual Acuity and a Change Due to Worsening of Cataracts During Part 1 Change due to cataracts at FU6, yes	0 Participants	0 Participants	0 Participants	—	—	—

SECONDARY outcome

Timeframe: BL, 3 and 6mo Follow-up of Part 2/3

Population: Safety Population: all subjects who have received at least one dose of the investigational product during Part 2/3 were analyzed.

The visual acuity assessment was performed by an ophthalmologist or an optometrist under the guidance of an ophthalmologist. Visual acuity is defined as acuteness or clearness of vision. Number of participants with a change in visual acuity and change in visual acuity due to the worsening of cataracts since Baseline are presented for Part 2/3 Follow-up Visits at 3-months (FU3) and 6-months (FU6). Change in visual acuity since Baseline is displayed under the left eye but applies to both eyes. Change in visual acuity (VA) is categorized as "yes" or "no". Change due to cataracts is categorized as "yes" or "no".

Outcome measures

Outcome measures
Measure	Part 2 (Randomized Period) Cohort 1-Placebo n=24 Participants Participants aged between 12 and 17 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.	Part 2 (Randomized Period) Cohort 1- Eltrombopag n=26 Participants Participants aged between 12 and 17 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was 37.5 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 2-Placebo n=15 Participants Participants aged between 6 and 11 years received eltrombopag matching placebo administered as a tablet QD for 7 weeks.	Part 2 (Randomized Period) Cohort 2-Eltrombopag Participants aged between 6 and 11 years received eltrombopag administered as a tablet for 7 weeks. The starting dose of eltrombopag was based on the body weight, participants with a weight of \<27 kg received 25 mg QD and participants with a weight of \>=27 kg received 50 mg QD. Participants of East Asian ancestry with a body weight of \<27 kg received 12.5 mg QD and participants with a weight of \>=27 kg received 25 mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.	Part 2 (Randomized Period) Cohort 3-Placebo Participants aged between 1 to 5 years received eltrombopag matching placebo administered as a dry powder for oral suspension QD for 7 weeks.	Part 2 (Randomized Period) Cohort 3- Eltrombopag Participants aged between 1 to 5 years received eltrombopag administered as a dry powder for oral suspension for 7 weeks. The starting dose of eltrombopag was 1.5 mg/kg QD and the dose calculations were based on the body weight. Participants of East Asian ancestry began at 0.8 mg/kg/day. The maximum dose allowed was 2 mg/kg, unless otherwise approved by the investigator, and could not exceed 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.
Number of Participants With a Change in Visual Acuity and a Change Due to Worsening of Cataracts Change due to cataracts at FU3, no	4 Participants	1 Participants	2 Participants	—	—	—
Number of Participants With a Change in Visual Acuity and a Change Due to Worsening of Cataracts Change due to cataracts at FU3, yes	0 Participants	0 Participants	0 Participants	—	—	—
Number of Participants With a Change in Visual Acuity and a Change Due to Worsening of Cataracts Change due to cataracts at FU6, no	4 Participants	2 Participants	3 Participants	—	—	—
Number of Participants With a Change in Visual Acuity and a Change Due to Worsening of Cataracts Change due to cataracts at FU6, yes	0 Participants	0 Participants	0 Participants	—	—	—
Number of Participants With a Change in Visual Acuity and a Change Due to Worsening of Cataracts Change in VA at FU6, no	16 Participants	22 Participants	6 Participants	—	—	—
Number of Participants With a Change in Visual Acuity and a Change Due to Worsening of Cataracts Change in VA at FU6, yes	4 Participants	2 Participants	3 Participants	—	—	—
Number of Participants With a Change in Visual Acuity and a Change Due to Worsening of Cataracts Change in VA at FU3, no	13 Participants	17 Participants	9 Participants	—	—	—
Number of Participants With a Change in Visual Acuity and a Change Due to Worsening of Cataracts Change in VA at FU3, yes	4 Participants	1 Participants	2 Participants	—	—	—

Adverse Events

Part 1 (Dose-Finding Period)

Serious events: 2 serious events

Other events: 15 other events

Deaths: 0 deaths

Part 2 (Randomized Period) -Placebo

Serious events: 2 serious events

Other events: 20 other events

Deaths: 0 deaths

Part 2 (Randomized Period) - Eltrombopag

Serious events: 4 serious events

Other events: 36 other events

Deaths: 0 deaths

Part 2/ 3 (Eltrombopag Open-Label Period)

Serious events: 8 serious events

Other events: 62 other events

Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure	Part 1 (Dose-Finding Period) n=15 participants at risk Participants aged between 1 and 17 years (Cohort 1 age group- 12 to 17 years, Cohort 2- 6 to 11 years and Cohort 3-1 to 5 years) received eltrombopag for 24 weeks. The starting dose for cohort 1 was eltrombopag 25 mg, (East Asian ancestry: 12.5mg, QD). For cohort 2 starting dose was based on the body weight (Weight \<27 kg: 25 mg QD, Weight \>=27 kg: 50 mg QD; east Asian ancestry subjects Weight \<27 kg: 12.5 mg QD, Weight \>=27 kg: 25 mg QD). For cohort 1 and 2 maximum dose allowed was 75mg. For cohort 3 starting dose was 0.7 mg/kg, QD and the dose calculations were based on the body weight. For all participants individual dose titration was allowed based upon platelet response.	Part 2 (Randomized Period) -Placebo n=21 participants at risk Participants aged between 1 and 17 years (Cohort 1 age group- 12 to 17 years, Cohort 2- 6 to 11 years and Cohort 3- 1 to 5 years) received eltrombopag matching placebo for 7 weeks.	Part 2 (Randomized Period) - Eltrombopag n=44 participants at risk Par aged between 1 and 17 years (Cohort 1 age group: 12 to 17 years, Cohort 2: 6 to 11 years and Cohort 3:1 to 5 years) received eltrombopag for 7 weeks. The starting dose for Cohort 1 was 37.5 mg QD. For Cohort 2, starting dose was based on the body weight. Par with a body weight of \<27 kg received 25 mg QD, and par with a body weight of \>=27 kg received 50 mg QD. Par of East Asian ancestry with a body weight of \<27 kg received 12.5 mg QD, and with a body weight of \>=27 kg received 25 mg QD. For Cohort 3, the starting dose was 1.5 mg/kg QD and 0.8 mg/kg/day for par of East Asian ancestry. The maximum dose allowed was 2mg/kg and could not exceed 75 mg daily. For all par, individual dose titration was allowed based upon platelet response.	Part 2/ 3 (Eltrombopag Open-Label Period) n=65 participants at risk Par aged between 1 and 17 years (Cohort 1 age group- 12 to 17 years, Cohort 2- 6 to 11 years and Cohort 3-1 to 5 years), completing Part 2 of the study received an Open -Label treatment of eltrombopag administered as a tablet or dry powder for oral suspension in Part 2/3. Par who received eltrombopag during the Randomized Period continued on the same dose unless adjustments were warranted according to the dosing guidelines. Par who received placebo during the Randomized Period followed the starting doses for each age Cohort specified for Part 2.
Blood and lymphatic system disorders Neutropenia	6.7% 1/15 • On-treatment adverse events (AEs) and serious adverse events (SAEs) are defined as events occuring from the start of the investigational product until the end of treatment (up to Study Week 31) SAEs and non-serious AEs were collected in members of the Safety Population, comprised of all participants who had received at least one dose of the investigational product.	0.00% 0/21 • On-treatment adverse events (AEs) and serious adverse events (SAEs) are defined as events occuring from the start of the investigational product until the end of treatment (up to Study Week 31) SAEs and non-serious AEs were collected in members of the Safety Population, comprised of all participants who had received at least one dose of the investigational product.	2.3% 1/44 • On-treatment adverse events (AEs) and serious adverse events (SAEs) are defined as events occuring from the start of the investigational product until the end of treatment (up to Study Week 31) SAEs and non-serious AEs were collected in members of the Safety Population, comprised of all participants who had received at least one dose of the investigational product.	1.5% 1/65 • On-treatment adverse events (AEs) and serious adverse events (SAEs) are defined as events occuring from the start of the investigational product until the end of treatment (up to Study Week 31) SAEs and non-serious AEs were collected in members of the Safety Population, comprised of all participants who had received at least one dose of the investigational product.
Respiratory, thoracic and mediastinal disorders Epistaxis	6.7% 1/15 • On-treatment adverse events (AEs) and serious adverse events (SAEs) are defined as events occuring from the start of the investigational product until the end of treatment (up to Study Week 31) SAEs and non-serious AEs were collected in members of the Safety Population, comprised of all participants who had received at least one dose of the investigational product.	4.8% 1/21 • On-treatment adverse events (AEs) and serious adverse events (SAEs) are defined as events occuring from the start of the investigational product until the end of treatment (up to Study Week 31) SAEs and non-serious AEs were collected in members of the Safety Population, comprised of all participants who had received at least one dose of the investigational product.	0.00% 0/44 • On-treatment adverse events (AEs) and serious adverse events (SAEs) are defined as events occuring from the start of the investigational product until the end of treatment (up to Study Week 31) SAEs and non-serious AEs were collected in members of the Safety Population, comprised of all participants who had received at least one dose of the investigational product.	1.5% 1/65 • On-treatment adverse events (AEs) and serious adverse events (SAEs) are defined as events occuring from the start of the investigational product until the end of treatment (up to Study Week 31) SAEs and non-serious AEs were collected in members of the Safety Population, comprised of all participants who had received at least one dose of the investigational product.
Blood and lymphatic system disorders Anaemia	0.00% 0/15 • On-treatment adverse events (AEs) and serious adverse events (SAEs) are defined as events occuring from the start of the investigational product until the end of treatment (up to Study Week 31) SAEs and non-serious AEs were collected in members of the Safety Population, comprised of all participants who had received at least one dose of the investigational product.	0.00% 0/21 • On-treatment adverse events (AEs) and serious adverse events (SAEs) are defined as events occuring from the start of the investigational product until the end of treatment (up to Study Week 31) SAEs and non-serious AEs were collected in members of the Safety Population, comprised of all participants who had received at least one dose of the investigational product.	2.3% 1/44 • On-treatment adverse events (AEs) and serious adverse events (SAEs) are defined as events occuring from the start of the investigational product until the end of treatment (up to Study Week 31) SAEs and non-serious AEs were collected in members of the Safety Population, comprised of all participants who had received at least one dose of the investigational product.	1.5% 1/65 • On-treatment adverse events (AEs) and serious adverse events (SAEs) are defined as events occuring from the start of the investigational product until the end of treatment (up to Study Week 31) SAEs and non-serious AEs were collected in members of the Safety Population, comprised of all participants who had received at least one dose of the investigational product.
Blood and lymphatic system disorders Febrile neutropenia	0.00% 0/15 • On-treatment adverse events (AEs) and serious adverse events (SAEs) are defined as events occuring from the start of the investigational product until the end of treatment (up to Study Week 31) SAEs and non-serious AEs were collected in members of the Safety Population, comprised of all participants who had received at least one dose of the investigational product.	0.00% 0/21 • On-treatment adverse events (AEs) and serious adverse events (SAEs) are defined as events occuring from the start of the investigational product until the end of treatment (up to Study Week 31) SAEs and non-serious AEs were collected in members of the Safety Population, comprised of all participants who had received at least one dose of the investigational product.	2.3% 1/44 • On-treatment adverse events (AEs) and serious adverse events (SAEs) are defined as events occuring from the start of the investigational product until the end of treatment (up to Study Week 31) SAEs and non-serious AEs were collected in members of the Safety Population, comprised of all participants who had received at least one dose of the investigational product.	1.5% 1/65 • On-treatment adverse events (AEs) and serious adverse events (SAEs) are defined as events occuring from the start of the investigational product until the end of treatment (up to Study Week 31) SAEs and non-serious AEs were collected in members of the Safety Population, comprised of all participants who had received at least one dose of the investigational product.
General disorders Pyrexia	0.00% 0/15 • On-treatment adverse events (AEs) and serious adverse events (SAEs) are defined as events occuring from the start of the investigational product until the end of treatment (up to Study Week 31) SAEs and non-serious AEs were collected in members of the Safety Population, comprised of all participants who had received at least one dose of the investigational product.	0.00% 0/21 • On-treatment adverse events (AEs) and serious adverse events (SAEs) are defined as events occuring from the start of the investigational product until the end of treatment (up to Study Week 31) SAEs and non-serious AEs were collected in members of the Safety Population, comprised of all participants who had received at least one dose of the investigational product.	2.3% 1/44 • On-treatment adverse events (AEs) and serious adverse events (SAEs) are defined as events occuring from the start of the investigational product until the end of treatment (up to Study Week 31) SAEs and non-serious AEs were collected in members of the Safety Population, comprised of all participants who had received at least one dose of the investigational product.	1.5% 1/65 • On-treatment adverse events (AEs) and serious adverse events (SAEs) are defined as events occuring from the start of the investigational product until the end of treatment (up to Study Week 31) SAEs and non-serious AEs were collected in members of the Safety Population, comprised of all participants who had received at least one dose of the investigational product.
Infections and infestations Urinary tract infection	0.00% 0/15 • On-treatment adverse events (AEs) and serious adverse events (SAEs) are defined as events occuring from the start of the investigational product until the end of treatment (up to Study Week 31) SAEs and non-serious AEs were collected in members of the Safety Population, comprised of all participants who had received at least one dose of the investigational product.	0.00% 0/21 • On-treatment adverse events (AEs) and serious adverse events (SAEs) are defined as events occuring from the start of the investigational product until the end of treatment (up to Study Week 31) SAEs and non-serious AEs were collected in members of the Safety Population, comprised of all participants who had received at least one dose of the investigational product.	2.3% 1/44 • On-treatment adverse events (AEs) and serious adverse events (SAEs) are defined as events occuring from the start of the investigational product until the end of treatment (up to Study Week 31) SAEs and non-serious AEs were collected in members of the Safety Population, comprised of all participants who had received at least one dose of the investigational product.	1.5% 1/65 • On-treatment adverse events (AEs) and serious adverse events (SAEs) are defined as events occuring from the start of the investigational product until the end of treatment (up to Study Week 31) SAEs and non-serious AEs were collected in members of the Safety Population, comprised of all participants who had received at least one dose of the investigational product.
Infections and infestations Impetigo	0.00% 0/15 • On-treatment adverse events (AEs) and serious adverse events (SAEs) are defined as events occuring from the start of the investigational product until the end of treatment (up to Study Week 31) SAEs and non-serious AEs were collected in members of the Safety Population, comprised of all participants who had received at least one dose of the investigational product.	4.8% 1/21 • On-treatment adverse events (AEs) and serious adverse events (SAEs) are defined as events occuring from the start of the investigational product until the end of treatment (up to Study Week 31) SAEs and non-serious AEs were collected in members of the Safety Population, comprised of all participants who had received at least one dose of the investigational product.	0.00% 0/44 • On-treatment adverse events (AEs) and serious adverse events (SAEs) are defined as events occuring from the start of the investigational product until the end of treatment (up to Study Week 31) SAEs and non-serious AEs were collected in members of the Safety Population, comprised of all participants who had received at least one dose of the investigational product.	0.00% 0/65 • On-treatment adverse events (AEs) and serious adverse events (SAEs) are defined as events occuring from the start of the investigational product until the end of treatment (up to Study Week 31) SAEs and non-serious AEs were collected in members of the Safety Population, comprised of all participants who had received at least one dose of the investigational product.
Infections and infestations Varicella	0.00% 0/15 • On-treatment adverse events (AEs) and serious adverse events (SAEs) are defined as events occuring from the start of the investigational product until the end of treatment (up to Study Week 31) SAEs and non-serious AEs were collected in members of the Safety Population, comprised of all participants who had received at least one dose of the investigational product.	4.8% 1/21 • On-treatment adverse events (AEs) and serious adverse events (SAEs) are defined as events occuring from the start of the investigational product until the end of treatment (up to Study Week 31) SAEs and non-serious AEs were collected in members of the Safety Population, comprised of all participants who had received at least one dose of the investigational product.	0.00% 0/44 • On-treatment adverse events (AEs) and serious adverse events (SAEs) are defined as events occuring from the start of the investigational product until the end of treatment (up to Study Week 31) SAEs and non-serious AEs were collected in members of the Safety Population, comprised of all participants who had received at least one dose of the investigational product.	0.00% 0/65 • On-treatment adverse events (AEs) and serious adverse events (SAEs) are defined as events occuring from the start of the investigational product until the end of treatment (up to Study Week 31) SAEs and non-serious AEs were collected in members of the Safety Population, comprised of all participants who had received at least one dose of the investigational product.
Eye disorders Conjunctivitis	0.00% 0/15 • On-treatment adverse events (AEs) and serious adverse events (SAEs) are defined as events occuring from the start of the investigational product until the end of treatment (up to Study Week 31) SAEs and non-serious AEs were collected in members of the Safety Population, comprised of all participants who had received at least one dose of the investigational product.	4.8% 1/21 • On-treatment adverse events (AEs) and serious adverse events (SAEs) are defined as events occuring from the start of the investigational product until the end of treatment (up to Study Week 31) SAEs and non-serious AEs were collected in members of the Safety Population, comprised of all participants who had received at least one dose of the investigational product.	0.00% 0/44 • On-treatment adverse events (AEs) and serious adverse events (SAEs) are defined as events occuring from the start of the investigational product until the end of treatment (up to Study Week 31) SAEs and non-serious AEs were collected in members of the Safety Population, comprised of all participants who had received at least one dose of the investigational product.	0.00% 0/65 • On-treatment adverse events (AEs) and serious adverse events (SAEs) are defined as events occuring from the start of the investigational product until the end of treatment (up to Study Week 31) SAEs and non-serious AEs were collected in members of the Safety Population, comprised of all participants who had received at least one dose of the investigational product.
Eye disorders Lenticular opacities	0.00% 0/15 • On-treatment adverse events (AEs) and serious adverse events (SAEs) are defined as events occuring from the start of the investigational product until the end of treatment (up to Study Week 31) SAEs and non-serious AEs were collected in members of the Safety Population, comprised of all participants who had received at least one dose of the investigational product.	0.00% 0/21 • On-treatment adverse events (AEs) and serious adverse events (SAEs) are defined as events occuring from the start of the investigational product until the end of treatment (up to Study Week 31) SAEs and non-serious AEs were collected in members of the Safety Population, comprised of all participants who had received at least one dose of the investigational product.	0.00% 0/44 • On-treatment adverse events (AEs) and serious adverse events (SAEs) are defined as events occuring from the start of the investigational product until the end of treatment (up to Study Week 31) SAEs and non-serious AEs were collected in members of the Safety Population, comprised of all participants who had received at least one dose of the investigational product.	1.5% 1/65 • On-treatment adverse events (AEs) and serious adverse events (SAEs) are defined as events occuring from the start of the investigational product until the end of treatment (up to Study Week 31) SAEs and non-serious AEs were collected in members of the Safety Population, comprised of all participants who had received at least one dose of the investigational product.
Eye disorders Vitreous opacities	0.00% 0/15 • On-treatment adverse events (AEs) and serious adverse events (SAEs) are defined as events occuring from the start of the investigational product until the end of treatment (up to Study Week 31) SAEs and non-serious AEs were collected in members of the Safety Population, comprised of all participants who had received at least one dose of the investigational product.	0.00% 0/21 • On-treatment adverse events (AEs) and serious adverse events (SAEs) are defined as events occuring from the start of the investigational product until the end of treatment (up to Study Week 31) SAEs and non-serious AEs were collected in members of the Safety Population, comprised of all participants who had received at least one dose of the investigational product.	0.00% 0/44 • On-treatment adverse events (AEs) and serious adverse events (SAEs) are defined as events occuring from the start of the investigational product until the end of treatment (up to Study Week 31) SAEs and non-serious AEs were collected in members of the Safety Population, comprised of all participants who had received at least one dose of the investigational product.	1.5% 1/65 • On-treatment adverse events (AEs) and serious adverse events (SAEs) are defined as events occuring from the start of the investigational product until the end of treatment (up to Study Week 31) SAEs and non-serious AEs were collected in members of the Safety Population, comprised of all participants who had received at least one dose of the investigational product.
Investigations Alanine aminotransferase increased	0.00% 0/15 • On-treatment adverse events (AEs) and serious adverse events (SAEs) are defined as events occuring from the start of the investigational product until the end of treatment (up to Study Week 31) SAEs and non-serious AEs were collected in members of the Safety Population, comprised of all participants who had received at least one dose of the investigational product.	0.00% 0/21 • On-treatment adverse events (AEs) and serious adverse events (SAEs) are defined as events occuring from the start of the investigational product until the end of treatment (up to Study Week 31) SAEs and non-serious AEs were collected in members of the Safety Population, comprised of all participants who had received at least one dose of the investigational product.	0.00% 0/44 • On-treatment adverse events (AEs) and serious adverse events (SAEs) are defined as events occuring from the start of the investigational product until the end of treatment (up to Study Week 31) SAEs and non-serious AEs were collected in members of the Safety Population, comprised of all participants who had received at least one dose of the investigational product.	1.5% 1/65 • On-treatment adverse events (AEs) and serious adverse events (SAEs) are defined as events occuring from the start of the investigational product until the end of treatment (up to Study Week 31) SAEs and non-serious AEs were collected in members of the Safety Population, comprised of all participants who had received at least one dose of the investigational product.

Other adverse events

Additional Information

GSK Response Center

GlaxoSmithKline

Phone: 866-435-7343

Results disclosure agreements

Principal investigator is a sponsor employee GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.
Publication restrictions are in place

Restriction type: OTHER